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ABSTRACT 
Health-care decision-makers are increasingly in need of information on the relative 
cost-effectiveness of healthcare interventions, evaluating meaningful outcomes in 
relevant populations. A gold standard for clinical and economic evaluation is the 
randomised controlled trial, in which context-specific factors are minimised to 
enable the assigning of treatment effect to the intervention under investigation. The 
limited general isabi lity of such evaluations may limit the relevance of study results 
to decision-makers. 
This thesis presents three technical critiques of methods by which researchers may 
increase the generalisability of economic evaluation whilst focusing on 
transferability of results across patient populations and clinical settings. Firstly, 
meta-regression techniques were applied to trials with pragmatic and explanatory 
features to investigate whether increased external validity from pragmatic trials are 
achieved at the cost of reduced internal validity. Secondly, a checklist to explore the 
scope for economic modelling techniques to increase general isabi I ity of results was 
applied to economic models identified in a literature review. Finally, a study design 
was developed for an observational patient record database (UK Mediplus 0) to 
determine the feasibility for its use in real-life cost-effectiveness analyses. 
The findings indicate that pragmatic design features may be introduced to trials 
without jeopardising internal validity. Decision-analytic models have scope to 
synthesise data on cost and effect from several data sources to estimate cost- 
effectiveness for different clinical scenarios, however few published models make 
attempts to increase general isability. The observational database has a potential to 
provide data on real-life drug use, resource use and clinical outcomes, however 
shortcomings in data quality and data management prevented the conduct of a full 
economic evaluation. 
Pragmatic trials and observational studies may provide valuable data on cost and 
effectiveness reflective of specific clinical practice settings. Economic models have 
scope for presenting cost-effectiveness estimates representative across a range of 
settings. These methods should be adopted alone or in combination in order to 
assess the genera I isabil ity of the results of economic evaluations. 
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CHAPTER1 
INTRODUCTION 
1.1 Background 
There is a growing interest world-wide in economic evaluation as a tool for the 
systematic assessment of costs and consequences of interventions in increasingly 
resource-constrained healthcare environments. Opportunity costs are associated 
both with the use of inefficient therapies in healthcare and with delayed introduction 
of new, efficient therapies and the results of these may be jeopardising nations' 
health and welfare. Pharmaceutical evaluation is time- and resource consuming, so 
there is increasing pressure to transfer findings across settings and countries. 
Economic evaluations of pharmaceuticals combine an estimate of effect and an 
estimate of costs associated with the use of a medication, relative to an alternative 
treatment strategy. Results may be presented in a cost-effectiveness ratio 
expressing incremental costs and effects of one therapy compared with another or 
no therapy. Frequently, randomised controlled trials (RCT) provide the basis for the 
effect estimate, whether the economic evaluation is based on a decision-analytic 
model or individual patient-level data. Randomised controlled trials may also 
provide the basis for cost estimates, predominantly in trial-based economic 
evaluations. 
Pivotal RCTs are designed to meet licensing requirements. A high degree of 
internal validity may be achieved by conducting evaluations in specialist settings, 
through the selective inclusion of patients, by allocating treatment to eligible 
patients through the process of randomisation, by blinding physicians and patients 
to allocated treatment and through the process of monitoring patient care. 
Concerns have been raised that laboratory care conditions of such a clinical trial 
may limit the external validity of the findings, and whether findings derived within the 
setting of a randomised controlled trial would automatically translate into clinical 
effectiveness as experienced in actual clinical practice. (Drummond and Davies 
1991, O'Brien 1996, Fayers and Hand 1997, Coyle et al 1998) For economic 
evaluations, this may also result in the recording of protocol-driven costs. 
Increasingly, attention has been focused on the external validity of economic 
evaluations and the interest to developing methods for evaluating healthcare 
interventions across settings has been growing. The issue of generalisability of 
economic evaluation studies is currently on the research agenda of the Health 
Technology Assessment Programme for the UK National Health Service (HTA 
project 98/22/05) and for the WHO guidelines for cost-effectiveness analyses. 
(Murray et al 2000) 
The users of economic evaluations are likely to ask themselves whether the results 
of a given evaluation are useful and applicable in their health care setting. First and 
foremost, the methods employed to produce the evidence should normally be 
scrutinised when assessing the validity of results. The question of usefulness 
would however also encompass a judgement about whether the results may be 
transferred in time, across populations or between clinical contexts. These three 
are the main axes across which the generalisabilty of an economic evaluation may 
be assessed. 
Key clinical components include the age and gender of the patient group, co- 
morbidities, severity of disease and patient acceptability to the intervention. Clinical 
trial setting, the practice within which patients are treated, the health care system 
within which a study is framed, or the country in which the study is being conducted 
may determine context-specific components. Finally, the introduction of new 
treatments, change in the perceptions of a clinical condition or an intervention or 
simply the more effective use of an intervention as experience accumulates are 
components that may determine generalisability of results in time. 
When assessing general isabi lity of economic evaluation evidence, whether 
pertaining to time, setting or population, decision-makers should examine closely 
the data used to produce the evidence. This thesis primarily focuses on 
general isabil ity across alternative patient populations and contexts, and therefore 
views generalisability in terms of the degree to which results from one evaluation 
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hold true for different patients and clinical settings. Key elements of economic 
evaluations that may be modified in order to reflect alternative settings and patient 
populations, or study designs that may provide real-life cost effectiveness estimates 
are outlined. Such an evaluation of alternative methods that may be used in 
isolation or in conjunction, may assist users of economic evaluations in assessing 
generalisability of results they encounter in published studies and to identify ways in 
which further data may be generated in order to make appropriate extrapolations. 
One of the problems with economic evaluation methodology is the paucity of 
empirical data to illustrate the extent to which environmental factors limit the 
generalisability of the evaluations and the degree to which effect estimate, resource 
use, and unit cost may differ across settings. There are also shortcomings in 
methods illustrating how these problems could be overcome. Neither has there 
been, previously, a systematic appraisal of the methods available to health 
economists to take these issues into consideration in economic evaluations. 
Methods need to be developed to evaluate outcomes of use of pharmaceuticals in 
clinical practice. 
The thesis provides a critical evaluation of methods that are available to 
[researchers that evaluate the generalisability of primarily clinical parameters in 
economic evaluations of pharmaceuticals] those wishing to increase generalisability 
of economic evaluations of pharmaceuticals. The research draws on insights of 
several fields of research in medicine, including health policy and economics, 
epidemiology and medical statistics, research disciplines that have added to an 
accumulating knowledge base surrounding clinical and economic evaluation 
methods. 
1.2 Aim, objectives and research questions 
The aim of this thesis is to assess the relative merits of methods that can be applied 
to increase generalisability of economic evaluations of pharmaceuticals across 
3 
clinical settings and to further develop methods currently available methods. 
Specific objectives and key research questions are outlined below. 
1.2.1 Research objectives 
To identify methods to increase external validity of estimates of costs and 
effectiveness in economic evaluation; 
To develop a framework for assessment of whether economic models 
accommodate variation between settings in analysis and presentation of 
results; 
To examine the degree to which economic models attempt to generalise 
cost-effectiveness estimates; 
To evaluate whether pragmatic trial design features provide effect estimates 
systematically different from explanatory features; 
To explore the feasibility of an observational patient record database to 
accommodate full economic evaluation; 
To apply observational study methodology to generate cost-effectiveness 
estimates based on clinical practice; 
To identify and consider key methodological issues for the development and 
future conduct of economic evaluations with increased external validity. 
1.2.2 Research questions 
How can learning from clinical evaluation methodology be incorporated into 
economic evaluation methodology to meet the need for data transferable 
between settings? 
Which design features characterise a pragmatic trial and do these provide a 
biased result? 
How can economic models incorporate setting-specific aspects in the 
evaluation? 
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Which purpose can observational data serve in the provision of economic 
evaluation data relevant to clinical practice? 
1.3 Source projects 
The thesis seeks to meet the research objectives through design, conduct and 
evaluation of three source projects, each exploring a single method that may be 
used in the process of evaluating generalisability of results of economic evaluations 
between clinical settings and populations. Pragmatic trial design, modelling 
approach and observational study design will be proposed as methods for 
increasing external validity of economic evaluation studies. Through the reporting 
of these projects, this thesis aims to contribute to an increasing knowledge-base on 
generalisation methodology by evaluating aspects of these approaches. Although 
these methods are explored individually in this thesis they are not viewed as 
alternative approaches but rather as complementary processes by which 
generalisability may be explored and achieved. The source projects do not focus 
on one particular therapeutic area, though pharmaceutical interventions in the 
clinical areas of osteoporosis, schizophrenia and treatment after myocardial 
infarction were used in the source projects for the purpose of demonstrating 
methods. 
1.3.1 Pragmatic trials 
Relevant clinical and economic data can be derived from real-life settings, but only 
at the cost of an increased risk of bias and confounding. Pragmatic trials adopt 
features to ensure a higher external validity to the setting within which the trial is 
conducted. (Schwartz and Lellouch 1967) The most important modifications of 
clinical trial design in pragmatic trials include research question and objectives; 
patient selection; omitting blinding of trial participants; relaxing of monitoring 
protocol; evaluating a final clinical endpoint and adopting intention-to-treat statistical 
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analysis. The adoption of pragmatic design features in economic evaluation trials 
has been extensively advocated. (Revicki & Frank 1999, Simon 1995, Coyle et al 
1998, Guscott and Taylor 1994, Roland and Torgerson 1998, Brixton et al 1998) 
Previous assessments of trial estimates as a function of quality aspects of 
randomised controlled trials through the use of meta-regression provided methods 
on which this source project could build and expand. (Schulz et al 1996, Moher et al 
1998) 
The first source project of this thesis examines whether pragmatic design features 
in clinical trials systematically moderate the effect size compared to trials adopting 
explanatory features, and therefore achieve higher external validity at the expense 
of internal validity. The evaluation makes use of two systematic reviews of 
pharmaceutical interventions in two therapeutic areas to examine the predictive 
effect of pragmatic design features on effect size. 
1.3.2 Economic models 
Economic models have been promoted as the method with which economic 
evaluation researchers may vary the model input in order to make the results 
applicable to different healthcare settings. (Buxton et al 1997, Briggs and Gray 
1999, Commonwealth of Australia 1995, CCOHTA 1996) 
Researchers and authors of guidelines have pointed to economic models as a 
relevant methodology to accommodate differences in regional variability. The 
second source project aims to assess the extent to which models in one therapeutic 
area have accounted for such differences to date. A checklist was developed which 
described aspects of clinical and economic features of the model, as well as checks 
for external validity. This was then applied to a selection of models identified in a 
systematic review. 
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1.3.3 Observational studies 
The scarcity of methods for generalising trial results to clinical practice settings led 
to the search for alternative approaches capable of providing real-life cost- 
effectiveness estimates. Observational databases in which patient information is 
collected longitudinally may be valuable sources of drug use data, reflective of 
clinical practice. The potential value of observational data in economic evaluation is 
outlined and a review carried out of the methodological and statistical tools adopted 
by researchers in epidemiology. The third source project presents the design and 
results of two studies that were developed as parts of a pilot project to evaluating 
cost-effectiveness for pharmaceuticals in an observational patient-record database. 
The studies examined whether an observational database in the UK (the 
Mediplus@ database) was a feasible tool for the conduct of a full economic 
evaluation of cost-effectiveness in clinical practice. The Mediplus@ database 
contains primary care patient records collected in clinical practice and may be a 
potential vehicle for economic evaluation in the primary care setting, provided that 
the database meets the requirements to clinical and economic evaluation. 
1.4 Structure and content of thesis 
A synthesis of different strands of literature outlining the need for economic 
evaluation and in particular, the generalisability of such evaluation, is provided in 
Chapter 2. This contains a brief review of the methodological foundations of 
economic evaluation analysis, as well as a review of the issue of generalisability in 
the context of clinical and economic evaluation. Finally, the decision-maker's 
expressed need for gene ralisabil ity of economic evaluation is evaluated from the 
viewpoint of those regulating formal submission of economic evidence required 
within some jurisdictions. Three methods through which analysts may explore 
external validity of evaluations emerge from this review, methods that researchers 
may use either individually or in combination. Chapters 3 through 5 are devoted to 
evaluating the relative merits of each of these methods separately. 
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Chapter 3 evaluates the pragmatic trial approach to generalising economic 
evaluations and Chapter 4 offers a critique of the degree to which economic models 
adopt values for adjustment of model parameters or for sensitivity analysis that 
would facilitate judgement of external validity. The aim of Chapter 5 is to provide an 
assessment of the feasibility of an observational database to provide data for a full 
economic evaluation, reflective of clinical practice. All chapters have a similar 
structure: a background that puts the source project into the context of the overall 
theme of generalisability; an outline of research aims and objectives; a detailed 
description of methods; presentation of results; a discussion of key findings and the 
merits of the examined methods to increase generalisability of economic 
evaluations. 
The focus of the three source projects differs. The emphasis of the first was to 
apply meta-regression techniques to analyse the balance between internal and 
external validity in pragmatic trials. Central to the second project was the 
systematic search for economic evaluation models and structured assessment of 
the degree to which models may accommodate context-specific variation in key 
model parameters. The last project focused on further methodological development 
by exploring the feasibility of observational patient record data for use in economic 
evaluations striving for high external validity. These differences in emphasis are 
reflected in the reporting of the source projects. For example, particular attention is 
given to the statistical methods adopted in Chapter 3, the development of an 
assessment framework is central to Chapter 4, and the application of economic 
evaluation to observational study designs has been given detailed consideration in 
Chapter 5. 
in the concluding chapter of the thesis, attention is turned to the impact of the 
individual source projects on the further development of methods to increase 
general isabil ity of economic evaluations. A discussion of the relative merits of 
pragmatic trials, models and observational data to synthesise relevant 
(generalisable) data for economic evaluation, provides an assessment of the 
contribution of this research in the field of generalisability. Methodological 
recommendations conclude the final chapter of this thesis. 
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CHAPTER 2 
POLICY AND RESEARCH CONTEXT: GENERALISABILITY OF 
ECONOMIC EVALUATION OF PHARMACEUTICALS 
The development of methods to increase the general isabil ity of economic 
evaluations of pharmaceuticals across settings is a focus throughout this thesis. In 
healthcare, the methods for clinical evaluation and economic evaluation are 
increasingly interrelated, so both play significant roles in this research. Strands of 
literature covering research areas relevant to general isabil ity of clinical and 
economic evaluation are reviewed in this chapter. Attention is also given to the 
requirements for the generalisability of economic evaluations by those jurisdictions 
that systematically use such information in policy-making. Finally, emerging 
themes underlying the research undertaken for the thesis are outlined. Before 
turning to the review of empirical research in the area of general isability of clinical 
and economic evaluation, it is useful to give the theoretical foundations of economic 
evaluation some consideration. 
2.1 Economic evaluation in healthcare decision-making 
Medical care has changed over the last decades, with new therapies being 
discovered that may prevent or treat previously untreated conditions, and new 
technologies replacing old procedures. The availability of new and costly health- 
related interventions has gradually exceeded society's ability to afford them. 
(Mosteller 1985) The reasons for the growth in healthcare spending include 
demographic changes in populations as the proportion of elderly increases, the 
development of new and more costly therapies and the increasing availability of 
lifestyle treatments. Also, previously untreated conditions may now be treated with 
new discoveries. 
A peculiarity of the market for medical care adds to this increase in aggregate 
healthcare costs. According to conventional economic theory, independent 
9 
producers and consumers trade goods freely according to price and quantity. Price 
in such a market will reflect the margin of consumer valuation of the goods. 
(McGuire et al 1988) The characteristics of the healthcare market deviate from 
assumptions underlying this model. In healthcare, the physician acts as an 
informed decision-making agent on behalf of the patient, and the costs are borne by 
a third-party, for example an insurance organisation or a national health service. 
Economic theories of supply and demand and their interaction with price and 
consumption of goods fail to achieve equilibrium in the healthcare environment. 
Supply and demand sides are no longer separated resulting in the absence of a 
working price mechanism and the phenomenon of supplier-induced demand. 
(McGuire et al 1988) 
The continuing rise in healthcare costs has forced a change in health-policy 
paradigm, where healthcare systems have moved from what is possible given 
technical constraints to what is possible given economic constraints. (Maynard and 
Bloor 1998) Writing on the UK National Health Service (NHS), Cochrane (1971) 
made the link at an early stage between the issue of clinical-effectiveness and 
efficiency in the health service, emphasising the role of clinical decision-makers to 
take this into account: 
"The main job of medical administrators is to make choices between 
alternatives. To enable them to make the correct choices they must have 
accurate comparable data about the benefits and costs of alternatives. " 
Williams (1992) took this new emphasis on cost-consciousness one step further by 
arguing that: 
'A caring, responsible and ethical doctor has to take costs into account. 
Indeed it is unethical not to do so! " 
Williams refers to the concept of 'opportunity cost' of resources, or the value of the 
resources in their best alternative use, alluding to the fact that resources spent in 
one area of the healthcare sector or on one patient group may not be used in other 
areas or on other patients. This focus on efficient use of resources in healthcare 
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has provided strong incentives for clinical decision-makers to take make use of 
health economic data when informing decisions. Clinical decision-makers include 
physicians, healthcare providing organisations and governments. The individual 
roles of these stakeholders differ, but their broad remit is to ensure safe and 
effective provision of care to the population. 
Economic evaluation techniques have been adapted to healthcare provision and 
developed for the analysis of individual services, interventions and programmes 
within healthcare from their origin in disciplines such as engineering. (Williams 
1993) In healthcare, economic evaluations may provide an alternative to the failing 
price mechanism in the healthcare market and a guide to resource allocation. 
(Russell et al 1996) A central measure in economic evaluation is the cost- 
effectiveness ratio. Implicit in the cost-effectiveness analysis is comparison 
between a treatment and an alternative. The cost-effectiveness ratio for the 
comparison is the difference in costs divided by the difference in effectiveness, and 
therefore expresses the incremental cost of obtaining an additional unit of health 
effect. (Torrance et al 1996) The health effect component of the cost-effectiveness 
ratio can be expressed differently. Economic evaluation analyses that express the 
health effect in terms of a physical unit such as life years gained are called cost- 
effectiveness analysis. Those analyses that value the health outcome by assigning 
a utility such as the quality adjusted life year gained (QALY) are denoted cost-utility 
analyses. Finally, cost-benefit analyses value the health outcome in financial 
terms. (Drummond et al 1997) 
Theoretical foundations for research methods may guide the conduct of research, 
understand its limitations and guide the decision-making process following 
introduction of new evidence. To date, health economists debate the theoretical 
foundations of the methods used in economic evaluation. The roots have 
predominantly been traced to welfare economics, which is concerned with the 
societal allocation of resources in order to maximise the welfare of an affected 
population. (Garber et al 1996, Hurley 2000) If the fundamental purpose of health 
economic analysis is to improve general welfare through improving health then it 
may be placed within this context. The strand of welfare economic theory 
advocated by some health economists is the von Neuman-Morgenstern 
utilitarianism, a theory that assumes that individuals have a well-defined utility- 
function and that the overall welfare of society is a function of such individual 
preferences. (McGuire et al 1988) 
Welfare economists disagree amongst themselves as to how healthcare decision- 
makers should prioritise societal resources, and economists broadly advocate two 
normative frameworks, the neo-classical framework and the extra-welfarist 
framework. (Hurley 2000) Neo-classical welfare theorists aim to maximise societal 
utility, with little emphasis on the distribution of the gain. Key assumptions 
underlying the utilitarian view is that social welfare is made up of from the welfare of 
each individual member of society, and that individuals are best judges of their own 
welfare. The aggregate social utility function resulting from a situation where an 
allocation makes at least one person better off and no one worse off it is said to 
present an actual Pareto improvement. A potential Pareto improvement may occur 
when those that are better off as a consequence of a resource allocation 
compensate for those that are worse off after the allocation. A resource allocation 
is Pareto optimal (i. e. allocatively efficient) if it is impossible to increase one 
persons utility without simultaneously decreasing another's. The benefit of 
healthcare interventions is of primary interest to those subscribing to the neo- 
classical view, and benefits in empirical welfare analysis are predominantly valued 
in monetary terms. Neo-classical Paretian welfare economic theory therefore 
provides the conceptual framework of cost-benefit analysis, consistent with the aim 
of maximising societal utility. (Hurley 2000) 
Williams (1993) made a case for the extra-welf arist perspective, which provides an 
alternative to defining social utility as an aggregate of individual utilities by giving 
special weight to health in social accounting and the distribution of health. From 
this perspective, health is viewed as the output of the healthcare sector and the 
social objective is to maximise health subject to resource constraints. (Garber et al 
1996) Benefits of healthcare interventions are predominantly expressed as a 
subjective health measure, for example quality adjusted life years (QALYs) gained. 
Cost-effectiveness analysis and cost-utility analysis compare health care 
programmes that produce similar units of outcome. Cost-effectiveness analysis has 
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been considered a framework for informing questions of technical efficiency, where 
two ways of achieving the same goal are compared, for example, the comparison of 
competing therapies in same clinical condition. In contrast, cost-benefit analysis is 
broader in scope because it assigns relative values to health-related goals to 
determine which goals are worth achieving. The cost-benefit analysis framework 
has therefore been viewed as appropriate for policy questions of allocative 
efficiency, where decision-makers aim to assess whether an intervention is 
worthwhile in the first place or whether the resources should be invested elsewhere. 
Cost-utility analysis may also be considered appropriate for decisions of allocative 
efficiency since the expression of outcome in one generic clinical term, the QALY, 
informs policy-decisions on the efficient allocation of resources between 
programmes that produce different specific health outcomes. 
The interpretation of results from cost-benefit analyses is, in principle, 
straightforward: if benefits exceed costs then the programme should be 
implemented. (Briggs and Gray 2000) Two broad rules can be adopted by 
decision-makers who use evidence produced by cost-effectiveness and cost-utility 
analyses. Rank-ordering all possible uses of resources in terms of their incremental 
cost-effectiveness ratio and working down the list implementing the most cost- 
effective interventions until the healthcare budget is exhausted is called the "league 
table approach". Inherently, this approach aims to maximise health within a given 
budget, but has been criticised for inappropriately comparing cost-effectiveness 
ratios derived from inconsistent use of methods and 'unthinking' decisions. 
(Maynard 1991, Drummond et al 1993) Alternatively, the shadow price decision 
rule incorporates a cost per QALY that decision-makers are willing to pay for 
additional health, i. e. an acceptable cost-effectiveness ratio reflecting decision- 
makers' willingness to pay. Interventions with an incremental cost-effectiveness 
below this threshold would then be adopted. Besides the fact that it has proven 
difficult to quantify the decision-makers' willingness to pay for additional health 
benefits, the shadow price rule has been criticised for being a "prescription for 
growth in healthcare expenditures". (Briggs and Gray 1999) 
The debate over theoretical foundation has guided research into issues such as 
costing methods and valuation of health, (Hurley 2000) but despite this, economic 
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evaluation is commonly looked upon as a pragmatic solution to the need for 
information to prioritise healthcare resources and maximise health. (Garber et al 
1996) Economic evaluation has amu Iti-discipli nary research approach to 
evaluation, encompassing disciplines such as economics, decision analysis, 
medical sociology, epidemiology and trial methodology. The most pragmatic view 
of economic evaluation may be that of a complementary process to clinical 
evaluation, but with the aim of informing healthcare utilisation decisions on a 
broader public health scale. 
Within the increased interest in health economics' contribution to healthcare 
provision, the focus on pharmaceutical expenditure has been particularly strong. 
(Maynard and Bloor 1998) Many measures have been undertaken in attempts to 
reduce and control healthcare costs, such as reference price systems, negative 
lists, and price and profit controls. (Freemantle and Bloor 1996, Bloor and 
Freemantle 1996, Bloor et al 1996) Government cost containment policies and 
price regulation may have driven the demand for economic evaluation analysis of 
pharmaceuticals. However, the regulatory demand for data on effectiveness of 
pharmaceuticals for registration purposes, and the resulting availability of such 
data, also provides a good basis for economic evaluation. 
Despite increasing interest in economic evaluation analysis of pharmaceuticals, 
there has been little evidence that such data contribute systematically to resource 
allocation decisions. (Drummond and Cooke et al 1997) There may be barriers to 
the use of economic evaluation data at both political and practical level. Firstly, 
there are a number of challenges to the discipline and concern that the 
methodology is being used adequately. (Udvarhelyi et al 1992, Drummond 1992, 
Byford and Palmer 1998) The thorny methodological issues include the valuation of 
health outcomes, discount rate, inclusion of future costs, statistical analysis and 
assessment of uncertainty. Secondly, economic models have been criticised for 
having a 'black box'feel to them. (Sheldon 1996) The lack of insight and ability to 
scrutinise methodology has led some researchers to propose that computer models 
might be submitted for peer review. (Hill et al 2000) Finally, economic evaluations 
of pharmaceuticals are frequently based on randomised controlled trial data, but 
critics have argued that pragmatic prescribing decisions may not best be informed 
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by estimates of 'cost-efficacy' in an ideal trial setting, rather by an estimate of 'cost- 
effectiveness' in settings reflecting clinical practice. (Coyle et al 1998) 
Drug evaluation, including economic evaluation, is a costly undertaking and there is 
a pressure to use data generated in one setting and apply the findings to different 
settings. Adapting economic evaluations to local circumstances by adequately 
accounting for different patients, settings, regions and countries may be essential to 
the value of the evidence to local decision- making. Little is known about how well 
cost and clinical data translate between clinical settings and across countries, and 
therefore whether cost-effectiveness ratios vary as a function of the setting in which 
it is conducted. Potential biases can enter the process of transferring data between 
settings, resulting in premature introduction of inefficient therapies or similarly, 
delaying the use of efficient therapies. Hence the importance of developing 
methods that can be adapted to make a systematic evaluation of generalising 
across settings. 
2.2 Generalisability in economic and clinical evaluation 
A convenient introduction to issues of general isability in clinical and economic 
evaluation research is provided by the following quotation: 
'7nternal validity implies that the differences observed between groups of 
patients allocated to different interventions may, apart from random error, be 
attributed to the treatment under investigation. In contrast, external validity, 
or generalisability, is the extent to which the results of a study provide a 
correct basis for generalisations to other circumstances. In itself, there is no 
external validity. The term is only meaningful with regard to specified 
'external' conditions, such as other patient populations or treatment 
regimens. Internal validity is a prerequisite for external validity: the results of 
a flawed trial are invalid, and the question of external validity becomes 
redundant. " (J uni et al 200 1) 
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A high degree of internal validity can be achieved in the randomised controlled trial 
(RCT), where the randomisation procedure, subject selection, monitoring 
procedures and scientific process, aim to address bias. Sackett (1985) argued that 
the double-blind placebo controlled trials that follow a defined protocol represent the 
4 gold standard'for drug-trials, primarily because of the ability of randomisation to 
deal adequately with bias. The focus of the conventional RCTs on internal validity 
may have resulted in limiting their usefulness and raised concern that the 
uncertainty in the assumption that overall results from clinical trials may be 
extrapolated to patients outside the trial jeopardises the external validity of trial 
results. (Lancet 1994, Rothwell 1995, Black 1996) The setting within which a study 
is conducted may encompass specific geographical and national location, type of 
healthcare facility, patient population and period of study. As the authors of the 
quote above point out, general isabi I ity may be irrelevant without reference to one or 
more specific settings outside that of the evaluation. 
The randomised controlled trial has been adopted as the 'gold standard' also for 
clinical estimate of effectiveness in the denominator of the cost-effectiveness ratio. 
(Drummond 1997) Researchers undertaking economic evaluations of 
pharmaceuticals over the last decades have rightly focused on internal validity of 
the study, ensuring validity of effect estimates and acceptance by the medical 
community. However, concerns have been raised that prescribing decisions may 
not be best informed by the results of randomised trials frequently conducted for 
licensing purposes, but rather by data reflecting clinical practice patterns of drug 
use and resource consumption. (Coyle et al. 1998) 
The limitations of trial evidence for use in economic evaluation need to be 
addressed by the development of methods to maximise external validity of the 
findings to other settings. In the process of developing such methods, lessons may 
be learned from the clinical literature regarding methods that could be used to 
optimise general isabil ity of clinical evaluations. Pragmatic trial methodology, meta 
analyses and observational data may serve this purpose in clinical research. 
Literature covering general isabi I ity in clinical evaluation will be reviewed before 
returning to the special case of generalisability within economic evaluation. 
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2.2.1 Issues of general isabi I ity in clinical evaluation 
Pharmaceutical development has a long tradition of systematic evaluation of clinical 
evidence. The practice of clinical trials has developed rapidly during the last 50 
years. This development was parallel to an increase in the regulatory requirements 
to the licensing of pharmaceuticals, some of which were introduced after the 
Thai idom ide-scandal in the 1960s. (Pocock 1983) The evaluation of quality, safety 
and efficacy is central to these requirements; they are the 'three hurdles' that a 
manufacturer needs to jump in order to get a drug licensed by influential regulatory 
bodies such as the Food and Drug Administration in the US (FDA), and the 
European Medicines Evaluation Agency (EMEA). 
Because treatment effects are often relatively modest, biases may overwhelm the 
effect of treatment unless these are adequately controlled for. The process of 
randomisation is considered crucial to the minimisation of bias in clinical 
evaluations. (Schulz et al. 1996) Random allocation of eligible patients to the 
intervention and control groups of a trial ensures that the features of the patients 
and their therapists are distributed across the treatment arms of the experiment by 
the play of chance. Randomisation does not make groups equal, but forms a good 
basis for comparison. (Freemantle et al. in press) Statistical methods examine the 
extent to which observed differences between groups may be attributable strictly to 
chance, indirectly providing information on the likelihood that a difference in 
outcomes observed in a trial may be attributable to the different treatments 
allocated to those groups. 
The clinical stage of drug development is broadly divided into four phases. 
(Piantadosi 1997) Phase I clinical trials are the first experiments using a 
pharmaceutical compound in a population, when investigators seek to assess the 
safety of the drug in the human body and identify an appropriate dose-range 
required to intervene with the clinical condition without causing serious side-effects. 
During phase 11 of clinical drug development, investigators assess the feasibility of 
the treatment and estimate treatment effects. Phase III trials are experiments of the 
therapy escalated to a larger sample of the patient population, where the impact of 
the therapy on the clinical condition of interest is compared to placebo or standard 
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therapy. In a regulatory context such trials are called pivotal, and these are 
frequently designed in order to meet, for example, the US Food and Drug 
Administration (FDA) requirement to licensing, of two trials in favour of new 
treatment showing significant inference at single sided 0.025 level for the primary 
clinical outcome measure. (Freemantle 2001) Finally, phase IV trials are often 
large-scale experiments looking for uncommon treatment effects after lisence has 
been granted. Key to trial conduct is a protocol uniform to all trial participants that 
determines the clinical management of patients in order to minimise the impact of 
the strategy of care on the treatment outcome and ensure internal validity of the 
findings from the trial. 
Inherent in the trial protocol of an RCT is a series of adjustments to clinical practice. 
Subjects included in clinical trials may be selected by narrow inclusion criteria. For 
example, the exclusion of the elderly and of women from cardiovascular trials 
restricts the scope for generalising results to these patients. (Wenger 1992) Run-in 
periods in trials, during which patients are selected for inclusion, may also 
contribute to an atypical trial patient population, for example, more compliant 
patients may be chosen. (Pablos-Mendez et al. 1998) Finally, blinding of patients 
and physicians to treatment allocation, the manipulation of pattern and quality of 
care by the trial protocol and the monitoring of trial participants may restrict the 
scope for generalisation of trial results. (Rothwell 1995) 
Trials that are designed to measure treatment outcome under ideal conditions have 
been labelled 'explanatory'. (Schwarz and Lellouch 1967) They can be viewed as 
models of clinical practice in which reality has been simplified and standardised to 
provide 'laboratory' conditions for the experiment. In clinical research, the term 
'efficacy' is frequently used to describe the performance of a treatment under such 
conditions. The adjustments in care demanded by the trial protocol are in place to 
ensure internal validity, but may limit the external validity of the trial. Extrapolating 
the findings from explanatory trials to clinical practice, where patients and 
physicians seek positive outcome in a real life environment, may not be 
appropriate. Pragmatic trials, meta-analysis and evaluation of observational data 
are methodological approaches that may be used in an attempt to increase the 
general isabi lity of evaluations. 
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Firstly, 'pragmatic' trials are designed to measure clinical-effectiveness under 
conditions reflective of clinical practice. (Swartz and Lellouch 1967, Roland and 
Torgerson 1998) Frequently, such trials relax the design features of explanatory 
trials, for example by inclusion of a more heterogeneous patient population, 
avoidance of blinding of participants to assigned treatment, comparison with active 
substance and use of a final clinical endpoint, such as mortality, as the primary 
clinical outcome. Trials are complex structures, comprising a number of features 
ranging from subject inclusion and care provision to statistical analysis. The 
suggestion that trials can be dichotomised as either explanatory or pragmatic is 
somewhat simplistic. Rather, trials can be viewed as part of a spectrum which 
stretches from those in which most aspects of the design reflect the clinical setting 
in which they are conducted to those that modify most aspects of subject 
constituency and care provision, according to the features they adopt. The more it 
reflects a real life practice situation, the closer the trial is to the 'pragmatic' end of 
the continuum. Achieving a study design that adequately ensures internal validity 
of the findings while increasing the external validity of the results may be a matter of 
striking the right balance in trial design features. The degree of external validity 
may, for example, increase throughout the four clinical development phases. 
Secondly, in clinical research, statistical pooling techniques have been developed 
as a means of summarising evidence from several trials investigating similar 
outcomes. (Egger and Smith 1997) Meta analysis has several merits. By 
combining a number of trials, it increases the power of the evaluation of a clinical 
question by reducing the probability of a false negative result. But more 
importantly, in this context, meta-analysis may also aid the generalising of trial 
results by combining, for example, trials with different patient case-mix or 
conducted in different healthcare settings, making results applicable to a more 
diverse patient population and to a variety of clinical settings. 
Finally, observational study designs represent a third alternative, achieving high 
external validity by basing the estimation of treatment outcomes on care received in 
clinical practice. It has been proposed that observational data are essential in 
clinical research and may expand the evidence base for healthcare therapies. 
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(Black 1996, Lewsey et al 2000, Radford and Foody 2001) Nevertheless, the major 
drawback is the lack of randomisation, which leaves the results of the studies 
susceptible to biasing factors that jeopardise study validity. Statistical modelling is 
routinely used to minimise confounding from observed variables (Hennekens and 
Buring 1987), with propensity analysis and instrumental variables methods 
providing further risk-adjustment techniques to control for residual confounding from 
unobserved differences in observational studies. (Radford 2001, McClelland et al 
1994) 
To understand the consequences of potential bias in estimating effect size, 
researchers have evaluated the way in which these estimates travel between 
randomised studies and observational (i. e. non-randomised) studies. Authors of 
empirical studies debate whether observational and randomised studies that 
evaluate the same treatment in similar populations systematically provide different 
magnitude and direction of the effect size estimate. Several authors have reported 
systematic comparisons of the two methods, but findings from these are 
inconclusive. (Coldiz et al 1989, Kunz and Oxman 1998, Reeves B et al 1998, 
Britton et al 1998, MacLehose et al 2000) For example, Concato et al (2000) 
evaluated 99 trials and observational studies in five therapy areas and found that 
the results of well-designed observational studies do not systematically 
overestimate the magnitude of effects of treatment as compared with randomised 
controlled trials on the same topic. Similarly, Benson and Harz (2000) found little 
evidence that estimates of treatment effects between observational and randomised 
evidence were consistently different, but both sets of authors were criticised for 
having used selected and unrepresentative samples of trials and studies. (Pocock 
et al 2000) In contrast, the findings of loannidis et al (2001), who reviewed 240 
randomised trials and 168 observational studies in 45 topics, found that 
discrepancies beyond chance between randomised and observational studies do 
occur and that differences in estimated magnitude of treatment effect are in fact 
very common. 
Clinical researchers have a variety of designs in their toolbox to answer different 
research questions about the clinical impact of pharmaceutical treatments. We have 
seen that pragmatic design features may be adopted in trial design to increase 
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external validity, that meta-analytic techniques may be used in generalisation and 
that observational studies may provide data with high external validity, albeit at the 
risk of jeopardising internal validity. These clinical evaluation tools are also 
available to those undertaking economic evaluations, providing the opportunity to 
present economic evaluation estimates with varying degree of external validity 
relevant to the clinical situation of interest to a decision-maker. 
2.2.2 Issues of general isabil ity in economic evaluation 
In the economic evaluation of pharmaceuticals, the cost-effectiveness ratio maybe 
estimated based on patient-level clinical and economic data or estimated in a 
decision-analytic modelling technique in which the analyst synthesises cost and 
outcome data from multiple sources. (Weinstein and Fineberg 1980, Drummond 
and Stoddart 1984, Johnston et al 1999) The cost-effectiveness ratio is a collapsed 
measure of both cost and effectiveness, and is sensitive to variation in estimates of 
both resource use and clinical-effectiveness. There is limited empirical data on how 
this statistic responds to setting-specific variation, but an analysis by Willke et al. 
(1998) provided convincing evidence that differences in healthcare setting are 
important to the cost-effectiveness ratio. 
Because of its status as the gold standard for clinical evaluation, the randomised 
controlled trial is commonly considered the preferred methodology on which to base 
the effect estimate in economic evaluations, whether it is a patient-level data 
analysis or a model-based evaluation. (Drummond et al 1997, Gold et al 1996) 
Problems encountered when running an economic evaluation alongside a clinical 
trial are extensively documented. (Drummond and Stoddard 1984, Drummond and 
Davies 1991, Donaldson et al 1996, O'Brien 1996, Gray et al 1997, Fayers and 
Hand 1997, Coyle et al 1998) Discrepancy between the setting of randomised 
clinical trials and that of clinical practice is a common theme. Of particular 
importance to economic evaluation is the fact that care modified by the trial protocol 
may result in the recording of protocol-driven costs and subsequent reduced ability 
to present a realistic view of resource consequences or distinguish between 
treatment arms of a trial. (Mauskopf et al 1996) Inadequacies in the design of trials 
21 
by selective choice of comparator, exclusion of patients with certain characteristics 
and limited duration of follow-up may not only limit the generalisability of trials but 
indeed bias the results. (Freemantle and Maynard 1994) Furthermore, technical 
challenges for researchers undertaking trial-based economic evaluations include 
sample size and statistical evaluation of trial-based evaluations originating from 
statistical properties of the cost-effectiveness ratio. (Briggs 2000, O'Hagan and 
Stevens 2001) To overcome the limitations of the conventional randomised clinical 
trial for economic evaluation, economic evaluations may be based on pragmatic 
trials, modelling exercises or observational studies. 
Firstly, clinical management patterns in trials adopting pragmatic features may, to a 
lesser degree, be manipulated by the protocol so it is increasingly common to 
incorporate economic parameters alongside them. (Oster et al 1995, Simon et al 
1995, Simon et al 1996, Revicki and Frank 1999) The increased conduct of 
economic evaluations alongside randomised clinical trials of pharmaceuticals in 
several research centres and across more than one country has also offered 
progress to the generalisation of cost-effectiveness estimates. Differences in 
demography and epidemiology of disease, clinical practice and conventions, 
incentives and regulations for healthcare providers, relative price levels and 
consumer preferences are key components of the threat to general isabil ity of 
economic evaluations across countries. (O'Brien 1997) A pharmaceutical 
intervention can be cost effective in one country but not in another. In an evaluation 
of tirilazad mesylate for subarachnoid haemorrhage, Willke et al (1998) used a 
regression-based approach to the trial data and found that there were significant 
country-specific differences in total patient costs. The authors concluded that 
generalisation of trial-wide cost results to specific countries would be inappropriate. 
Unfortunately, one limitation of multi-centre studies is that they are rarely powered 
to detect centre-specific difference in treatment effect and costs, so only relatively 
large cost differences can be detected. The most common method of estimating 
treatment costs per patient is to take average or standard unit cost for each 
resource item of interest and apply this to all costs recorded. (Schulman et al. 1996) 
A less common approach is to use unit costs specific to each centre. (Glick et al. 
1998) Raikou et al (2000) showed in a simulation experiment that there is a 
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difference in the estimates gained from these two methods, and that a calculation 
based on average or standard unit costs would overestimate treatment costs. This 
poses a dilemma for the analysis of m ulti-centre cost-eff ectiveness studies. 
Generalisation according to Juni et al (2000) is reliant upon relevance to a specific 
setting, so results would need to be presented with unit costs relevant to each 
participating centre. The remaining question is whether individual centre-specific 
cost-effectiveness can be presented by assigning unit costs to the aggregate trial 
results or only to the patients in the relevant centre. 
Secondly, the model-based approach to economic evaluation can, potentially, 
evaluate the relative cost-effectiveness of therapies under a variety of 
circumstances and settings. A model may be based on inclusion of data from more 
than one clinical trial, incorporate the opinion of clinical experts, and make use of 
large longitudinal databases with patient-level information. The construct of a 
model enables testing of general isability by incorporating a range of model inputs 
reflective of different scenarios. Briggs and Gray (1999) proposed the sensitivity 
analysis as an appropriate stage in a modelling exercise for exploring uncertainty 
relating to location and population. External validity of an economic evaluation 
may, for example, be increased by the use of a pooled effect estimate from many 
clinical trials. (Pang et al 1999) 
Finally, there have been suggestions that observational data could be applied when 
generating information on resource consumption and treatment patterns in clinical 
practice. (Gold 1996, Drummond 1998, Sheldon 1996) One advantage of using 
clinical trials as a framework for economic evaluation is that they provide the 
opportunity to collect and analyse patient-specific resource use data, a feature also 
shared by most observational data. (Johnston et al 1999) More frequently, large 
observational databases are being used to assess clinical and cost-effectiveness of 
pharmaceuticals, particularly in the US, where these databases exist for the 
purposes of reimbursement. (Hornberger and Wrone 1997, Sacristan and Soto 
1994) Economic evaluation undertaken in an observational context dispenses with 
the need for a protocol for care, enabling recording of resource quantities as they 
would normally occur. Also, being less resource-consuming to run than clinical 
trials, observational studies may enable researchers to study larger patient 
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population over longer periods of time, measuring clinically relevant final endpoints 
rather than intermediate endpoints. (Drummond 1998) 
Effect estimates with observational data are not protected from bias, and the 
degree to which an estimate is biased is not knowable. (Davies and Crombie 1999) 
For data to be useful for clinical evaluation, the researcher must be able to make an 
attribution of causality between the pharmaceutical intervention and the observed 
outcomes. This hinges on appropriate study design, valid data recording and 
management and appropriate analysis to control for observed and unobserved 
confounding factors. The feasibility of any potential source of data for economic 
evaluation should be assessed prior to its undertaking. 
The methods outlined above can be applied to meet the current limitations to 
generalisability of clinical and economic evaluations, the underlying assumption 
being that decision-makers really do need this information. An overview of current 
guidelines for researchers undertaking economic evaluation may give an indication 
of the extent to which those regulating the conduct and submission of economic 
evidence pay attention to this issue. 
2.3 Economic evaluation guidelines and generalisability 
The first section of this chapter stated that clinical decision-makers include 
physicians, health care providing organisations and governments. Regulatory 
authorities, whose role frequently is to police the conduct of evaluations and the 
uptake of new medical technologies, are also an audience for economic evaluation 
evidence on health care interventions and their guidance may be influential on 
those conducting such analyses 
The primary focus of clinical trials conducted prior to marketing is meeting the 
requirements of license-granting bodies such as the FDA, EMEA or national 
regulatory agencies. There is no value-statement inherent in the licensing process 
concerning the use of a compound in clinical practice. Due to the breakdown of the 
price mechanism in the health care market, price or profit regulations have been 
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introduced in most countries to regulate the price paid by the government for 
pharmaceuticals. (Bloor et al 1996) Also, healthcare providers consider 
pharmaceutical reimbursement systems to be a crucial part of the healthcare 
provision. (Freemantle and Bloor 1996, Maynard and Bloor 1997) Decisions on 
price and reimbursement status of a pharmaceutical are separate from licensing. A 
challenge to the manufacturer is therefore to persuade a second set of regulators 
that their compound is worth reimbursement and a given unit price, and the 
submission of economic data to support these processes is a 'fourth hurdle' to 
market access. (Freemantle 1999) The uses of economic evaluation information of 
pharmaceutical therapies include price negotiations, reimbursement negotiations 
and prescribing decisions. (Johannesson 1995) 
The perspective of an economic evaluation, as well as the choice of patient- and 
context-specific data, may have relevance to the generalisabilty of an economic 
evaluation. The perspective of an economic evaluation determines which health 
outcomes and costs are relevant to the study. For example, a cost-effectiveness 
analysis (CEA) done from the societal perspective is comprehensive, counting the 
health effects and costs experienced by all those who are significantly affected by 
the intervention including the health service, employers, patients and carers. In 
comparison, a CEA done from the health services perspective would primarily count 
costs that are directly relevant to the care organisation and may omit costs and 
outcomes that are not of direct interest to the decision-maker. The appropriate 
perspective for economic evaluation is generally considered that of the society. 
The US panel on Cost- Effectiveness in Health and Medicine analysis advised that 
the societal perspective should be used in all such analyses. (Gold et al 1996) 
There is however a risk that a study that incorporates a range of resource use 
applicable to patients and society in one setting may have less scope for 
transferability to a setting in which patterns and costs of care vary profoundly. 
Recently, jurisdictions have introduced the right to formally require economic 
evaluation data for reimbursement decisions, most notably Australia, the province 
of Ontario in Canada and in the UK. (Commonwealth Department of Human 
Services and Health 2000, Canadian Co-ordinating Office for Health Technology 
Assessment 1997, National Institute for Clinical Excellence 2001) The need for 
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good quality data and comparable studies has resulted in the publication of 
guidance on the conduct of economic evaluations, but do these explicitly recognise 
the need for generalisability of study results? 
The Australian guidelines were introduced to aid submissions for new 
pharmaceuticals to be listed on the government's reimbursement list, the 
Pharmaceutical Benefits Scheme (PBS). The submissions are reviewed by the 
Pharmaceutical Benefits Advisory Committee (PBAC). (Hill et al 2000) The 
guidelines emphasise that "an explicit preference is given for randomised trials over 
non-randomised studies" for preliminary submissions. However, the guideline 
acknowledges the limitations of such studies by issuing a section on how to 
address these limitations through modelling. (Appendix J of the Guideline): 
The use of models include "To examine the impact of differences between 
subjects enrolled in the trials and patients who would be likely to obtain the 
drug on the PBS and between the settings of the trials and the community 
setting of the PBS in Australia. Both affect the generalisability of the trials to 
the PBS context. Important patient factors which may affect outcomes are 
identified in (c) of Appendix C. There may also be important differences in 
the mix of patients who will receive the drug on the PBS. Two concerns of 
the PBAC here are that there may be patients in the community who have 
disease which is less severe than that of subjects who participated in the 
randomised trials. There also may be patients in the community for whom 
the main comparator can be expected to perform better than in the trials. 
Both could diminish the difference in effectiveness between the proposed 
drug and main comparator and, therefore, increase the incremental cost- 
effectiveness ratio. Factors relating to the setting include extrapolating 
results of trials conducted in hospitals to use outside the hospital and the 
effect of more rigorous follow-up, which may swamp important differences in 
the convenience and acceptability of the drug compared with alternative 
treatments, with resulting effects on patient compliance and thence 
response to treatment. 
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The guideline also states that models may also be important to "modify resource 
use patterns measured in the trials to reflect more closely those in Australia (and/or 
to add likely changes in resource use patterns not measured in the trials). " 
The Canadian guidelines provide assistance for the conduct of studies 
accompanying applications reimbursement status on the province of Ontario's 
reimbursement formulary. (CCOHTA 1995) The Canadian Health Technology 
Assessment programme has assumed responsibility for the academic contents of 
the guideline. Guideline 11 of the document concerns "efficacy versus 
effectiveness" and states: 
'Ideally, pharmacoeconomic studies should report on drug effectiveness 
rather than efficacy. Because effectiveness data are generally not available, 
appropriate modelling techniques based on sound pharmacoepidemiology 
(e. g. using epidemiologic studies to estimate patient compliance with 
therapy in the real world) are permissible. All assumptions used in such 
extrapolation techniques must be stated explicitly and thoroughly tested in 
sensitivity analysis. " 
In this context, retrospective data represents "viable but not ideal alternative 
information sources", and the use of meta-analysis is advocated. For resource use, 
guideline 19 states: 
"In considering international trials it should be noted that resource quantities 
cannot be directly imported to the Canadian system, because of the major 
differences in the way that healthcare is delivered in many countries. As a 
minimum, resource quantities must be re-validated for Canadian practice. 
Some may, in fact, be transportable into Canada, but an explanation and 
justification is required. The default assumption is that resource quantities 
are not directly transportable. J" 
In the UK, the National Institute for Clinical Excellence was set up in 1999 to 
appraise clinical and economic evidence for pharmaceuticals assessed for wider 
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use on the National Health Service (NHS). (Hutton and Maynard 2000) Relating to 
gene ralisability of study results, the guidance document states that: 
"The settings, populations and methods by which outcomes and costs are 
measured in the original studies from which the data are drawn should be 
described and the implications of generalising the data to the NHS in 
England and Wales explained. " 
This brief review of the guidelines for Australia, Canada and the UK reveals that 
advice to those who conduct and review economic evaluations on generalisability is 
limited. This is summarised well in the Canadian guideline after a section outlining 
"portability of economic evaluations" (guideline 24): 
"There is no precise process which is recommended at the present time to 
adapt studies from one jurisdiction to another. It is the responsibility of the 
investigator to think carefully about the issues discussed above in the 
planning, interpretation and communication of study results; and it is the 
responsibility of the "user" to think diligently when using study results in the 
context of decision-making. " 
Philosophically, the guidelines support the use of 'effectiveness data' but in practice 
randomised clinical trial data are preferred. All the guidelines call for setting- 
specific information and at present modelling is predominantly the too] 
recommended to provide this. The dilemma faced by decision-makers is that many 
submitted economic evaluations will have been conducted at phase III in the stage 
of clinical development of the pharmaceutical compound, where clinical trials tend 
to be towards the explanatory end of the spectrum of external validity (see section 
2.2.1). In future, regulatory bodies such as NICE and the PBAC may require follow- 
up information on cost-effectiveness to retain a certain reimbursement status or 
guideline recommendation. To inform such decisions, researchers will need to be 
equipped with the appropriate tools for increasing the transferability of economic 
evaluation between clinical settings. Economic evaluation data relevant to the 
current setting needs to be at hand when therapy recommendations are made, so 
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an evaluation of the current methodologies available to increase external validity of 
studies is a research priority. 
2.4 Themes of the thesis 
Economic evaluation is a rigorous, comparative approach with strong links in 
welfare economic theory. A series of pragmatic compromises are made to balance 
quality and feasibility when economic evaluation is conducted to inform clinical 
decision-makers. Economic modelling and the adoption of pragmatic design 
features in clinical trials are both relevant current methodologies with potential for 
increasing general isabi I ity, and observational studies may help meet the need for 
locally applicable data. Against the backdrop of this literature, the need to assess 
the relative merits of these available methodologies that can be adopted by 
investigators to increase general isabi I ity of economic evaluations of 
pharmaceuticals emerged. 
Out of this multi-disciplinary review, a number of key themes emerge of particular 
relevance: 
o The use of pragmatic trials in economic evaluation and the impact of study 
design on effect estimate. (Revicki and Frank 1999, Simon et al 1995, 
Schulz et al 1995) 
The increasing of general isability through the use of economic modelling 
techniques. (Buxton et al 1997, Briggs and Gray 1999, Sculpher at al 2000) 
Applying lessons learned from observational study designs and medical 
statistics to expand economic evaluation methodologies to generalise 
findings. (Hennekens and Buring 1987, Hornberger and Wrone 1997, 
Drummond 1998) 
Each of these themes recur through the three source projects of the thesis which 
are reported in chapter 4 through 6, and in the concluding chapter of the thesis. 
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CHAPTER 3 
EFFECT SIZE IN PRAGMATIC TRIALS: STRIKING THE BALANCE 
BETWEEN INTERNAL AND EXTERNAL VALIDITY OF TRIALS IN 
SCHIZOPHRENIA AND POST-MI 
3.1 Introduction 
Clinical trials adopting a pragmatic design compare treatments under conditions 
in which they would be applied in clinical practice. (Schwarz and Lellouch 1967) 
Limited protocol modification of the treatment patterns enables the collection of 
resource use data reflective of regular practice. Pragmatic trials therefore 
provide a basis upon which economic evaluations may be conducted, and such 
trials are increasingly conducted to provide clinical decision-makers with data 
relevant to clinical practice setting. (Revicki and Frank 1999) 
Concerns have been raised that poorly designed and conducted trials, as well 
as studies with an observational design, may bias effect estimate. (Schulz et al 
1995, loannidis et al 2001) So it is of interest to examine the design features of 
pragmatic trials that distinguish them from conventional randomised controlled 
trials and evaluate whether increased external validity is achieved at the cost of 
internal validity. 
This chapter examines aspects of pragmatic trial methodology in more depth. 
Firstly, a framework that aims to assess features of pragmatism in randomised 
controlled trials is developed. Secondly, methods used to investigate the impact 
of trial quality on effect size are applied to a sample of trials with both pragmatic 
and explanatory features to investigate the impact of trial design on effect size. 
Finally, the results are discussed to determine the merits of pragmatic trials for 
provision of externally valid results without loss of internal validity, a finding that 
would support adoption of such trials for economic evaluation. 
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3.2 Background 
The basic function of clinical research is to compare the outcome of different 
treatments. Researchers may exercise a varying degree of control over the 
circumstances in which the comparison is undertaken, ranging from 'laboratory' 
to 'clinical practice' conditions. Schwartz and Lellouch (1967) proposed the 
terminology 'explanatory' and 'pragmatic' attitudes to randomised controlled 
trials (RCTs), respectively, to characterise the two extremes. For example, an 
explanatory attitude would be delivery of two treatment strategies under 
equalised conditions, while a pragmatic attitude would be delivery of two 
treatment strategies under conditions where the physician rather than the 
protocol determines the conditions. Furthermore, trials designed with 
explanatory attitudes may assess results by means of intermediate endpoints, 
such as regression of cancer tumour, or a functional disability such as pain 
levels. A pragmatic design would assess results by a measure of practical 
importance, such as mortality. Other design attitudes that Schwarz and 
Lellouch judged pragmatic include comparison with active substance rather than 
placebo, selection of a broad range of suitable patients rather than restrictive 
inclusion criteria, and analysis of patients according to the intervention to which 
they were assigned, regardless of whether they dropped out or swapped 
treatment during the course of the trial. The authors conclude that an 
explanatory comparison of treatments seeks to verify a biological hypothesis 
and understand the differences between two treatments, whereas a pragmatic 
comparison seeks to inform a treatment decision on the basis of "which of the 
two treatments should we prefer? " 
Explanatory RCTs run the risk of providing a low external validity to general 
clinical practice because of subject and centre exclusions, non-participation and 
blinding of the study participants to the treatment allocation inherent in the trial 
protocol. Clinical decision-makers face heterogeneous populations and 
conditions that may differ from those in a RCT setting, so adopting pragmatic 
study design features, such as expanding the inclusion criteria, applying a 
multicentre design and encouraging practitioners to invite all eligible patients, 
provide solutions to this problem. Also, avoiding the blinding of the participants 
and leaving some control of the therapeutic regimen to the clinician and the 
patient would reflect the circumstances under which a drug will be used in 
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clinical practice. (Freemantle and Drummond 1997) 
Evaluation of an intervention in a naturalistic setting enables collection of 
resource data that reflects a clinical practice pattern. Pragmatic trials provide 
particularly good basis for economic evaluation of resource consumption as well 
as clinical outcomes. (Revicki and Franck 1999) For example, Simon et al 
(1996) evaluated effectiveness and cost of two treatment strategies in 
depression, fluoxetine versus tricyclic antidepressants, using an RCT in which 
inclusion criteria were broad, management of care was determined by the 
physicians, neither patients nor physicians were blinded, and the data were 
analysed according to original treatment allocation. Similarly, Oster et al (1995) 
analysed costs and effectiveness of cholesterol-lowering drugs in the CRIS trial, 
which applied wide inclusion criteria, minimised intervention by leaving 
management decisions to the physician and measured number of 'successfully 
treated patients', i. e. patients that achieved blood cholesterol below a certain 
guideline threshold, by intention to treat analysis. 
Pragmatic trials relax many design features to increase external validity, but 
maintain the element of randomisation. The process of randomly allocating 
treatment to patient groups is a key trial design feature aiming to maximise trial 
validity, and randomisation is incorporated in checklists evaluating clinical trial 
quality. (Chalmers et al 1981, Coldiz et al 1989, Moher et al 1996, Moher et al 
2001) Several research teams have sought empirical evidence of the impact of 
randomisation on effect size in clinical research, but findings are inconclusive 
(see section 2.2.1). (Concato et al 2000, loannidis et al 2001) Similarly, 
researchers have suggested that randomised clinical trials where quality is 
'poor' according to key criteria may bias effect estimates. Schulz et al (1995) 
analysed the methodological quality of 250 controlled trials from 33 meta- 
analyses and found a 30% larger effect size where treatment allocation was not 
appropriately concealed. Moher et al (1998) analysed 127 trials from 11 meta- 
analyses and found a 37% larger estimate of benefit in trials that used 
inadequate allocation concealment. 
As we have seen, pragmatic trials randomise patients, but adopt design 
features that make them more reflective of clinical practice. Is there a risk that 
trials that are 'contaminated by reality' may bias effect estimates? If this is the 
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case, then increased external validity would be achieved at the cost of low 
internal validity of such studies. There is little empirical evidence that pragmatic 
design features influence the estimate of effect. In the analysis reported in this 
chapter the design features of pragmatic trials were examined, which 
distinguish them from explanatory randomised controlled trials. First, a 
checklist of design features characteristic of a pragmatic trial was developed 
and applied to 318 trials included in 19 meta-analyses in two therapeutic areas. 
Generalised linear models were fitted to systematically assess whether design 
features that characterise pragmatic trials impact their outcome. The methods 
used were derived form those employed by Schulz et al (1995) and 
subsequently by Moher et al (1998), amongst others. 
3.3 Objectives 
The objectives of this project were: 
o To identify and describe pragmatic design features that trial investigators 
may adopt to increase external validity of a randomised clinical trial. 
To assess whether pragmatic design features alone, or in any 
combination, provide effect estimates systematically different from those 
provided by explanatory design features. 
3.4 Methods 
3.4.1 Development of a checklist of pragmatic design features 
Authors have frequently used a dichotomised trial definition of 'explanatory' 
versus 'pragmatic trials' (Roland and Torgerson 1998, Revicki and Frank 1999) 
in spite of the fact that Schwartz and Lellouch (1967) concluded their original 
work with " most real problems contain both explanatory and pragmatic 
elements". The original authors therefore view pragmatism on a continuum, 
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where, to a varying extent, trials adopt design features that make them more or 
less reflective of clinical practice. 
A checklist was derived for the purpose of this review, to identify pragmatic 
design features in clinical trials, the criteria for which were developed based on 
literature describing attributes of pragmatic trials in different therapy areas. The 
checklist aimed to be generic and covered different dimensions of trial design, 
such as description, inclusion criteria, treatment, assessment and analysis. 
Design features that were considered, a priori, the most important components 
of a pragmatic trial are listed in Table 3.1, which comprises the checklist. 
Trial description 
Pragmatic trials are often designed as long term trials to enable measurement 
of final clinical endpoints. In this analysis, trials of 12 or more months duration 
were characterised as long-term. Large trials may be considered pragmatic as 
these have a higher potential to include a range of patients. The size of 300 
was chosen as a cut-off for the purpose of the analysis. The sensitivity of the 
analysis to a cut-off of the median, 200,400,500 and 1000 patients was also 
assessed. Resource consumption data are sometimes collected alongside 
pragmatic trials, so the recording and subsequent costing of outcomes such as 
hospitalisations and concomitant drug use were classified as a pragmatic 
feature. 
Since human behaviour is influenced by what is known or believed, knowledge 
of the treatment regimen may affect patient or physician behaviour and 
assessment of treatment outcome. In order to reduce such bias, patients and 
physicians are frequently blinded to treatment allocation in clinical trials, (Day 
and Altman 2000) but in clinical practice, neither patients nor physicians are 
ignorant of the administered treatment, so pragmatic trials evaluating treatment 
in real-world settings are sometimes conducted unblinded (open). (Freemantle 
and Drummond 1997, Buxton et al. 1997) 
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Inclusion criteria 
Explanatory trials may include selected patients with a greater capacity to 
benefit from treatment, and elderly patients may frequently be excluded from 
clinical trials. (Wenger 1992) It is difficult to make an age cut-off a generic 
measure, as patient groups targeted by different treatments vary. This analysis 
used patients over 70 years old as a cut-off point. Explanatory trials are often 
conducted in specialist settings under expert care, for example in hospital. 
Trials that are undertaken in regular clinical practice would include outpatients, 
thereby increasing the external validity of the sample, so the inclusion of 
outpatients was considered a pragmatic trial feature. Also, multi-centre trials 
are more likely to reflect a diversity of treatment provision, resulting in higher 
external validity. Multi-centre design was therefore classified as a pragmatic 
feature. 
Treatment 
Regulatory requirements for trials designed to demonstrate the efficacy of an 
intervention include comparison to inert substance, or placebo. In clinical 
practice, however, the treating physician is faced with a choice of no therapy or 
an alternative treatment strategy. Trials aiming to increase external validity of 
an evaluation may compare the intervention under study with an active 
substance, such as that considered the most frequently used in the relevant 
clinical setting. (Buxton et al 1997) Monitoring of patient compliance is often 
incorporated in the trial protocol of randomised clinical trials and may include 
interview during frequent physician visits, serum level measurements or pill- 
counts. To increase external validity, a reduction in such intervention may be 
made in order to reflect a clinical practice setting, (Buxton et al. 1997) and 
minimal monitoring of compliance was considered a pragmatic design feature in 
this analysis. 
Analysis 
'Intention to treat' is an analytical strategy used in RCTs comparing patients in 
the groups to which they were originally assigned, regardless of whether they 
did not receive treatment, stopped taking medication or changed treatment 
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during the course of the trial. A trial adopting 'intention to treat' analysis 
evaluates the strategy of one treatment compared with another, rather than the 
outcome of an isolated intervention and is considered a pragmatic trial feature. 
(Schwarz and Lellouch, 1967) This design principle was first deemed 
'pragmatic' by Schwarz and Lellouch and since then has become a common 
feature of trial methodology seeking an unbiased solution to treatment switching 
or attrition (patients in a control group ultimately receiving treatment intended for 
the intervention group) or where patients do not actually receive the treatment 
intended. Hollis and Campbell (1999) found that there is no single definition of 
an intention to treat analysis and that the approach is often both inadequately 
described and applied. An in-depth investigation of the quality of the intention 
to treat analysis was beyond the scope of this study. Therefore, trials that 
explicitly reported the use of intention to treat analysis were recorded as having 
adopted this pragmatic design feature. 
Table 3.1 A checklist of characteristics of a pragmatic design. 
Trial design aspect Pragmatic design feature Score 
Trial description The trial is a long term trial (> 12 months) (Y/N) 
The trial is large (ý! 300) (Y/N) 
Trial presents resource consumption data (Y/N) 
Trial is single blind or open (Y/N) 
Inclusion criteria Patients over 70 are included (Y/N) 
Trial included outpatients (Y/N) 
The trial is multi-centre (Y/N) 
Treatment Comparator is active substance (Y/N) 
Patient adherence is not monitored (Y/N) 
Analysis Intention to treat analysis was used (Y/N) 
3.4.2 Material 
The checklist in table 3.1 was applied to 318 randomised controlled trials 
identified in two systematic reviews in two therapy areas (Table 3.2). These 
were published as Clinical Practice Guidelines in the therapy areas of 
schizophrenia and secondary prevention of myocardial infarction. (Geddes et al. 
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2000, Eccles et al 1998, Data on File) Identification of trials for inclusion in 
these reviews followed systematic reviewing methodology, searching the 
electronic databases MEDLINE, EMBASE, SIGLE and the Cochrane Controlled 
Trial Register as well as the grey literature for unpublished trials. Trials were 
included in the reviews if either published or unpublished by December 1 s' 1998. 
These systematic reviews conducted meta-analyses at the level of therapy, for 
each therapy considered. Table 3.3 provides an overview of the therapies 
included, all of which were reviewed by the North of England Clinical Practice 
Guideline Projects. The majority of the studies evaluated pharmaceutical 
interventions, although diet and cardiac rehabilitation were also included. A full 
reference list to all trials included in the review is provided in appendix 1. 
Table 3.2 Contents of the systematic reviews 
Therapeutic area Meta-analyses Trials Patients 
Schizophrenia 7 52 12649 
Post - MI 12 266 248717 
Total 19 318 261366 
Table 3.3 Meta-analyses included in the therapy areas. 
Scizophrenia Amisulpride, Clozapine, Olanzapine, Quetiapine, 
Risperidone, Sertindole, and Alternative atypical 
antipsychotic drugs 
Post-Ml Cholesterol lowering statins, Beta-blockers (short term), 
Beta-blockers (long term), Beta-blockers (+conventional), 
ACE inhibitors (Unselected patients), ACE inhibitors 
(Selected patients), Calcium channel blocker (Myocardial 
infarction), Calcium channel blocker (Heart failure), Nitrates, 
Dietary measures, and Antiplatelet agents 
Some information that was of interest to this analysis had already been 
extracted for the original guideline reports (Table 3.4). 
A key aspect of trial quality is concealment of treatment allocation. (Schulz et al 
1995, Moher et al 1998) The strength of the randomisation relies on the degree 
to which the procedure conceals the allocation sequence and therefore prevents 
participants in the trial from including patients on the basis of the treatment next 
in the sequence. (Altman and Schulz 2001) This quality feature was included in 
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the analysis in order to analyse the impact of allocation concealment on a 
different subset of trials from those evaluated by the previous authors. Data 
extraction for the two original reviews involved double checking and discussion 
between two independent assessors to resolve disagreements. A separate 
extraction of these data for the current analysis would have duplicated research 
effort without any significant contribution to precision, so was not undertaken. 
Primary endpoint differed between the trials in the review. Primary outcomes 
from the post-Ml trials included neuroendocrine activity, blood pressure, heart 
rate and mortality. The trials in schizophrenia recorded a range of outcomes, 
including the disease-specific scores to measure psychopathology and 
schizophrenic symptoms (Brief Psychiatric Rating Scale [BPRS] and the 
Positive and Negative Syndrome Scale [PANSS]). Binary events of mortality in 
trials in MI and drop-out in trials in schizophrenia were chosen for the purpose 
of this analysis, and since both outcomes are undesirable in their respective 
therapy area, effect of treatment would aim to reduce the incidence of each 
(table 3.4). 
Table 3.4 Data extracted in the existing systematic reviews of trials in post- 
MI and Schizophrenia. 
Extracted information 
Authorship details 
Variable 
Author / Research group and year 
Comparisons Intervention drug and control drug 
Double-blind Y/N 
Allocation was reported to be concealed Y/N 
Number of patients in trial n 
Loss to follow-up % 
Follow up (duration) Year 
Events (mortality or drop out) n 
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3.4.3 Statistical analysis 
Microsoft Excel was used for data management. The trials were retrieved and 
data extracted according to the checklist in Table 3.1 and the information in 
Table 3.4. The Excel file was then transformed into a SAS statistical system file 
and SAS v8 was used for modelling. Generalised linear modelling is adopted in 
this chapter. (McCullagh and Nelder 1989) 
Definition of outcome 
All cause mortality was available from all of the trials in post-MI, as were 
dropout rates from all trials in schizophrenia. The Odds Ratio (OR) of effect 
was based on these two binary trial outcomes and used as outcome in the 
statistical analysis. Effect estimates are calculated on the basis of prevention of 
an adverse outcome (a reduction of events). The greater the reduction in 
events as a result of treatment in a trial the larger the treatment effect estimated 
by that trial. The summary OR in all trials was calculated and an OR of less 
than 1.0 indicated that treatment intervention was more effective than the 
controls overall. 
Interaction terms between each pragmatic trial feature and treatment were then 
fitted. Results of the analyses are reported in terms of a ratio of ORs (ROR). 
By the modelling convention adopted here, explanatory trial features are the 
reference case. A ROR of less than 1.0 for an interaction term indicates that 
trials adopting pragmatic features yielded larger estimates of treatment effect, 
on average, than the reference group of trials adopting the corresponding 
explanatory feature. Conversely, a ROR greater than 1.0 for an interaction term 
indicates that pragmatic trial features yielded a smaller estimate of treatment 
effect than explanatory trials. By way of illustration, trials that adopted one 
particular pragmatic feature on average estimated an effect size of 0.9, and 
trials that adopted the corresponding explanatory design feature on average 
estimated an effect size of 0.8 (i. e. reduction of odds of events by 10% and 20% 
respectively). The RORs would be 0.9/0.8 = 1.125, indicating that the ORs in 
the pragmatic trials are on average 12.5% higher than that in the explanatory 
trials. Since treatment effect is defined as reduction in the odds of an event, 
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this estimates a 12.5% smaller effect size in the trials adopting the pragmatic 
feature. 
Fitting models 
The specific methods used for this project were derived from those first 
developed by Schulz et al (1995) and subsequently used by Moher et al (1998). 
The general approach to model development was described by McCullagh and 
Nelder (1989). Generalised linear models with logit link and binomial error were 
fitted to assess whether the trials applying one or more of the design features in 
Table 3.1 differ systematically from those that do not in predicting power of the 
ratio of OR (ROR) as estimated in the meta-analyses. (See section 5.1.1 of this 
thesis for an outline of generalised linear modelling. ) The models were fitted 
using PROC GENMOD. They included specified hierarchical factors reflecting 
the structure of the data, where a trial feature is shared by trials included in 
different meta-analyses in different therapy areas, so take into account the 
measurement variability within each level (analogous to multilevel models). 
These models accounted for the effect of treatment, trial, meta-analysis and 
clinical area (post MI or schizophrenia) by the fitting of appropriate classification 
variables. 
The interaction effects between treatment and each factor indicating pragmatic 
design feature were of primary interest. The main effects of all the indicators of 
pragmatism were explored in conjunction with the interaction with treatment and 
factors significant at conventional statistical level p<0.05 were then combined 
in a model. Interaction effects between significant variables were also explored. 
The combination of factors that provided the lowest residual deviation was 
selected for the final model. 
Overdispersion 
Odds ratios (OR) are themselves estimates and subject to measurement error. 
The estimates generated from trials conducted in selected cohorts will reflect 
the distribution of the underlying treatment effect in the whole population with 
the condition. There is reason to believe that such data will be overdispersed 
(i. e. have extra-binomial variability) and the final model will be a poor fit. Model 
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fit can be assessed by investigating the value of the scale factor (standard 
deviance divided by residual degrees of freedom on the appropriate strata). If 
this is close to 1 the model fits well, however if the value is high then 
overclispersion should be addressed. PROC GENMOD does not enable fitting 
of random effects models and therefore this analysis accounted for extra 
binomial variability (overdispersion) by inflating the scale parameter by the 
mean residual deviance on the appropriate stratum. (McCullagh & Nelder 1989) 
3.5 Results 
Eighty-two (25.9%) trials were long term trials of more than 12 months duration. 
Resource consumption was reported in 23 (7.1 %) trials (table 3.5). Eighty-nine 
(28%) trials were single blind or open trials. Patient adherence was not 
reported monitored in as much as 66.3% of the trials. About two thirds of the 
trials included outpatients in primary care. 
Table 3.5 Characteristics of trials (total number of trials 318) 
Design feature 
The trial is a long term trial (> 12 months) (Y/N) 
Trials (%) with pragmatic 
feature 
82(25.9) 
The trial is larcie (ý! 300) (Y/N) 100(31.4) 
Trial presents resource consumption data (Y/N) 23(7.1) 
Trial is single blind or open (Y/N) 88(27.8) 
Patients over 70 are included (Y/N) 99(31.1) 
Trial included outpatients (Y/N) 219(64.1) 
The trial is multi-centre (Y/N) 97(30.4) 
Comparator is active substance (Y/N) 147(46.3) 
Patient adherence is not monitored (Y/N) 211 (66.3) 
Intention to treat analysis reported (Y/N) 90(28.2) 
Allocation was NOT concealed or unclear (Y/N) 267(84.1) 
Overall, treatment was associated with a 13% reduction in the odds of an event 
versus controls (summary Odds Ratio = 0.87,95% Cl = 0.82 to 0.93, 
p<0.0001). In other words, mortality / drop-out was on average 13% lower in 
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the treatment arms of the trials, estimating an overall treatment effect of 13%. 
The relationship between treatment and events may be different for trials in 
schizophrenia and post-MI, and this was explored by examining the value of the 
interaction between treatment and therapy area. The ROR for trials in the area 
of post-Ml compared to those in schizophrenia was 0.55 (0.41 to 0.73, 
p<0.0001), that is, trials in post-MI predicted on average 45% larger effect size 
than trials in schizophrenia. 
The associations between pragmatic design features and treatment effect were 
then explored individually for each pragmatic feature (Table 3.6). All models 
accounted for the effect of treatment, trials, therapeutic area, meta-analysis and 
the interaction effect between treatment and therapy area. Extra-binomial 
variation was accounted for by inflating the standard error by the root of the 
scale factor. 
The effects estimate in those trials that applied pragmatic design features 
including multi-centre design, collection of resource data and inclusion of 
patients aged over 70 did not vary more than would be expected by chance. 
Trials with a sample size of over 300 patients, were single blind or open, or 
included outpatients, appeared to bias the effect estimates (Table 3.6). Large 
trials (>300) provided, on average, an effect estimate 80% smaller than small 
trials (ROR = 1.80). In order to assess the sensitivity of the analysis to the 
choice of trial size as cut-off point, the sizes 200,400 and 1000 were explored. 
For cut-off size of 200, the ROR was 1.54 (1.55 to 1.22, p=0.003), for cut-off 
size of 400 it was 1.44 (1.18 to 1.46, p= 0.0003), and for cut-off size of 1000 it 
was 1.58 (1.33 to 1.88, p< 0.0001). The analysis of large trials was not 
sensitive to change in trial size outside of the range 200 - 1000 patients. 
Trials that included outpatients provided an effect estimate 24% larger than 
trials that only included inpatients. Trials that were single-blind or open 
provided an effect estimate that was 23% smaller than trials that were double- 
blind. Trials that reported to have used intention-to-treat analysis provided more 
conservative effect estimates, with a 19% lower effect estimate than those 
applying alternative statistical analyses. Those trials that did not report an 
adequate concealment of allocation reported 15% higher effect estimates. 
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Table 3.6. Association between indicators of individual pragmatic trial 
features and estimates of treatment effect. Ratio of odds ratio for 
the interaction effects of the trial design features with treatment. 
Pragmatic design feature 
The trial is a long term trial (> 12 months) 
ROR (95% Cl) 
0.65 (0-38 to 1- 12) 
P- value 
0.12 
The trial is large (ý! 300)* 1.80 (1.47 to 2.21) <0.0001 
Trial presents resource consumption data 1.02 (0.89 to 1.17) 0.78 
Trial is single blind or open* 1.23 (1.08 to 1.40) 0.002 
Patients over 70 are included 1.08 (0.93 to 1.24) 0.31 
Trial included outpatients* 0.76 (0.66 to 0.88) 0.0002 
The trial is multi-centre 1.09 (0.90 to 1.31) 0.39 
Comparator is active substance 0.97 (0.83 to 1.15) 0.75 
Patient adherence is not monitored 1.06 (0.93 to 1.20) 0.39 
Intention to treat analysis was reported* 1.19 (1.02 to 1.38) 0.03 
Concealment of allocation not reported* 0.85 (0.75 to 0.97) 0.017, 
* significant at conventional 0.05 level 
The interaction between trial size and double-blinding was of interest to the 
analysis (Table 3.7). The interaction term was fitted by adding new variables to 
the model that were the product of treatment and size, of treatment and double- 
blinding and of treatment, double-blinding and size. Twenty trials were large 
single-blinded or open trials. The RORs for these trials compared was 0.46 
(0.31 to 0.69, p<0.0001), which meant that the odds ratios in the large open 
trials were, on average, 54% smaller than in small open trials and large double- 
blind trials. The large open trials therefore estimated 54% larger treatment 
effects. The interaction effect between trial size and blinding status varied 
across the four possible interactions (Table 3.8). 
There was no interaction effect between trial size and the inclusion of 
outpatients (ROR = 0.99 (0.64 to 1.55), p=0.97). Neither was there an 
interaction effect between open-trial design and the inclusion of outpatients. 
(ROR = 0.90 (0.62 to 1.31), p=0.57). 
Those pragmatic trial features with a significant interaction effect with treatment 
were included in the final model, along with the relevant significant second-order 
interactions. The trial features of intention-to-treat analysis and treatment 
allocation not concealed did not bias effect estimates when included with the 
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other significant variables (Table 3.9). The final model included therapy area 
interaction with treatment, outpatient interaction with treatment, large-trial 
interaction with treatment, open-trial interaction with treatment and the second- 
order interaction between treatment, open-trial and large-trial (Table 3.10). 
Table 3.7 Interaction effect between blinding and size* 
*In the presence of interaction treatment and therapy area, ROR = 0.41 (0.31 - 0.54) 
P<0.0001 
Table 3.8 Interaction effect between different attributes of blinding and trial size 
Table 3.9 Model of all variables that individually biased effect estimate in 
randomised controlled trials 
Design feature 
The trial is post-MI 
ROR (95% C11) 
0.39 (0.29 to 0.52) 
p-vallue 
<0.0001 
Intention to treat analysis was reported 0.90 (0.74 to 1.09) 0.27 
Concealment of allocation not reported 0.91 (0.79 to 1.06) 0.24 
Trial included outpatients 0.78(0.65 to 0.94) 0.008 
The trial is large (-,: --300) 2.37 (1.82 to 3.10) <0.0001 
Trial is single blind or open 2.40 (1.64 to 3.52) <0.0001 
Interaction open / size 0.39 (0.26 to 0.60) <0.0001 
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Table3.10 Final model of pragmatic design features that in combination 
biased effect estimate in randomised controlled trials 
Design feature 
The trial is post-Ml 
ROR (95% C11) 
0.38 (0.28 to 0.50) 
p-value 
<0.0001 
Trial included outpatients 0.80 (0.67 to 0.96) 0.015 
The trial is large (ý! 300) 2.35 (1.82 to 3.04) <0.0001 
Trial is single blind or open 2.42 (1.65 to 3.54) <0.0001 rInteraction 
open / size 0.40 (0.26 to 0.60) <0.0001 
3.6 Discussion 
Pragmatic trials provide a method for clinical experiment reflecting clinical 
practice setting. They have been viewed as good vehicles for economic 
evaluations that seek to evaluate cost-effectiveness in clinical practice for a 
number of reasons, including their ability to provide resource-consumption data 
reflective of regular treatment pattern. (Revicki and Frank 1999) The question 
of clinical trial quality and design continues to be one of great importance to 
clinical medicine. Empirical research has provided inconclusive evidence as to 
whether non-randomised, observational studies provide biased effect estimates. 
The risk of pragmatic trials being 'contaminated by reality' (Freemantle and 
Drummond 1997) and so effecting this same bias was examined in this project. 
Methods and main findings 
Schultz et al (1995) developed the methodology to investigate the impact of trial 
quality on effect estimate using multiple regression models. This was replicated 
to explore the impact of 'pragmatic' design features on effect size relative to the 
corresponding 'explanatory' design features. The difference in odds ratios 
estimated by each design was expressed through the ratio of odds ratio (ROR), 
which expresses a difference in relative odds of effect rather than absolute odds 
of effect. The analysis approach adopted here proved valid in previous 
analyses, accounting for confounding by therapy area by including the 
interaction term between treatment and area. It also went some way towards 
controlling for overdispersion by inflating by the scale factor. 
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Schultz et al (1995) explored the impact of quality features such as 
concealment of allocation and double-blinding and found that trials that did not 
adequately conceal treatment allocation provided effect estimates on average 
30% larger than trials where treatment allocation was concealed. This finding 
was confirmed by Moher et al (1998), who found that inadequate allocation 
concealment was associated with an increased estimate of benefit of 37% 
compared with trials that used adequate methods. In addition, Schulz et al. 
found that trials that were not double-blind exaggerated effect size by an 
average of 17% compared with trials that were double-blind. 
The analysis presented in this chapter used a similar multiple regression 
analysis approach to study the impact of pragmatic design feature on effect 
size. The only features that overlapped Schulz et al's study was open trial 
design and lack of concealment of allocation. Results indicated that single-blind 
or open trials reduced the effect estimate by 23% in contrast to the findings of 
Schulz et al, but in line with their findings, lack of adequate reporting of 
allocation concealment exaggerated effect size significantly by 15%. This effect 
did however disappear in the presence of the interaction effect between study 
size and blinding. This may indicate that study blinding confounds the quality 
indicator variable of concealment of allocation: an open study does not need to 
conceal allocation. 
Other features of interest to this analysis were primarily related to level of 
pragmatism in trials. The majority of pragmatic design features did not produce 
effect estimates systematically different from the corresponding 'explanatory' 
feature. Long-term and multi-centre trials, trials where an active substance was 
used as a comparator, or where patient adherence was not monitored failed to 
provide systematically different effect sizes from those adopting the 
corresponding 'explanatory' design feature. This analysis does therefore not 
provide disincentives to those wishing to relax such trial features to achieve an 
environment for the experiment more reflective of clinical practice. 
Trial size (>300), inclusion of outpatients and the reporting of intention-to-treat 
analysis were all features that didproduce different effect estimates. Trials that 
included more than 300 patients in total averaged an effect estimate that was 
less than half that of trials of total size below 300. A possible explanation for 
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this may be that trials including more than 300 patient will usually require the 
contribution of a large number of centres. This might impact upon the level of 
organisation required (which may itself reduce bias) and dilute the effect of 
& enthusiastic' centres that may provide large estimates unrepresentative of 
treatment effect. In contrast, those large trials that were single-blind or open- 
label trials reported an average treatment effect that was exaggerated by 60%. 
Conversely, in the small, double-blind trials included in the analyses, there was 
an average relative reduction in the odds of an event of 60%, and these trials 
exaggerated effect size by 60%. Is this empirical evidence of publication bias, 
indicating that small trials have a higher likelihood of being published if they are 
positive rather than neutral or negative to the intervention? The results of this 
analysis are in line with work by loannidis et al (1998), who identified that 
smaller trials may provide more optimistic effect estimates than large trials. 
Trials that included outpatients estimated effect size of 20% larger than those 
that only included inpatients (hospitalised patients). Patients living in the 
community may be less severely ill than those that are hospitalised, so the 
inclusion of outpatients that may have a greater potential to benefit from 
treatment could result in more optimistic results for these trials. In contrast, the 
use of intention-to-treat analysis may provide more conservative estimates of 
effect, since by definition this analysis includes all randomised cases in the final 
analysis, regardless of whether the patients swapped treatment, were lost to 
follow-up or dropped out completely. The adoption of intention-to-treat analysis 
was based on whether the trial reports had claimed the use of the analysis, 
rather than through scrutiny of the methods. Schulz et al (1995) excluded the 
aspect of intention-to-treat analysis from their trial assessment because of lack 
of inter-assessor reproducability on this variable. Indeed, Hollis and Campbell 
(1999) found that only 55% of trials that stated that they use intention-to-treat 
analysis in fact analyse the data according to treatment allocated during 
randomisation. This may have introduced a bias to the analysis, as the analysis 
is evaluating reporting rather than actual analysis. It is however difficult to 
assess the direction in which this potential bias would have influenced the 
results. 
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A checklist of pragmatism 
A series of decisions taken by the trial investigators place the trial somewhere 
on the continuum between the ideal type explanatory and the ideal type 
pragmatic trial. The features on the checklist enabled scoring according to 
criteria determined 'pragmatic' or 'explanatory'. The underlying view conveyed 
here is that trials may adopt one or more of these design features and therefore 
achieve a varying degree of pragmatism. 
Is the devised checklist appropriate for assessing pragmatism in other clinical 
trials? The checklist was generic and could be used to score trials according to 
pragmatism, but there were a number of difficulties in scoring the trials this way. 
For example, the judgement of many features is limited by the information 
provided in published trials. Even though the adoption of a certain feature, say 
monitoring of patient compliance, is not reported, it may well be a characteristic 
of a trial. Lack of reporting of such features would have confounded the 
analysis. 
Furthermore, what is considered a large trial may vary by therapeutic area and 
indeed by the frequency of the outcome being measured and the resulting 
power to detect differences at conventional levels of certainty. For example, a 
trial of size 300 with a dichotomous outcome of 1% may be a small trial, 
whereas a trial with a sample size of 300 with an outcome of, say, 40% may be 
considered a large trial. 
There is no absolute definition of what constitutes a large trial, and separating 
small trials from large is not straightforward. The initial intent was to use the 
median as the cut-off, but this was strongly influenced by the large number of 
very small studies in the cardiovascular area. Cappelleri (1996) used a rule 
based on sample size of more than 1000 patients qualifying as a large trial. As 
a pragmatic decision the size 300 was determined as the cut-off in this analysis. 
Sensitivity analysis suggested that the association between size of trial and 
average effect size was not dependent upon the definition small above a trial 
size of 200, and this may be because of the large number of small trials (<1 50 
patients) in the post-MI meta-analyses. 
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Pragmatic trials may adopt other features that were not considered feasible or 
appropriate to include in this review. For example, pragmatic trials may assess 
the impact of treatment on a relevant choice of final endpoint, while explanatory 
trials often use intermediate endpoints. It was not possible to define a generic 
pragmatic outcome for clinical trials other than mortality, and mortality is not a 
final outcome of direct relevance in therapy areas such as mental health. Also, 
pragmatic trials frequently aim to include patients that are representative of the 
population that will use the medication when it reaches general clinical practice. 
Characteristics such as severity of disease, gender distribution of the patient 
sample and age distribution are examples of characteristics that may determine 
the degree of transferability of trial results between populations. Mortality from 
cardiovascular disease does, for example, differ between men and women and 
in different age groups. Similarly, the inclusion of remittent patients in trials in 
schizophrenia may impact the potential of the sample to demonstrate benefit 
from the treatment, as such patients are likely to be treatment resistant. It was 
difficult to develop generic indicators of pragmatism based on these, so they 
were not included in the checklist. 
Similarly, explanatory trials frequently fix the dose of the drug under 
assessment or titrate and adjust the dose up to a fixed level. Pragmatic trials 
may leave decision of dose to the treating physician, allowing a flexible dose 
range. This was a difficult distinction to make, so the adoption of a flexible dose 
range was not included in the analysis of pragmatism. 
Limitations of the study 
This analysis was based on a large number of trials and patients from 
comprehensive literature reviews in two therapy areas, and included more trials 
than previous authors (318 vs 250 in Schulz et al 1996). However, the study 
has limitations. Key features that may have introduced bias include the 
selection of trials and subset of meta-analyses, the choice of binary outcome 
and the fact that data extraction was undertaken by one researcher only for the 
purpose of consistency. Firstly, only trials in one therapeutic area were 
selected, and these had already undergone a 'quality-check'for inclusion in the 
meta-anaiyses of the clinical guideline. This may have excluded some relevant 
trials. Secondly, post-Ml trials constitute the vast majority of the trials included 
in this analysis. A powerful area-effect was detected in terms of effect size, in 
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that trials in Post-Ml on average predicted 45% larger effect size. The outcome 
of mortality recorded in post-Ml trials is objective, but drop out-rate in trials in 
schizophrenia may not be objective, as the definition of 'drop out' may vary 
between trials. The choice of outcome for the analysis may have introduced a 
confounding by area. Finally, decision on several of the pragmatic design 
features included a judgement on the part of the researcher. For example, 
some trials did not explicitly state that outpatients were included, and judgement 
of anecdotal information in the trial reports had to be made. 
Because of these limitations, the findings may not automatically be extrapolated 
to other therapeutic areas, or to other trials adopting pragmatic features. 
3.7 Conclusions and recommendations 
Some of the results provided in this report were consistent with previous 
findings, such as the lack of concealment of allocation may bias trial results. 
However, this effect disappeared in the presence of open-label and large trials, 
as the latter are more predictive of treatment effect. Evaluation identified a 
tendency for small double-blind trials to systematically provide more optimistic 
estimate of effectiveness. It would not be a rational response to the data 
presented here to abandon meta-analyses of small trials because of the risk of 
publication bias, or the use of small trials in economic evaluation. But where 
only small trials are available for meta-analysis and economic evaluations, some 
caution should be exercised in the interpretation of the results. Meta-analysis of 
small trials may not be considered sufficient for health policy, although it may 
provide very useful data to support design of future large-scale randomised 
trials to evaluate clinical outcomes and resource consumption. The decision to 
apply the results of meta-analysis of small-scale clinical trials to individual 
patients is more difficult. Patients, particularly those with life threatening 
conditions, may only have a single opportunity to benefit from treatment, and 
meta-analysis of small trials may still provide the best available estimate of 
treatment effect compared with the alternatives. 
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The literature does not present any similar analysis to this and judgement of 
generalisability of findings to other therapy areas is difficult. These results 
cannot be directly attributed to the treatment areas in the meta-analyses, as this 
was accounted for through the area treatment interaction. However, other 
therapy areas may have other traditions for trial design and conduct. For 
example, small trials may be over-represented in the cardiovascular area, and 
may provide different associations between design features and effect 
estimates. Similar analyses of pragmatic design features should be replicated 
in those therapy areas where extrapolation of these findings does not seem 
appropriate. 
Pragmatic trials adopt design features that make them more reflective of clinical 
practice and such trials have been judged feasible vehicles for economic 
evaluation. To ensure that the effects of the intervention are captured by 
clinical trials, long term follow-up of patients is essential. The cost of RCTs, 
however, increases with the length of follow-up and this can discourage funding 
bodies from undertaking pragmatic trials. They may be expensive, lengthy and 
the data analysis may be difficult due to a tendency of crossover between 
treatments. (Simon et al 1995) However, pragmatic studies could 'bridge the 
gap' between the insufficiency of RCTs and the issue of bias in observational 
studies. The findings of the meta-regression of pragmatic trials presented in 
this chapter did not provide empirical evidence of bias in pragmatic trial design. 
Basing an economic evaluation on pragmatic trials increases the external 
validity of the evaluation without jeopardising the validity of the effect estimate, 
so economic evaluations should be incorporated in large pragmatic trials. 
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CHAPTER 4 
THE MERITS OF ECONOMIC MODELLING AS A MEANS OF GENERALISING 
COST-EFFECTIVENESS ESTIMATES: ASSESSMENT OF ECONOMIC 
MODELS IN OSTEOPOROSIS. 
4.1 Introduction 
Concerns about the generalisability in economic evaluation of pharmaceuticals across 
healthcare settings has led to a search for methods to accommodate for setting-specific 
characteristics, increasing their relevance to local healthcare decision-makers. 
Economic models may have the potential to vary parameter estimates over a range of 
values reflecting both healthcare management systems and clinical characteristics in 
variety of settings. There is currently little empirical evidence examining the methods by 
which models may increase general isabi lity, or indeed whether current methods adopt 
such methods. 
In this chapter, economic models are examined for the degree to which they attempt to 
accommodate for setting-specific differences and present their findings in a manner that 
increases their generalisability. A checklist incorporating dimensions of the modelling 
process that could increase external validity was applied to economic models published 
in the therapy area of osteoporosis. The merits of economic modelling as a means of 
increasing generalisability of cost-effectiveness analyses are discussed in view of the 
findings. 
4.2 Background 
Decision analytic modelling is widely used in assessing the most cost-effective 
intervention from mutually exclusive alternatives. In health economic evaluation, models 
are predominantly used to structure decision problems, to inform treatment decisions 
under uncertainty. The use of models as vehicles for cost-effectiveness analysis has 
been extensively described in the literature (Weinstein and Fineberg 1980, Gold et al 
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1996, Briggs and Schulpher 1998, Buxton et al 1997) and the general advantages and 
limitations of modelling in healthcare decision-making highlighted by several authors. 
Sheldon (1996) outlined a number of problems that make models susceptible to bias, 
including model framing, construction, the reliability of estimates included and the way in 
which sensitivity analysis is performed. In contrast, based on experience with health 
technology assessment in the UK National Health Service, Brennan and Akehurst (2000) 
advocated the following uses of economic models in decision-making: extending results 
from single trials; combining multiple sources of evidence; generalising results from one 
specific context to another; informing future research strategies and exploring 
uncertainty in current knowledge base. 
The inclusion of data to populate transition probabilities for clinical and economic events 
is a key component of economic modelling. Data for economic models are often 
synthesised from several sources. (Nuijten 1998) Resource use data may be collected 
within the setting of a clinical trial or in databases where such use is routinely recorded. 
Estimates of disease prevalence and incidence are frequently based on observational 
data and assumptions of treatment patterns, such as therapy after response, therapy 
after treatment failure and second choice therapy, may be based on observational data 
or'expert opinion'. Estimates of treatment effect may be derived from one or more 
randomised controlled trials, while medical records and observational databases may 
provide information on the incidence of side effects and adverse clinical events. 
An evaluation that relies on a compilation of data from many sources, some of which are 
based on regular clinical practice, may provide an opportunity to increase the 
generalisability of the evaluation, augmenting the external validity in relation to other 
patient populations and settings. Variation in healthcare systems, unit costs and patient 
population base are factors that may impact on estimates of both costs and effects, 
influencing general isabil ity of cost-effectiveness estimates. Models carry the potential to 
accommodate for such factors, by varying their structural and parametric assumptions in 
a sensitivity analysis. (Manning et al 1996) 
Quality assessment of clinical research is developing apace. Clinical scientists and 
editors of biomedical journals developed the Consolidated Standards of Reporting Trials 
(CONSORT) statement, listing essential items for reporting of randomised controlled 
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trials. (Begg et al 1996, Moher et al 2001) Others have developed quality scales for the 
assessment of published randomised controlled trials. (Moher et al 1996) Researchers 
in the area of health economics have attempted to develop frameworks for reporting and 
assessing the quality of economic models. (Eddy 1985, O'Brien 1996, Drummond and 
Jefferson 1996, McCabe & Dixon 2000) Schulpher et al (2000) derived attributes of 
good modelling practice within a series of dimensions, including model structure, time 
horizon, data identification approach and internal validity. But to date, authors have only 
to a very limited extent incorporated issues of general isabi I ity in such modelling 
assessment frameworks. 
Regulatory bodies acknowledge the importance of local relevance of data submitted for 
reimbursement and clinical guidance purposes (see section 2.3), but few formal 
requirements exist regarding generalisability to models that are submitted to jurisdictions 
requiring such information. 
The outcome of full economic evaluations is a collapsed measure of costs and effects in 
the cost-effectiveness ratio. Inherently, resource consumption data and unit cost values, 
as well as clinical effectiveness estimates and valuation, may be more or less 
generalisable. Data determines the generalisability of the model and the applicability of 
the results depends on the range of inputs that were explored in the model. Models may 
seek to generalise costs and effects separately, and also to express uncertainty in all 
parameters simultaneously through probablistic modelling. (Briggs 2000) What are the 
merits of modelling as a method for generalising the results of an economic evaluation to 
a broader healthcare setting? 
There is little empirical evidence of the degree to which published models take local 
circumstances into account when presenting results and a framework is needed for 
assessing a model's explicit attempt to generalise parameter estimates for clinical 
effectiveness and costs. Applying this framework to health economic models in one 
therapeutic area would provide a meaningful comparison of study methodology. The 
selection of one therapeutic area enables the study of differences across study results 
that may be explained by location. This chapter outlines the development of such a 
framework and reports an assessment of published models in the therapy area of 
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osteoporosis. Several studies published since 1980 on the treatment and prevention of 
this condition provide a rich source of comparison of methods and results. 
4.3 Objectives 
The objectives of the review were to 
o Describe the methods that may be employed by health economists to increase 
external validity of economic models. 
o Systematically assess economic models in osteoporosis for the degree to which 
they make use of these methods to increase generalisabiiity of the evaluation. 
o Assess the relative impact of the adoption of these methods on the cost- 
effectiveness estimate of the evaluation. 
4.4 Methods 
4.4.1 Development of a framework for model assessment 
Literature on generalisability and external validity of clinical and economic evaluations 
was used as background material for the development of a comprehensive framework 
for assessing aspects of external validity of models. (Mason 1997, Revicki and Frank 
1999, O'Brien 1997). The cost-effectiveness ratio is a composite measure of relative 
resource use and clinical outcomes of healthcare therapies, so a framework to evaluate 
separately the degree to which cost-effectiveness models attempt to increase 
generalisability needs to take into account factors that influence costs, effectiveness and 
external consistency. 
Unit costs and clinical management patterns may vary between geographical areas. For 
example, the average length of stay in hospital for patients with hip fracture is 29.6 days 
in Aberdeen and 41.7 days in Peterborough. (French et al 1994) In Denmark it is 
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reported to be 21 days. (Ankjaer Jensen 1996) The level of healthcare resource use 
and costs of services are likely to differ substantially between settings, both nationally 
and internationally. (O'Brien 1997) Models that incorporate such regional or national 
variation in unit cost and treatment patterns may reflect such regional variation, 
increasing the external validity of the analysis. 
Secondly, the clinical effect estimate of the technology evaluated in a model may 
depend on underlying population and the compliance levels of the target population. 
Models may undertake adjustments to generalise those assumptions of explanatory 
trials that might not hold in real life. For example, characteristics relevant to the target 
population should be specified and where an underlying study has been based on a 
population not relevant to a particular decision-maker, a model could account for this by 
adjusting baseline risk estimates. Compliance is generally acknowledged to be higher 
within the context of controlled clinical trials than in clinical practice, so may contribute 
substantially to the reduction in efficacy when a drug is used in a different environment. 
(Revicki & Frank 1999, Bombardier & Maetzel 1999) Patients may choose to decline 
treatment, accept and discontinue therapy or accept and use therapy intermittently. 
Reduced compliance in a clinical practice setting is likely to result in reduced 
effectiveness of the drug, so models that evaluate the population -based impact of a 
strategy in clinical practice may provide a more representative estimate by factoring in 
the reduced compliance in the analysis. (Hughes et al 2001) The use of pooled effect 
estimates based on many trials may help increase external validity, (Pang et al 1999) as 
may the synthesising of head to head comparisons that have not previously been 
subject to direct comparison. 
Finally, checks can be made for external consistency by validating intermediate outputs 
to external sources of population-based data and comparing the result of the model with 
other studies in the literature or economic evaluations of similar technologies. (Schulpher 
et al. 2000) 
The development of a generic checklist (Table 4.1) enabled an assessment of the 
degree to which the economic models adopted the aforementioned techniques, as well 
as the calculation of summary scores for the studies included in the review. Differences 
across results may have varied across countries, changed over time or varied according 
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to the assumed level of compliance, so a quantitative assessment was planned to 
investigate the impact of 'generalisation techniques' on estimated cost-effectiveness. 
Ten aspects of model evaluation were identified (Table 4.1), covering cost estimates (Q 
1-4), clinical estimates (Q 5-9) and a check for external consistency of the model (Q 10). 
Table 4.1 A framework for assessing generalisability of decision-analytic cost- 
effectiveness models 
Question Dimension of Question for appraisal 
general isability 
1 Costs Did the model attempt to reflect variation in different resource use 
patterns between healthcare environments nationally (e. g. varying 
hospitalisation rates and length of stay)? 
2 Costs Did the model attempt to reflect variation in different resource use 
patterns between healthcare environments internationally? 
3 Costs Did the model attempt to reflect a range of costs relevant to a 
different healthcare environment nationally? 
4 Costs Did the model attempt to reflect a range of costs relevant to different 
healthcare environments internationally? 
5 Eff ects Were the effect estimates based on epidemiological studies, 
pragmatic trials or meta-analyses? 
6 Eff ects Were the effect estimates from the underlying studies moderated to 
reflect the target population of the model? 
7 Eff ects Did the model accommodate for difference in compliance rates 
between those observed in clinical trials and those likely in usual 
care? 
8 Eff ects Were head to head comparisons synthesised? 
9 Eff ects Were intermediate outputs of the model compared to external 
sources? 
10 External Were the results compared to other relevant studies? 
consistency 
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4.4.2 Material for the application of the framework 
Therapy area 
Osteoporosis is a disease characterised by low bone mass density (BIVID) and 
deterioration of bone tissue, leading to enhanced bone fragility and consequent increase 
in fracture risk. High age and low BIVID are important risk factors for osteoporotic 
fractures (Dennison and Cooper 2001), and therapies aimed at the treatment or 
prevention of fractures target the mechanism of bone loss. Screening procedures that 
assess BIVID have been developed to identify patients with a low bone mineral density 
and subsequent high fracture risk. (Hailey et al 1998) Osteoporosis is manifested by the 
occurrence of hip fractures, wrist fractures and vertebral fractures (Royal College of 
Physicians 1999) and is most prominent in postmenopausal women. In many western 
countries the remaining lifetime risk of a hip fracture in white women at menopause is 
approximately 14%. (Cooper 1996) In the UK, it has been estimated that the cost of 
fractures occurring in women over the age of 50 is in excess of P-700 million per year, of 
which hip fracture comprises 87%. (Dolan & Torgerson 1998) 
Development of fractures is a complex function of osteoporosis, age and other risk 
factors that evolve over time. The majority of trials have evaluated the impact of 
hormone replacement therapy (HRT) and other osteoporosis treatments on the 
intermediate endpoint BMD. (Royal College of Physicians 1999) Only recently have 
studies evaluated the impact of osteoporosis therapies on the final endpoint of fracture 
risk. (Torgerson and Bell-Syer 2001, Cummings et al 1998) Historically, there has been 
a scarcity of literature evaluating final endpoints. (OTA 1995) Decision-analytic models 
enable final outcomes to be estimated from intermediate outcomes, and also, final 
outcomes can be assumed from findings in epidemiological studies. The use of 
economic modelling to assess cost-effectiveness of interventions in this therapy area 
has therefore been of particular relevance. 
Previous reviews of economic evaluations in the osteoporosis area have provided 
narrative summaries of information and have scrutinised the methods adopted. (J6nsson 
et al 1995, Torgerson and Reid 1997, Torgerson & Reid 1999, Schulpher et al 1999) The 
methodological shortcomings of models in this area include the frequent use of non- 
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empirically derived quality of life weights, inappropriate application of decision rules and 
shortfall of stochastic models. (Schulpher et al 1999) 
Economic model inclusion criteria 
Full economic models evaluating therapeutic interventions in osteoporosis were 
reviewed, and primary studies that considered both costs and benefits of treatment in 
comparison with one or more alternatives were included. Only studies published in 
English were included. Economic evaluations that did not describe the construct of a 
model were excluded from the assessment, as were simple cost analyses and 
secondary reviews of economic evaluation models. 
Computerised searches for published papers reporting economic evaluation models of 
drugs in osteoporosis were conducted in the bibliographic databases Medline, Cochrane 
collaboration database and the NHSEED (NHS Economic Evaluation Database). Key 
words included cost and cost analysis (all subheadings) health economics, economic 
evaluation, economic*, cost*, osteo*, bispho*, hormone replacement, etidronate, 
alendronate, HRT, ORT, ERT and English language. Searches were extended to 
bibliographies of retrieved articles. Reference lists of other review articles in the area 
were scrutinised and specialists in the field of economics of osteoporosis were 
consulted. Searches were undertaken in May 1999. 
For included studies, information relevant to the review was extracted onto a data 
extraction form by the author (HU) for each separate study (appendix 2). (CRID 2001) 
This information was then summarised in data tables, which provided the basis for 
assessment of the studies. 
4.5 Results 
Overview 
Six publications were excluded from the review (Table 4.2). These were either review 
articles (Delva 1993), postal surveys (Torgerson et al 1995), merely technical reports on 
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model structures and not used to evaluate specific intervention strategies (J6nsson et al. 
1995, Ross et al, 1998, Zaethraeus et al, 1998), or duplicate publications (J6nsson 
1996). 
Table 4.2 Table of excluded studies 
Study Reason for exclusion 
Delva 1993 Review article. 
Jbnsson 1995 Report a model evaluating cost utility of osteoporosis interventions, 
however base the analysis on a fictive intervention with a certain 
eff icacy. 
J6nsson 1996 Duplicate of Jonsson 1995. 
Ross 1998 Describes a model to evaluate cost of osteoporosis, but does not 
evaluate specific treatment regimes. 
Torgerson et al 1995 Reports the result of a postal questionnaire survey and not a full model. 
Zaethraeus 1998 Describes a model, but does not evaluate specific treatment regimes. 
A total of 19 publications reporting economic evaluation models were identified that 
satisfied the inclusion criteria (Table 4.3). The majority of these which were decision 
analytic models, including four Markov state transition models. Five were simple decision 
trees. (Frances (1996), Torgerson et al. (1996) Torgerson (1993), Goddard (1990), 
Visentin (11996)) A reference list for all the included models can be found in appendix 3. 
The first economic model in osteoporosis was published in 1981 (Weinsten 1981). Of 
the studies published in the 1980s, six were from the United States. Eight studies were 
from European countries, all of which were published in the 1990s. 
Half of the studies were cost utility analyses (Table 4.4) and of these, only one used 
utilities derived by patients. (Daly 1996) The others based quality of life (QoL) weights 
on those originally assumed by Weinstein (1981). Target populations were 
predominantly women living in the community, though one specifically evaluated 
treatment of women in nursing homes. (Torgerson 1993) None of the studies evaluated 
cost-effectiveness from a broader perspective than that of the health service sector. 
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Adoption of generalisation techniques 
Most studies applied unit cost data to the analysis relevant to the country for which the 
study was targeted (Table 4.5) and three used regional cost estimates (Cheung 1992, 
Geelhoed 1994 Rosner 1998). None of the models accommodated differences in 
treatment patterns within regions or across countries. Responses to questions 1 through 
4 of the assessment framework revealed that none of the investigators attempted to use 
cost estimates applicable to a broader audience of decision-makers within or between 
countries by using a range of costs or treatment patterns representing geographical 
differences. 
A common feature of the models in this review was the use of epidemiological studies to 
estimate the relative fracture risk reduction in the treated populations (Table 4.6). Three 
models based the hip fracture risk reduction estimates on individual clinical trial data 
(Francis et al. 1996, Rosner et al. 1998, Torgerson et al. 1995). Ankjer-Jenssen et al. 
(1996) based the effect estimate for one of the therapies on a meta-analysis of several 
trials. Of these, only Francis et al. (1996) provided some information about the 
characteristics of the population from which the estimates were derived. Fourteen 
studies did not provide any patient information enabling comparison with the target 
population of the model. The remaining three studies predominantly restricted patient 
information to age range. (OTA 1995, Rosner et al. 1998 and Tosteson et al. 1990). 
Questions 5 through 9 of the assessment framework relate to a clinical effectiveness 
estimate of the models (Table 4.1). For the most part, those studies that did not use 
estimates of effectiveness from clinical trials based the effect estimate on assumptions 
supported in epidemiological literature (Table 4.6). As a result, the effect estimate in 
many studies was based partially on methods more reflective of clinical practice than 
explanatory randomised controlled trials. Two studies (Goddard 1990 and OTA 1995) 
provided a description of patient characteristics in the studies on which the model's 
assumption of effectiveness was based. The scope for decision-makers to compare the 
population on which the original effect estimate was based with that of the population 
targeted by the economic model (question 6 of the checklist) was, therefore, limited. 
With the exception of Rosner et al. (1998), there was no incidence of explicit adjustment 
in risk reduction from underlying study to the target population of the model. 
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Most studies identified in this review evaluated more than one treatment strategy. Of 
these, only Rosner et al. (1998) and OTA (1995) analysed incremental cost- 
effectiveness based on a synthesised head-to-head comparison. The remainder 
reported average cost-effectiveness ratios from comparing each treatment strategy with 
no treatment (Table 4.6). 
Finally, five studies facilitated assessment of the external consistency of results by 
contrasting their findings with other economic evaluation studies in the area (Table 4.6) 
Generalisability and the cost-effectiveness ratio 
Between them, the studies evaluated different interventions, including a range of clinical 
outcomes in their calculations of costs and effects of treatment, expressing their results 
on different currencies from different years (Table 4.3). Furthermore, the results of the 
studies were expressed partly in terms of cost-effectiveness analysis and partly of cost- 
utility analysis (Table 4.4), so comparison of results across studies was not 
straightforward. Nevertheless, an assessment was planned to investigate the impact of 
generalisation techniques on the estimated cost-effectiveness. 
Not infrequently, assumptions of compliance and duration of treatment were made 
without adjustment. For example, OTA (1995) assumed 100% compliance in 10,20,30 
and 40 years respectively. The definition of compliance differed between the eight 
studies that took this into consideration, but often it meant simply that patients 'declined 
to accept' therapy (e. g. Clark et al. 1992) or that patients 'accepted but discontinued' 
(e. g. Daly et al. 1992) (Table 4.7). 
In general, the cost-effectiveness estimate was found to be sensitive to the assumption 
of compliance, but the decision recommendation remained unchanged (Table 4.7). For 
example, Tosteson et al. (1990) assumed 100% compliance over 15 years in the base 
case model, but varied compliance to 30% in the sensitivity analysis and found that cost- 
effectiveness estimates were sensitive to assumption of compliance. 
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The main base-case results of the studies did not reveal any systematic differences 
across results that may be explained by location (Table 4.8). Neither systematic variation 
in cost-effectiveness estimates within countries or systematic changes over time were 
apparent from the overview. The models compared a range of interventions and 
presented the result in a variety of outcomes. Ankjaer-Jenssen (1996) reported 
average cost per hip fracture avoided in screened and unscreened populations 
comparing three different interventions. In contrast, Tosteson et al. (1991) compared 
cost-utility of two different interventions in patient populations with different life 
expectancy. The large range of interventions, patient populations and outcomes 
recorded in the models prevented quantitative assessment of the impact of model 
features on the reported cost-effectiveness and with 19 studies, the review was 
underpowered for the conduct of such an assessment. 
Study score 
Table 4.9 provides an overview of individual study scores according to each item on the 
checklist. This information is a synthesis of the information incorporated in Tables 4.5 
and 4.6, aiming to give an overview of the degree to which models in osteoporosis 
published prior to 1999 have attempted to generalise the study results. 
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Table 4.9 Summary table showing overall score for each study on all dimensions 
of extemal validity. 
Study (year) 
Ankjaer-Jensen 
1996 
01 
No 
02 
No 
03 
No 
04 
No 
05 
In part 
06 
No 
07 
Yes 
08 
No 
09 
No 
010 
Yes 
Total 
'Yes' 
score 
2 
Cheung 1992 No No No No In part No No No No No 0 
Clark 1992 No No No No In part No Yes No No Yes 2 
Daly 1992 No No No No In part No Yes No No Yes 2 
Daly 1996 No Yes No No In part No No No No No 1 
Francis 1996 No No No No No No No No No No 0 
Garton 1997 No No No No No No Yes No No Yes 2 
Geelhoed 1994 No No No No In part No Yes No Yes No 2 
Goddard 1990 No No No No In part No No No No No 0 
OTA 1995 No No No No No In part No No Yes Yes 2 
Rosner et al 
1998 
No No No No Yes Yes Yes Yes No No 4 
Torgerson 
1993 
No No No No In part No Yes No No Yes 2 
Torgerson 
1995 
No No No No In part No No No No No 0 
Tosteson 1990 No No No No No Yes Yes No Yes No 3 
Tosteson 1991 No No No No No Yes No No Yes 
I 
No 2 
Visentin 1997 No No No No Yes Yes No No No Yes 3 
Weinstein 1980 No No No No In part No No No No NA 0 
Weinstein 1983 No No No No In part No No No No No 0 
Weinstein 1990 No No No No In part No No No No No 0 
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4.6 Discussion 
Study scope 
Previous authors have reviewed and made exhaustive recommendations on the most 
cost-effective prevention and treatment of osteoporosis (Schulpher et al 1999) and it was 
beyond the remit of this review to add to them. Attempts have also been made to 
develop a standardised framework for evaluating the quality of health economic models. 
(Eddy 1985, Schulpher et al. 2000) The diversity of decision analytic models and the 
types of data and settings used have made quality assessment a difficult task and it was 
not within the scope of this review to systematically assess the quality of health 
economic models in the area of osteoporosis. The purpose of this review was to 
develop a framework for assessment of model generalisability and to apply this 
framework on a sample of economic models in which such methodologies are applied. 
Model assessment 
To increase the external validity of an economic model, the developer could explore the 
impact of parameter estimates of costs and effects of treatment under circumstances 
different from those of the data underlying the base-case estimates. The checklist 
designed for this review considered cost estimates such as healthcare management 
systems, as well as clinical estimates such as characteristics of patient populations and 
treatment patterns. Although not exhaustive, it provided a comprehensive framework for 
evaluating the models in the review. 
Cost estimates 
None of the 19 economic models of therapies in osteoporosis published prior to May 
1999 included a range of costs to reflect a variety of settings. Also, in spite of the fact 
that therapy traditions and healthcare management differ across units of healthcare 
providers, both nationally and internationally, none of the studies accommodated for 
such variation. Neither did the models incorporate variations in treatment patterns in 
different areas. As a result, though the studies frequently applied at an aggregate 
national level, they may not have relevance to regional or local healthcare decision- 
makers or, indeed, national decision-makers concerned about regional variability. 
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Health and social care systems operate differently. Many factors are likely to influence 
the resource use, costs and outcome of treatment in the countries involved (O'Brien 
1997, Drummond 1992), but none of the studies attempted to extrapolate from their 
results to another country or continent. Successful, large-scale, international economic 
evaluation studies have been conducted despite a series of obstacles and an increasing 
number of publications provide a solid foundation for such research. Some prospective 
studies have compared trial-wide clinical results with costs based on trial-wide utilisation, 
while using unit prices for the country in question. (Menzin 1996, Jonsson 1997, 
Schulman 1996) This method estimates country-specific cost-effectiveness, making 
some adjustment for gross price differences across countries, but does not allow for 
differing treatment patterns (Willke et al 1998), which could be captured by applying 
national costs to national trial data and then pooling the data. (Glick et al. 1998) 
Modelling studies could provide useful frameworks for exploring the impact of varying 
unit costs and treatment patterns, but this asset was not exploited in the osteoporosis 
evaluations included in this review. 
Effectiveness estimates I- 
According to drug regulatory requirements, the development of a knowledge base for a 
pharmaceutical compound progresses from an initial assessment of drug efficacy in 
phase I to phase III randomised controlled trials, through to assessment of effectiveness 
in pragmatic randomised trials and observational studies. (Piantadosi 1997) Assuming 
that economic modellers base their analysis on the best available data, one could expect 
the model input to be more naturalistic as experience with a drug has accumulated over 
time. This does not seem to have been the case with hormone replacement therapy 
(HRT). The knowledge base has predominantly constituted non-randomised, 
epidemiological studies from the initial stages of routine use in menopausal women. 
Randomised studies have been carried out only recently. (Royal College of Physicians 
1999) This is reflected in the material on which the economic models base their effect 
estimate. The general absence of randomised clinical trial data for use in the clinical 
effectiveness estimates in osteoporosis models is striking. Early modellers between 
1980 and 1995 based the effect estimate on assumptions supported by epidemiological 
literature. Later studies based their effect estimates on randomised clinical trials. (OTA 
1995, Torgerson 1995, Rosner 1998) Nevertheless, a recent study by Rosner et al 
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(1998) emphasised that hip fracture was excluded as main outcome because of scarcity 
of clinical trial data in the literature, so vertebral fractures were used as the main 
outcome. 
Most economic models in the review omitted a description of the patient population 
characteristics on which the effect assumption was based. This is a key area for 
decision-makers trying to assess a model's relevance to a specific population and its 
omission severely restricts the value of information presented. 
The concept of clinical compliance with medication is complex. Definitions such as 
intermittent therapy, omitted tablets, therapy breaks, and lack of adherence to 
administration regime have been used to describe the phenomenon. (Hughes et al. 
2001) This definition may be important to the interpretation of the results. The authors 
of those studies in this review that take compliance into consideration used different 
definitions, but for the most part, assumption of compliance was based on the fraction of 
patients that initiate therapy, 'willingness to start therapy'. (Clark and Schuttinga 1992). 
Thereafter, patients are assumed to continue for a defined period of time, frequently in 
excess of 5 years. 
An asset of economic modelling studies is that they may synthesise head-to-head 
comparisons where no direct trial-comparisons exist. (Buxton et al 1997) Standard 
decision rule methodology is to compare treatments to each other in an analysis of 
incremental cost and effectiveness. The studies in this review, however, with the 
exception of OTA 1995, and Rosner 1998, calculated cost-effectiveness compared to no 
treatment and contrasted treatments by presenting average cost-effectiveness ratios. 
This practice limited the scope for the synthesis of head to head comparisons, a practice 
that could have increased the external validity for decision-makers who face therapy 
choices between treatments in clinical practice. 
External consistency 
The question of whether intermediate outputs were compared to external sources is 
relevant to those studies in this review where hip fracture is modelled from a change in 
bone mass density, and where survival is modelled from hip fracture. There is a trade- 
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off as to whether available information at the modelling stage should be used in 
validation or whether it should provide an additional knowledge base. (Schulpher et al. 
2000) In this review, Tosteson (1990 and 1991), Geelhoed et al (1994) and OTA (1995) 
did make this check of external consistency of intermediate outputs by contrasting hip 
fracture risk modelled from bone mineral density with population-based hip fracture risk 
stratified by age. Less than half of the studies (7) contrasted the methodology or the 
results of their evaluation with those of other economic evaluations in osteoporosis. It 
would be reassuring to see more researchers contrasting their findings to other studies 
with similar objectives. 
The merit of models as tools for generalisability 
The checklist developed in this chapter to assess the degree to which economic models 
seek to increase external validity demonstrates that there is significant potential for these 
studies to inform decision-makers on general isabil ity of the results. However, this 
comprehensive review of published models in osteoporosis treatment and prevention 
reveals that studies to date perform modestly in terms of adopting these aspects. 
In stochastic model evaluations, the sensitivity analysis may be a relevant stage in the 
process to explore alternative data input relevant to larger decision-making audiences. 
Future use of probablistic evaluation is likely to become increasingly developed and 
adopted, and this will enable researches to use a range of values and reflect the 
sensitivity of the results in the form of cost-acceptability curves. (Briggs 2000) 
An underlying assumption, of this review is that a study attempting to increase the 
external validity of its findings is one that varies costs over a range of nationally and 
internationally relevant unit costs and also varies the therapeutic pattern within and 
between countries. Furthermore, it bases effect estimates on pragmatic trials or meta- 
analyses, moderates these estimates to the target population of the model and 
accommodates for reduced compliance rates in clinical practice. Finally, the model 
performs incremental analysis between the synthesised head to head comparisons, 
compares intermediate output with external data sources and compares the output of the 
model with relevant studies in the field. 
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Are these realistic expectations for published reports of economic evaluation models? 
Restricted space in scientific journals limits the scope for the researchers to describe 
even methodology appropriately. As already mentioned, the concept of external validity 
is meaningless unless it is related to a particular setting, population or time, so the 
degree to which a model reflects variation in costs and eff ects should follow from the 
objectives of the study. If a model intends to inform a decision on treatment strategy by 
the National Institute for Clinical Excellence (NICE) then the report benefits from 
evaluating a national range of costs and benefits. Similarly, if the report is intended for 
an international audience in an international journal, then it would benefit from reflecting 
a span in costs, treatment patterns and populations between countries. It may not be 
fair to expect researchers to report additional information from an expanded analysis of 
range of costs to a huge range of alternative settings, but it would be relevant for models 
to evaluate the robustness of the results under assumptions from more than one setting. 
Study limitations 
There are a number of limitations with this model evaluation. Firstly, the small number of 
studies in only one therapeutic area limits the scope for extrapolation of the findings. 
The study did not provide enough power to conduct a regression analysis evaluating the 
impact of increased generalisability on cost-effectiveness estimates. The relatively low 
number of studies (19) did not provide enough power for such analysis, and furthermore, 
the use of a range of measures of effectiveness in the analyses reduced the opportunity 
to generate one uniform expression of cost-effectiveness. 
Secondly, only studies published in English were included, and these were 
predominantly published in international journals aimed at international audiences. This 
may have introduced a bias to the study that undermines the issues of local adaptability 
that were explored. Few models assessed in the review attempted to generalise results 
across settings. Economic models in osteoporosis may nevertheless have been used 
with the purpose of generalising economic evaluations to specific settings, however 
reports developed for specific local healthcare decision-makers may not have been 
published internationally. A comprehensive review of submissions to regulators such as 
the Pharmaceutical Benefits Advisory Committee in Australia or National Institute for 
Clinical Excellence in the UK may have provided a different empirical result. 
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Thirdly, the checklist was limited to evaluating sensitivity analysis on parametric 
assumptions only. For example, it is a structural assumption that the risk of hip fracture 
is altered only after a given duration of therapy. Parametric assumptions describe the 
magnitude of the structural assumption, for example the length of time the risk of hip 
fracture is altered by treatment. Assessing the sensitivity of results to changes in 
structural assumptions is more labour-intensive, as it may require reprogramming of 
computer models and this was not attempted. 
Finally, the data extraction recorded only information that was reported in the paper, and 
the research is restricted by the degree to which models are described in detail. Space 
restriction in scientific journals may limit scope for presentation of comprehensive 
sensitivity analyses, and the findings of this review would reflect that rather than a 
genuine lack of attention to generalisability by the authors of the models. 
4.7 Conclusions and recommendations 
Economic modelling and data collection requires a series of key decisions on the part of 
the economist. Modellers can adopt several techniques in order to increase the 
generalisability of both resource consumption estimates and clinical estimates of 
economic evaluations. By using a relevant range of data sources or making data 
adjustments representative to a broad audience of decision-makers, models may 
increase external validity of the evaluation. 
The findings of this review demonstrate that modellers in the area of osteoporosis either 
omit information that is essential for assessing external validity of a model or do not 
incorporate aspects specifically aimed at increasing the external validity of the model. 
There may be good reasons for this, for example limitations on space in scientific 
journals. Inclusion of such factors in future economic models in this area would however 
increase the ability of models to reflect a larger span of alternative clinical practice 
scenarios. Presentation of future economic models in a manner that enables replication 
of the model would furthermore facilitate the incorporation of local data for local decision- 
makers. 
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This review may have revealed a need for more standardised reporting of economic 
models. A framework analogous to the CONSORT statement advising researchers on 
how to report the construct, the data search and the findings of models may enable 
easier assessment of model quality as well as assessment of data aspects and the 
degree to which the model can be generalised to a population under consideration. In 
spite of previous efforts (Drummond and Jefferson 1996), no widely established 
framework exists for the reporting of economic models. In contrast to clinical trial 
methodology, economic evaluation methods are still in development and establishing of 
firm quality criteria may provide disincentives for further methodological developments. 
However, standardised reporting would facilitate quality assessment. Inclusion of the 
checklist of general isability that was developed in this chapter in such a statement would 
facilitate decision-makers assessment of local study applicability. 
For the term external validity to have meaning an evaluation needs to be related to a 
particular setting, patient group or a particular country. Restrictions of generalisability of 
a model may therefore differ across different decision-making audiences. The 
framework that was developed in the current chapter provides a comprehensive tool to 
assess the cost and the effect estimate of economic models. Therefore, it may be used 
by readers of economic models for the assessment of local applicability of the model. 
The findings of this review point to three main areas of future research. Firstly, the same 
checklist should be applied to a larger subset of models incorporating models from 
different therapy areas. Increasing number of models would increase the power to 
undertake a regression analysis of the impact of increased generalisability on model 
estimate and would enable exploring of features that may influence generalisability. 
Secondly, the same checklist could be applied to unpublished models submitted to a 
regulatory authority to assess whether such models to a larger extent attempt to 
generalise results. This could take an analogous form to the quality assessment of 
submissions to the Australian Pharmaceutical Benefits Advisory Committee, conducted 
by Hill et al (2000). Finally, the vast majority of these studies were published before the 
era of guidelines for the conduct of economic evaluations. Advice by such reference 
cases for the conduct of economic evaluations that have emerged in recent years (NICE, 
Australian, Canadian guidelines) would therefore not have influenced the conduct of the 
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models included in this review. It would therefore be of interest to see whether more 
recent models to a larger extent take issues of general isabi I ity into consideration in order 
to meet the need of decision-makers for locally adaptable data. 
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CHAPTER 5 
DEVELOPING AND DEMONSTRATING METHODS FOR ECONOMIC 
ANALYSIS IN AN OBSERVATIONAL PATIENT RECORD DATABASE. 
5.1 Introduction 
To health economists, patient record databases are currently most commonly 
known to supply partial data for transition probabilities in decision-analytic models. 
(Nuiten 1998) The search for methods by which economic evaluations may 
achieve a higher external validity has pointed to the use of clinical data that are 
reflective of clinical practice circumstances such as pragmatic trials (see chapter 3). 
Another potential source for such data are electronic patient record databases, that 
link patient demographic data and clinical data at patient level and contain 
information on the treatment of patients under local healthcare delivery conditions. 
Such databases may represent larger study populations than is normally available 
for clinical trials, and as a result, computerised patient record databases have been 
used as tools in epidemiological evaluations of drug safety. (Jick 1998) Such 
databases may also have the potential to constitute vehicles for full economic 
evaluation of costs and outcomes of pharmaceutical interventions, however this 
remains to be established. 
At their best, routinely collected electronic data may have the potential to provide 
easily accessible data that can be identified and analysed in a short timeframe at 
reasonable costs relative to a prospective clinical trial. A formal feasibility study in 
the context of health economic research may provide valuable insight into whether 
such databases should be given further consideration as data source for full 
economic evaluation, either in the present format or with some enhancements. A 
study evaluating such feasibility should evaluate whether the database meets 
fundamental data requirements at satisfactory data quality. 
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This chapter outlines the process of evaluating the UKCPD database (UK Clinical 
Practice Database, Mediplus@) for provision of data to economic evaluation. A 
critical appraisal of the UK Primary Care Database (MediPluse hereafter) is 
provided in section 5.1 before the aim and research objectives for a feasibility study 
are outlined. Section 5.2 outlines the study designs for two pilot studies that were 
developed to evaluate data quality and feasibility of the Mediplus@ database in the 
therapeutic area of osteoporosis. Section 5.3 presents the results of the studies. 
Finally, the findings are discussed in section 5.4 in light of strengths and 
weaknesses of the database approach to increasing economic evaluation 
generalisability. 
5.2 Background and study material 
5.2.1 On observational data 
Observational databases in the UK 
There are many sources of observational data. Examples are national and regional 
registers and national statistics, such as activity data from Prescriptions Pricing 
Authority and clinical surveys, such as the morbidity survey by the Royal College of 
General Practitioners. Large healthcare administrative databases are common in 
the US and within other private, insurance-based healthcare systems for billing 
purposes. Generally, socialised healthcare systems, such as those in Europe, has 
offered less incentive for the healthcare provider to record activity at a detailed 
patient level, routinely collecting longitudinal patient data. To be of potential use in 
the economic evaluation of healthcare interventions, data should be in a form where 
exposure to health technologies can be identified at patient level, and where patient 
health can be followed over time. A number of databases constructed of 
computerised patient records with routinely recorded patient-level data are available 
in UK. (Lis et al 1997) 
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The vast majority of UK citizens are registered with a personal general practitioner 
(GP), who provides primary care and acts as a "gatekeeper"to secondary care. 
Increasingly, the GP uses a computer to record patient level data in healthcare, 
enabling commercial organisations, public health bodies and research centres in 
the UK to construct databases of computerised longitudinal information on large 
patient numbers. Examples of comprehensive UK-based patient record databases 
include the General Practitioners Research database (GPRD), the UK Primary Care 
Database (Mediplus@) and the Medicines Monitoring Unit (MEMO). These 
databases code clinical and administrative information systematically and store 
data electronically in a formatted record. Data from these sources are available for 
academic or commercial research. 
The coverage of these three databases differs on parameters such as patient 
numbers and geographical area. Patient records are anonymously supplied to the 
GPRD and Mediplus@ databases from selected practices across the whole of the 
UK. Data collection for GPRD has been operating since 1987 and currently, the 
patient records of approximately 2.7 million patients, equivalent to about 4.7% of 
the UK population, are recorded in the database (http: //www. gprd. com/). The 
Mediplus@ database has been collecting since 1992, and it contains the primary 
care records of 1.8 million patients. About 600 GPs in about 150 general practices 
in England, North-Ireland, Scotland and Wales contribute data and there are 
records of 1.8 million patients in the database. Needless to say, there is a constant 
turnover of patients, as some die or move area and so change their GP. Similarly, 
new patients join the practices on the data collection panel. So approximately 1 
million patients in the database are alive and registered with the GP. (IMS Health 
1998) MEMO (based in Scotland) accesses patient records of GPs from the county 
of Tayside with a patient population of about 400,000 patients 
(http: //www. dundee. ac. uk/memo/). The MEMO database differs somewhat from the 
others in that it combines information from a variety of population-based datasets 
and is therefore complete for one particular geographical area. Furthermore, 
MEMO provides the additional opportunity to link primary care records with 
secondary and specialist care records. 
The GPRD was set up primarily as a source for medical and public health research 
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purposes. (Rodriguez and Gutthann 1998) In contrast, Mediplus@ was set up by a 
commercial agency to provide information on market research to the 
pharmaceutical industry. (IMS Health 1998) Common to the GPRD and Medipluse 
databases is the routine assessment of the quality of information provided by the 
GPs. Only practices that satisfy given quality criteria are included in the research 
databases. The GP recording of information in the GPRD has been extensively 
validated (van Staa et al 1994, Jick et al 1991, Jick et al 1992) and the database 
has served as material for an extensive published literature on drug safety (Jick et 
al 1998). Although none of these databases were constructed with the purpose of 
supplying data for economic evaluation of pharmaceuticals, cost-effectiveness 
evaluations have been published using the MEMO database. (e. g. MacDonald et al 
1995) 
Longitudinal collection of demographic data, treatment choice and clinical 
diagnoses give opportunity to evaluate associations between interventions and 
patterns of care with clinical outcome. In the development of further methodologies 
to generalise economic evaluation adopting current methodology in the areas of 
economic evaluation, epidemiology and medical statistics are key to the evaluation 
of the merits of an observational database for this purpose. The Medipluse 
database is the focus for this particular evaluation and its structure will be described 
in detail in section 5.1.2. However, prior to evaluating details of this specific 
database, general research methodology for the conduct of evaluations using 
observational data is provided. 
Observational study designs and measure of association 
In a randomised controlled trial (RCT) the process of randomisation to treatment or 
control group ensures that patients differ only by the play of chance, and the 
treatment allocation. This enables attribution of observed effects and provides 
good foundation for the statistical analysis of the trial results. Fundamentally, 
randomisation contributes to the development of an unbiased effect estimate of 
treatment. 
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The process of randomisation is not a feature in clinical studies with an 
observational design. There are two basic types of observational analytic 
investigation: the case-control and the cohort study. In a case control study, a case 
group or series of patients who have a disease of interest and a comparison group 
of individuals without the disease are selected for investigation, and the proportions 
with the exposure of interest in each group are compared. This design looks 
backward from a disease to a possible cause. In contrast a cohort study looks 
forward from an exposure to an outcome. Subjects are classified on the basis of 
the presence or absence of exposure to a particular factor and then followed for a 
specified period of time to determine the development of disease in each exposure 
group. Case control studies are always retrospective, whereas cohort studies may 
be conducted both retrospectively and prospectively. (Hennekens and Buring 1987) 
The alternative design strategies offer advantages and disadvantages and the 
choice of either depends on the nature of the disease under investigation, the type 
of exposure and the available resources. The case-control design is particularly 
efficient for investigation of a relatively rare disease. The cohort design is best 
suited to investigations of relatively common outcomes that will incur in sufficiently 
large numbers over a period of follow-up of reasonable duration. (Hennekens and 
Buring 1987) 
Clinical studies, whether randomised or observational, may report odds ratio (OR) 
or relative risk (RR) as the measure of association between exposure and risk of 
outcome. The OR and the RR express a comparison of disease frequency in the 
treatment and control group combined into a single summary parameter. The 
relative risk indicates how much more likely one group is to develop a disease than 
the comparison group by expressing the ratio of the proportions either population. 
Table 5.1 shows the general layout of the 2X2 table that arises in this situation. 
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Table 5.1 General presentation of the results from a prospective study as a2X2 table 
The risk in the exposure group is al(a+c) and the risk in the control group is blb+d. 
Relative risk is therefore: 
RR = 
ala+c 
bld+b 
In case-control studies, where patients are selected on the basis of disease status 
(outcome), it is usually not possible to calculate the rate of development of disease 
given the presence or absence of exposure. The relative risk is not a valid estimate 
for this design, as any given value can be achieved by varying the number of cases 
and controls. The alternative method is based on calculations within each group. 
The ratio alc is the odds of outcome in the exposure group. Equally, the ratio bld is 
the odds of outcome in the control group. Combining these provides the odds ratio: 
OR = 
alc 
bld 
If the outcome of interest that defines the cases is rare, then a will be small and 
al(a+c) will be approximately equal to alc and similarly, b will be small and blb+d 
will be approximately equal to b1d. The relative risk will be approximately equal to 
the odds ratio. For case-control studies, the outcome of interest is usually rare, so 
the odds ratio offers a method of getting an approximate relative risk. (Altman 1997) 
Analysis of epidemiological studies 
The validity of observed associations between an exposure and a disease in clinical 
research can be assessed through consideration of whether the association is due 
to alternative explanations such as chance, bias or confounding. (Hennekens and 
Buring 1987) Statistical tools to assess this include hypothesis testing, estimation 
and statistical modelling. 
Hypothesis test, estimation and the play of chance 
The play of chance may always affect the results observed in a study, simply 
because of random variation from sample to sample. Hypothesis testing involves 
conducting a test of statistical significance and quantifying the degree to which 
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sampling variability may account for the results observed in a particular study. 
Denoted as H0, the null hypothesis represents the assertion that there is no 
relationship between exposure and outcome. The alternative hypothesis, denoted 
as H1, is the assertion that there is some relation between the exposure and the 
disease. The test statistic is a function of the difference between the values that 
were observed in the study and those that would have been expected if the null 
hypothesis were true as well as the variability in the sample. The significance test 
leads to a probability statement, or P-value, that indicates the likelihood of obtaining 
the study result by chance alone assuming that there is truly no association 
between the exposure and outcome under consideration (i. e. Ho is true). The level 
of the p-value that indicates an association is statistically significant is arbitrarily 
determined, but by convention in medical research this is set at 0.05. Thus, the Ho 
is rejected if the P-value is less than 0.05, as this is taken to mean that chance is an 
unlikely explanation of the findings. The expected value of the RR and OR is 1 
under the null hypothesis. The most frequently encountered hypothesis tests in 
medical literature are the chi-square test for discrete data and the Mest for 
continuous data. (Altman 1997) 
The P-value reflects both the magnitude of the difference in effect between the 
groups and the sample size. One problem inherent in the interpretation of the P- 
value is that even a small difference may be statistically significant if the sample 
size is sufficiently large, and conversely a larger effect may not achieve statistical 
significance if the sample size is insufficient. Increasingly therefore, estimation and 
confidence intervals are used to draw inference in clinical research. The 
confidence interval, or the range within which the true magnitude of effect lies with a 
given degree of certainty, is a related but more informative measure of the role of 
chance than the P-value. (Gardner and Altman 1989) The confidence interval 
provides the information of the P-value in terms of whether the association is 
statistically significant at a specified level. For example, if the null value (e. g. 1.0 for 
the relative risk estimate) is included in a 95 percent confidence interval, then the 
corresponding P-value is by definition greater than 0.05. The advantage of 
estimation over hypothesis testing is that the width of the confidence interval 
indicates the amount of variability inherent in the estimate and therefore expresses 
the precision of the estimate in addition to the effect of sample size. 
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Statistical modelling and the role of bias and confounding 
In a randomised clinical trial, observed and unobserved influences (prognostic 
factors) are randomly allocated to trial participants and potential differences in trial 
outcome between the exposure group and the control group may therefore be 
attributed to the exposure (i. e. treatment) or the play of chance. This is not true for 
observational data, where factors beyond the control of the researcher influence the 
selection to the groups. Basic hypothesis tests may therefore be insufficient and 
indeed misleading for analysis of data produced by observational studies. The use 
of statistical modelling techniques that take observed differences between the study 
groups into account and that may bias or confound the findings is therefore 
essential when drawing inference of comparative effectiveness. 
The aim of statistical modelling is to build a parsimonious mathematical 
representation in which an outcome variable is expressed as a combination of one 
or more variables that may modify the effect of exposure. Variables are included to 
a model to explore whether they can explain the observed variation in outcome 
between individual observations in a study sample. The analysis provides 
coefficients and standard errors for the coefficients from which the statistical 
significance of the explanatory variable may be calculated. Statistical modelling, or 
multivariate analysis, enables the exploring of the impact of several potential 
explanatory variables individually and in any combination. (Altman 1997) A large 
number of multivariate models have been developed for specialised purposes, each 
with a particular set of assumptions underlying its use. The choice of model is 
based on underlying study design, the nature of the variables and assumptions of 
interrelationship between the exposure and outcome. 
The simplest approach to analysing the relationship between the values of 
explanatory variables and continuous outcomes is by the use of linear regression 
models. To fit a regression line the standard method is to minimise the sum of 
squares of the distances of the observations to the line and obtain an ordinary least 
squares regression (OLS). The general equation of a regression line is 
a +bx 
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Where Y is the outcome variable, a is a constant corresponding to outcome when 
explanatory variables take the value of zero, b is the regression coefficient and X is 
the explanatory variable. The regression coefficient produced by the analysis 
expresses the variability in the response variable that can be attributed to different 
values of the predictor variable, e. g. the increase in outcome for each unit increase 
in the explanatory variable. (Altman 1997) Underlying such analyses are the 
assumptions that the values of the outcome variable have a normal distribution for 
each value of the predictor variable, and that the relationship between the two 
variables should be linear. 
The simplest approach to modelling binary outcomes is logistic linear regression. 
For such outcomes an appropriate regression model would predict the proportion of 
individuals with the characteristic for a combination of explanatory variables. The 
probability of individuals having a certain binary outcome (characteristic) is 
transformed on to a logit scale for the reason that impossible probabilities outside of 
the range 0 to 1 can not be predicted on this scale. Here, the proportion of 
individuals with the characteristic is p, and 1-p is the probability that they do not 
have the characteristic. The odds of the characteristic is therefore 
Logit(p) ý-- 10ge [(P) / (17P)l 
When comparing the odds of having a particular characteristic in two groups (p, and 
p2) the general equation is 
11 - 12 == logit (pl) - logit(p2) = log [pi / (1-pi)] - log 
[P21 (1-p2)] 
which is the log of the odds ratio (OR) of an outcome. Therefore, the odds ratio for 
an explanatory variable in logistic regression (i. e. the degree to which the risk of 
outcome changes as a consequence of having the attribute) can be obtained 
directly from the regression coefficient. An underlying assumption of the logistic 
regression is that the relation between the dependent variable and each continuous 
explanatory variable is linear. Furthermore, it assumes that the effects of each 
variable are independent of each other. 
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Some studies aim to compare the time to outcome between two patient groups. 
The data from such a study will define a time origin and the time of occurrence of 
some particular outcome or each patient. The observations for those patients that 
do not experience outcome by the end of follow-up are censored, and the patients 
have varying lengths of follow-up time during which an outcome may occur. The 
analysis of data that describes the time to a particular event is called survival 
analysis, or Cox proportional hazards regression analysis (Collett 1994). The 
hazard ratio provided by is Cox regression analogous to the relative risk, however it 
incorporates the aspect of time. A strong assumption underlying this analysis is 
that of proportional hazards, which means that the impact of the different variables 
on outcome is constant over time. No particular distribution is assumed for the 
survival times, but a strong assumption is made that the effects of the different 
variables on survival are constant over time and additive in a particular scale. 
(Collett 1994) 
Linear regression models for binary and continuous outcomes are based on 
assumptions that may not hold for many types of data. For example, it may not 
always be reasonable to assume that data are normally distributed when modelling 
counts or proportions. The generalised linear models (GLMs) extend the traditional 
linear models and are applicable to a wider range of data analysis problems, 
particularly when dealing with multiple explanatory factors simultaneously. 
Generalised linear models constitute a family of linear models that allows the 
outcome (the "linear predictor") to be calculated from a non-linear link function and 
allows the response probability distribution to be any member of an exponential 
family of distributions (McCullagh and Nelder 1989). Many widely used statistical 
models fit into the family of generalised linear models. These include classic linear 
models with normal errors, logistic and probit models for binary data and log-linear 
models for multinomial data. Binary data, continuous data and counts can all be 
analysed by the same model class. 
The GLM is specified by selecting an appropriate link function, which defines the 
relationship between the observations and the linear predictor, and a response 
probability distribution. For binary outcomes where the linear predictor (response) 
is a probability, the link function is a logit link. For data where the linear predictor 
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presents means (i. e. the variable is continuous) the link function is expressed as an 
identity function. For data where the linear predictor is counts, the link function is a 
log link. The error structure expresses the distribution of deviation from expectation 
of the model. For binary outcomes the error structure is binomial. For continuous 
outcomes the error structure is normal, and for counts the error structure is 
specified as a Poisson distribution. 
Prognostic variables can be included in models in a mechanistic way by using a 
forward or backward selection approach. (Altman 1997) In forward regression the 
relationship between each potential explanatory variable and the outcome variable 
is examined. The variable that has the strongest association with the dependent 
variable will be entered into the model as a factor. Subsequently, the variable 
amongst the others that explains the largest amount of the remaining variability is 
then added to the model. Variables are added until the addition of an extra variable 
is not statistically significant at a chosen level (usually p<0.05). In backward 
regression all those variables that a priori were considered potentially important 
explanatory variables are included in the model to start with and then unimportant 
variables are removed one at a time until all those variables remaining in the model 
contribute significantly at a chosen level. Backward regression approach has the 
advantage that it increases the patient material for which it bases its calculation for 
each variable that it removes. Consequently the power to detect significant 
variables increases as the model is reduced. The disadvantage comes when the 
impact of several potential explanatory variables is explored and the potential for 
multiple significance testing and false positives arises. To minimise this problem, 
only factors that are plausible confounders should be included in a model selection 
exercise. 
The aim of modelling is to arrive at a regression that fits the data reasonably well. 
The model fit is described by the residual deviance between the observations and 
the regression line. A modelling exercise therefore always seeks to reduce the 
residual deviance to find the best predictive model. An integrated part of a 
modelling exercise it to assess how well a statistical model fit the data by 
considering the proportion of the variation in outcome that can be explained by the 
variables in the model. Model fit in regression models can be explored by 
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examining two values, the statistic R2 and the residual deviation. R2 is the 
proportion of the total sum of squares of all included covariates that can be 
explained by the regression. This can be expressed as a percentage and will 
crudely assess the degree to which the model fits the observations in the dataset. 
The value of R2 is expected to increase as the number of variables in the model 
increases, even though each added variable does not relate to the dependent 
variable (Altman 1997). Exploring the residual deviation is therefore essential. A 
residual is the difference between an observed and a fitted value and each 
observation will have a residual. The variance of the residuals produced by a 
regression line expresses the amount of variability (random variation') that is 
unexplained by the covariates in the fitted model. The variance and standard 
deviation of the residuals is therefore a measure of 'goodness-of-fit' of the line 
produced by the model. (Altman 1997) 
The residuals are normally distributed for a well-fitting model of continuous 
outcome. Therefore, the residuals produced by generalised linear models with 
normal error may be explored visually by producing a plot of the residuals, for 
example against the fitted values or against each of the explanatory variables. For 
models with binary and Poisson error however, there is no requirement for the 
residuals to be normally distributed. When assessing model fit for such models the 
issue of overdispersion becomes more important. A measure of overdispersion is 
obtained by dividing the value of the residual deviance by the degrees of freedom. 
When the model fits well then these are expected to have the same value. 
5.2.2 Critical appraisal of the UKPCD (Mediplus@) database 
The European Health Outcomes Research team at Eli Lilly and Company Ltd. 
(Windlesham, Surrey) funded the project over the course of which the Mediplus@ 
database was evaluated. There was increasing interest in the conduct of 
observational studies to evaluate real-life cost-effectiveness of the drugs in clinical 
practice. The Health Outcomes team in the UK affiliate of Eli Lilly (Basingstoke, 
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Hampshire) had access to the Mediplus@ database through a continuous 
subscription with IMS Health. Combined with an academic interest in exploring the 
use of observational databases for economic evaluation, this provided joint 
research interest in evaluation of Mediplus@ for such analysis. The evaluation 
process included choice of a research area of interest, a critical review of published 
literature on the database to assess a potential for evaluation and finally exploring 
of practical features of the data that would eventually feed into a specific study 
design. 
Identifying a therapeutic area worthy of further research 
At the time when the study was initiated, Eli Lilly and Company had recently 
launched a pharmaceutical treatment in the therapy area of osteoporosis. The 
company was interested in planning a future evaluation of the drug in a clinical 
practice setting in the UK. Two studies were planned. The first study would be a 
pilot study evaluating the ability of the database to provide data to a full economic 
evaluation in the therapeutic area of osteoporosis. The second study would include 
the drug marketed by Eli Lilly and Company in the same therapeutic area. 
The chosen subject of the study was the cost and consequences of the use of 
osteoporosis medications in UK clinical practice. A number of economic 
evaluations in the therapeutic area of osteoporosis have been published. 
(Torgerson et al 1997) These economic evaluations have to date predominantly 
been based on decision -an aiytic models, and these were reviewed in Chapter 4 of 
this thesis. (Sculpher et al 1999) Health economic models are constructed in order 
to predict the impact of a therapy under circumstances of uncertainty. Clinical and 
economic assumptions incorporated in such models may or may not reflect the 
clinical practice reality in which the pharmaceutical eventually will be used. For 
example, lower compliance rate in clinical practice may adversely affect the 
effectiveness of the therapy when routinely used outside of a trial. The review in 
Chapter 4 revealed that many models assume full compliance with therapy over 
several years, and omit exploring the impact of reduced compliance on the cost- 
effectiveness ratio. Furthermore, costs that are relevant to the population of 
patients in clinical practice, such as cost of side effects of treatment, was not 
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incorporated in the previous economic evaluations. Finally, in previous economic 
evaluations, the fracture risk reduction has been modelled from the change in BMD 
at fracture-susceptible sites from trials, or based on assumptions with basis in 
epidemiological studies (see chapter 4). (Tosteson 1991, Weinstein 1980) 
Three issues were therefore of particular interest to the use of clinical practice data 
in this therapy area. Firstly, the primary clinical outcome in registration trials of 
osteoporosis therapies is frequently bone mass density (BMD), a measurement that 
is widely recognised as a risk factor for osteoporotic fractures. (Marshall et al 1996) 
For the purpose of economic evaluation however, hip fracture is a more relevant 
outcome because of the costs and human suffering associated with them (Dolan 
and Torgerson 1998). It is therefore of interest to an economic evaluation to assess 
the relative effectiveness of osteoporosis medications to preventing hip fractures as 
manifested in clinical practice. 
Secondly, the effect of preventive medications for osteoporosis may rely upon the 
duration of treatment. Economic models are frequently based on the assumption 
that medication is used over a period of several years, for example 15 years in a 
study by Tosteson et al. (1990). In clinical practice, however, some patients cease 
to take medication before the preventive effect is experienced. It was therefore of 
interest to identify the degree to which patients cease to take pharmaceutical 
therapies in osteoporosis in clinical practice. 
Finally, the use of the bisphosphonates in treatment of osteoporosis (alendronate 
and etidronate) has been associated with gastrointestinal conditions (Ettinger et al 
1998 a, Ettinger et al 1998 b) . Gastrointestinal conditions such as 
dyspepsia and 
perforation are frequently treated with drugs such as the H2 antagonists (H2s) and 
the proton pump inhibitors (PPIs). The costs of treating these side effects have not 
previously been assessed in the UK clinical practice setting. 
Together, these provided rationale for further study and good background for the 
design of a feasibility study for which the intention was to explore these issues and 
arrive on recommendations for future use of the database for economic evaluation 
studies. 
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Data review 
The availability of observational databases and evaluation methodology provide 
material and methods on which to build when aiming to develop further 
methodology to increase the external validity of economic evaluations. There is 
indication that the Mediplus@ database potentially provides a wealth of clinical 
practice information. What are the fundamental data requirements for an economic 
evaluation in primary care, and is Mediplus@ likely to meet these data requirements 
of contents, quality and structure? Prior to analysing data from a specific study in 
the database, literature covering the contents and construct of the database was 
reviewed. Through this review, the coverage of the data was assessed, the risk of 
contamination during data entry procedure was appraised, the data structure was 
reviewed, and the data retrieval procedures were evaluated. 
Specific requirements for economic evaluation data depend on the type of analysis 
undertaken and its sophistication. The problem in question, the institutional 
framework and the perspective of the analysis will determine the data requirements. 
Fundamentally, patient level resource consumption in the sectors relevant to the 
perspective of the analysis must be identified, measured and valued. Similarly, 
clinical consequences at patient level must be identified and measured. (Drummond 
et al 1997) Furthermore, data requirements vary profoundly according to the 
disease area, whether the condition is prevalent in primary or secondary care, 
whether the condition is chronic or based on treatment episodes and whether it is a 
physical or mental disorder. A study undertaken from the perspective of primary 
care should collect costs that occur in the primary care sector. These include cost 
of study medication and relevant concomitant medication, healthcare activity costs 
such as GP visits and nurse visits and cost of clinical tests and assessments. The 
relevant clinical outcome needs to be identified, and the timing of outcome may be 
of importance. Finally, a key principle of clinical and economic evaluation is the 
presence of a control group either in the form of 'no treatment' or alternative 
intervention. (Pocock 1984) 
Fundamental to a study aiming to evaluate context specific effectiveness of a 
therapy is the inclusion of subjects who reflect the population to which results intend 
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to be extrapolated. Judging by demographic information, the Medipluse database 
covers a population of GPs and patients reasonably reflective of UK general 
practice. Deviations include age distribution of the GPs on the data panel, 
geographical representation and size of the GP practices. A larger proportion of 
younger GlPs (<45 years) and fewer older GlPs than in the UK as a whole are 
included on the panel. The areas of Northern and Yorkshire and South and West 
are ove r- represented and Scotland and Northern Ireland underrepresented. A 
greater proportion of participating practices are large (6-9 partners) compared with 
the UK average. (IMS Health 1998) 
Is the recording of data likely to provide valid and accurate information? Monitoring 
of data recording is a key part of the conduct of randomised clinical trials. (ICH 
1996) Data recording regular activity in clinical practice, where monitoring 
procedures do not exist, may be more susceptible to contamination by human error. 
The general practices on the data collection panel for Mediplus@ use computers 
with software provided by IMS Health. A data file of the daily clinical record entries 
is created in each practice and transmitted by modem to IMS daily. General 
practitioners were included on the Mediplus@ panel after a trial period of data entry 
and quality training. There is a regular audit of recording at practice-level with 
feedback at quarterly intervals and requirements to meeting predetermined 
standards of data quality. The data quality standards cover areas such as patient 
coverage and prescription details. For example, the IMS minimum requirement for 
percentage of prescriptions entered onto computer is 80%. An audit in 1998 
revealed that 98% of practices met the requirement. (Lawrenson et al 1998) 
Practices who consistently fail to reach the minimum standards are eliminated from 
the panel. (IMS Health 1998) The quality audits are in place to assure a minimum 
quality standard. However, contrary to conditions of an ideal epidemiological study, 
(Jick et al 1998) the Mediplus@ system does not enable source validation of the 
outcomes against written clinical records or original hospital records. 
Does the construction of the data in Mediplus@ enable identification of the essential 
costs and outcomes for economic evaluation study, such as demographic data, 
resource consumption and clinical conditions? The recording of gender and age is 
complete in the database. For reason of confidentiality, a virtual birthday is 
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assigned at January 1" in the year of birth for all patients in the database. This 
enables identification of patients by age and sex. Indicators for resource 
consumption items in the database include medication use and cost, GP activity 
and referral and admissions. Drug prescriptions are recorded by generic name and 
trade name as well as by code in the Anatomical Therapeutic Chemical (ATC) 
international system for classification of drugs. The cost of the issued amount of 
medication is calculated in the database as a function of pack size and MIMS price 
(Monthly Index of Medical Specialities). The date at which the prescription was 
issued, either by the GP or the practice nurse through repeat prescription, is 
recorded and this may provide indication of GP activity. Clinical conditions are 
recorded in the Read code system. (Chisholm 1990) The construction of 
Mediplus@ patient records is based around clinical conditions and all activity 
undertaken is linked to a condition. The providers call this "problem based" record 
keeping, where "problem" equals clinical condition, provided valid and accurate 
recording. (IMS Health 1998) In theory this would enable evaluation of all aspects 
of care being evaluated as a function of a clinical condition. For example, a patient 
with a diagnosis of asthma would have a series of prescriptions issued, clinical 
assessments undertaken and perhaps also referrals to specialist care. All these 
activities should be linked to the condition of asthma. Similarly, all activity 
undertaken in association with a condition of hypertension on the same patient 
would be linked to hypertension rather than asthma. The construct of the database 
and the 'problem based' records is illustrated in Figure 5.1. 
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Figure 5.1 A simplified diagram showing the construct of the Medioluso database and 
how levels of information can be linked. 
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Data collection, the quality audit, and the management and upkeep of the 
Mediplus@ database is administered by IMS Health, a commercial organisation that 
specialises in the provision of market information to healthcare industries, such as 
the pharmaceutical industry. (http: //wwww. imshealth. com) Customers can buy data 
or full analyses from the Mediplus@ database prepared by researchers at IMS 
Health for a fee. The data fee is calculated on the basis of the number of patients 
and number of variables included in the datafile. A researcher at IMS Health 
conducts the process of extracting data from the masterfile of the whole database 
to a datafile containing the information specified for any specific study. Once the 
datafile is extracted from the main database there is limited opportunity to go back 
and seek more information or review whole patient records. Similarly, there is 
limited opportunity for the external customer wishing to undertake the study to gain 
insight in the data extraction step. 
Approval to conduct an analysis for publication must be gained prior to the work 
starting through submitting a protocol for review by an Independent Scientific and 
Ethics Advisory Committee. Any manuscript to be submitted for publication should 
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be made available for review by I MS Health for comments at least 4 weeks prior to 
submission. IMS Health then comments on citation but does not'approvey or 
disapprove' publications. Seventy-five titles have been published from the 
Mediplus@ database; 27 of these are study results published in scientific journals, 
and the rest were predominantly abstracts and posters. A publication list from IMS 
Health 2001 can be found in appendix 4. There are examples of drug utilisation 
studies (Jones et al 1995) and epidemiological studies (Farmer et al 1997, Farmer 
et al. 1998). The Mediplus@E] database has not previously provided data for a full 
economic evaluation. 
Towards an evaluative design 
The access to full patient records of more than a million patients appear to be a rich 
opportunity for the study of clinical effectiveness and cost-effectiveness of 
pharmaceutical interventions in clinical practice. The review of literature and 
exploring of data construct and recording revealed that the Mediplus@ database 
may have a potential for generating data for a full economic evaluation of 
osteoporosis drugs. A feasibility study adopting a rigid design and clear objectives 
would clarify remaining issues surrounding data contents and quality and enable 
assessment of whether the Mediplus@ database satisfies basic data requirements 
for the conduct of economic evaluation of pharmaceuticals and explore whether the 
available data are appropriate for such analysis. 
The Mediplus@ database provides, in theory, opportunity for both retrospective 
cohort study and case-control design. For economic evaluation, where the cost- 
effectiveness of one or more therapies is evaluated, the cohort design is more 
appropriate as this is based on inclusion according to exposure rather than 
outcome. Therefore, the conduct of a retrospective cohort study was planned. 
The decision to include patients who received the six most prevalent treatments for 
postmenopausal osteoporosis in the UK was made. The bisphosphonates 
Alendronate (FosamaXTM ) and cyclical etidronate (Didronel PMOTM) were included. 
Two hormone replacement therapies, the so-called non-bleed HIRT combinations, 
were included. These contain conjugated oestrogen/medroxyprogesterone 
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(Premique TM ) and oesterogen/norethisterone (KliofeMTM). For simplicity the HIRT 
therapies were called HRT(P) and HRT(N) throughout the report. Finally, tibolone 
(LivialTM ) and raloxifene (EvistaTM)were included, where the indication for 
prescription at the time of study was prevention of osteoporosis. (BNF 2000) 
Two studies were planned. The first study was a feasibility study of the potential for 
Mediplus@ to enable economic evaluation of therapies in the treatment of 
osteoporosis. The second study was a reiteration of the feasibility study at a later 
time to evaluate effectiveness of raloxifene at a time when a larger number of 
patients had initiated therapy on the drug. Aspects of the Medipluse database of 
strategic importance to the design was explored at the database terminal at the UK 
affiliate of Eli Lilly and Company at Basingstoke, Hampshire and IMS Health 
headquarters in Pinner, London. 
Patients 
The Mediplus@ database enables identification of patients by gender, age and 
medication use. The purpose of the pilot studies was to evaluate an association 
between exposure to selected pharmaceutical interventions and clinical 
effectiveness and resource use. Therefore, patients were included in the studies on 
the basis of the medication that they had received. It was possible to identify 
medication use through searching by relevant Anatomical Therapeutic Chemical 
(ATC) codes. 
The inclusion of patients in the control group according to the condition of 
osteoporosis was done in a similar database analysis in the GPRD database. (van 
Staa et al 1998) As outlined earlier, the "problem based" recording in Mediplus@ 
should in theory enable the identification of a subset of women that have the 
diagnosis of osteoporosis but are not prescribed any of the study interventions. It 
did however become apparent in the exploring of the data that this was unfeasible. 
This was illustrated by two findings in an exploratory analysis at the terminal. 
Firstly, the bisphosphonates are almost exclusively prescribed in treatment and 
prevention of osteoporosis. However, for many women prescriptions of the 
bisphosphonates were issued under different clinical problem heading, for example 
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"Asthma" or "Hypertension". Secondly, it is reasonable that in an activity driven 
record only actions taken against a condition would trigger the recording of the 
conditions. In other words, a patient may well be at risk or suffer from a condition, 
but unless any action is taken by the GP no recording of the condition is likely to be 
made. 
Clinical outcomes 
The incidence of hip fracture was primary clinical endpoint for the economic 
analysis. A Read code (Chisholm 1990) for hip fracture was available to indicate 
the presence of outcome in the patient records. Duration of treatment in clinical 
practice was also evaluated. Attrition is a key element of treatment success and 
difference in patients' adherence to the drug regime may be an indication of which 
drug is more tolerated by the patients. The event of premature cessation of therapy 
is not routinely recorded in the Mediplus@ database. Therefore, a stop date was 
imputed based on the duration of the medication supplied at last prescription of 
study drug and the date of prescription. This enabled estimation of treatment 
duration by subtracting start date from stop date in the data analysis step. 
Resource use 
Acquisition cost for the prescriptions of index drug can be extracted directly from 
the database. The cost of medication quoted in Mediplus@ is the manufacturers 
listed price as published in MIMS (IMS Health 1998) and is identified at chemical 
substance level (ATC level). 
There is a formula incorporated in the database design that estimates number of 
GP visits based on number of entries in the patient record. Entries to the patient 
record can be made by telephone contact to the surgery, and at repeat 
prescriptions, when results from tests reach the practice, etc. All entries are dated, 
but more than one entry can be made on one day. Therefore, the number of dates 
entered can not be used as a direct estimate for GP visits. In order to see whether 
the Mediplus@ formula gives a realistic presentation of GP visits it was decided to 
collect information on the number of dates entered and compare this with the 
estimated visits. 
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Referrals to specialities and hospital admissions are recorded in Read codes and 
are identified in the notes attached to patient entries (see Figure 6.1). There is a 
date attached to every entry, and consequently it is possible, in theory, to quantify 
the number of referrals in a patient record for the purpose of economic evaluation. 
5.3 Aim and objectives 
The decision to undertake an evaluative study in the Medipluse database 
developed from the research need to develop further methodologies to provide 
economic evaluation data with high external validity. At the same time, Eli Lilly and 
Company was interested in making best use of current databases to provide 
information of real-life cost-effectiveness of one of their pharmaceuticals. The 
clinical rationale for study combined with the availability of data led to the 
formulation of specific research objectives for a project aimed at assessing the 
feasibility of Mediplus@ for economic evaluation. 
The feasibility project was planned in August 1999. Raloxifene (Evista TM) was 
registered in the UK in September 1998 and only very few patients had been 
exposed to the therapy at the time that the study was planned. Therefore, two 
studies with separate objectives were planned. The first study would evaluate the 
feasibility of the database for full economic evaluation of pharmaceutical 
interventions and explore this through a pilot study in the therapy area of 
osteoporosis. The second study was developed after the analysis of the first study 
was completed at a time that more patients had been exposed to Raloxifene. The 
second study would include those components of a cost-effectiveness evaluation 
that the first study deemed feasible, and apply those to raloxifene and a comparison 
group 
As section 5.5 will show, only certain variables in the Mediplus@ database satisfied 
the information need and quality standards for the conduct of an economic 
evaluation. Design of the second study was dependent on the first study. 
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Consequently, only those variables from the first study that met the data 
requirements were used as input to the design of the second study, and this is 
reflected in the objectives and the study design of the second study. 
Aim 
To evaluate whether the potential wealth of information contained in the UK Primary 
Care Database (IMS Mediplus@) make it a feasible tool for a full economic 
evaluation, including evaluation of treatment patterns as well as clinical and 
economic outcomes of treatment. 
Objectives for the First study 
o To evaluate the incremental costs and effectiveness associated with the use 
of therapy with tibolone, alendronate, etidronate, HRT(P) or HRT(N) (study 
drugs) in women over the age of 55 in UK general practice setting (study 
population) between January 1s' 1996 and December 31st 1998 (study 
period). 
To assess resource consumption in primary care in the study population 
associated with the use of the study drugs during the study period. 
To assess the risk of hip fracture and its determinants associated with 
initiation of treatment with the study drugs in the study population during the 
study period. 
To assess the extent to which the study population discontinue treatment 
with the different study drugs during the study period. 
Objective for the Second study 
o To assess and compare drug use patterns and costs associated with the 
use of raioxifene and the bisphosphonates in UK clinical practice. 
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5.4: Methods 
5.4.1 Design of first study: Pilot study of osteoporosis drugs in Mediplus@ 
Data extraction 
The UK Primary Care Database (UK MediPlus@) was used to derive information 
from computer records of 1 million active patients from approximately 140 general 
practices throughout the UK. A SAS analyst and researchers at the IMS Health 
(UK) main offices in Pinner, London, developed the analytical files according to a 
detailed design document. Five analytical files were created and linked by a unique 
patient number. The files contained observations on predetermined variables 
describing demographic data, therapy progress, concomitant medication, referrals 
and clinical events respectively. The statistical variables for the first study are 
provided in appendix 5.1 through 5.5. 
Patients 
Inclusion and exclusion 
Patients were identified from the computer records according to the following 
inclusion criteria: 
0 Patients received a first prescription ('index prescription') of either of the 
study drugs (see table 1) during the period of January Ilst 1996 through 
December 31 s' 1998. 
* Patients were women at the age of 55 years or older when the index 
prescription was issued. 
* GP practice to which the patient beionged was active in the database in 
December 1999. 
9 Patients were active in the database in December 1999. 
0 Patients were included in the study provided that they were active in the 
database 9 months or more before the index date. This criterion was 
developed to ensure that all patients had a previous recording history in the 
database of at least 9 months. 
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9 The patients had a period of 6 months prior to the index date during which 
no drug with an impact in osteoporosis was issued. 
Patients were excluded based on the following criteria: 
0 Patients who had a prescription of two different study drugs on the index 
date. 
0 Patients who appeared in more than one study cohort (1996,1997 and 
1998). 
The patients included in the control group were matched to the exposure group by 
age and gender and were included on the basis that they were not exposed to the 
selected medications. Two patients were included in the control group per patient 
initiating therapy with study drug. Two reasons explain the choice of a 2: 1 ratio. 
Firstly, the providers of the database, IMS, provide a data charge that is dependent 
on the number of patients included in any given study. Limited budget would 
therefore encourage an economical use of the data. Secondly, there is little 
statistical efficiency to be gained by including more patients in the in the control 
group. The variance of the effect estimate, i. e. the probability of events in the 
intervention group less the probability in the control group, cannot be reduced by 
reducing the variance of the effect estimate in the control group only. The general 
formula for the standard error for the difference between proportions is 
(I 
- 
P, P2 (1 - 
P2) 
SEdiff 
n, 
') + 
n2 
For a study with 1000 patients in the intervention group, the probability of event in 
intervention group 0.7 and the probability of event in the control group 0.3, the SEdiff 
would be 0.022 for a 1: 1 ratio inclusion of patients to the control group. When 
including 2000 patients in the control group in a 2: 1 ratio, the SEdiff would drop to 
0.019. The value of the SEdiff would be 0.017 for 5000 patients in the control group, 
and indeed stay 0.017 for inclusion of 10.000 patients in the control group. Thus, 
the return in terms of greater precision in the estimate by including more patients in 
the control group diminishes rapidly beyond the 2: 1 ratio. 
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Study medication 
Hormone replacement therapy (HRT) is more frequently used in a younger 
population of women for treating menopausal symptoms rather than as prevention 
strategies for osteoporosis. The inclusion of women over the age of 55 aimed at 
excluding those women that were prescribed HIRT for postmenopausal symptoms. 
Indeed, for women older than 60 years, the main reason for using HIRT is for 
fracture prevention. (Ettinger 1999) The bisphosphonates are on the other hand 
indicated in a population of women with a high risk of osteoporosis or where the 
condition already is manifested (BNF 2000). 
The Mediplus@ database is constructed such that GPs can record drug 
prescriptions either by trade name, generic name or by chemical substance. 
Identification of medication was therefore based on both product name and 
substance name to ensure inclusion of all eligible patients (see table 5.2). 
Etidronate and HRT(N) were exemptions as the same substances are shared with 
different products. Drug dose and form of administration was not considered. 
Table 5.2. Study drugs of interest to the evaluation 
Substance 
Tibolone 
Product 
LivialTM 
Basis for selection 
Substance + Product 
Alendronic acid FosamaXTM Substance + Product 
Conjugated oestrogen and 
medroxyprogesterone (HRT(P)) 
Premique TM 
I 
Substance + Product 
Etidronate DidroneIPMOTM roduct (multi-substance)' 
Oesterogen and norethisterone (HRT(N)) KliofeMTM Product' 
'The same substance is used in a formulation used in a different therapeutic area. 
2 The same hormone combination is shared by a different product, Elleste Duet ContiTM. 
Women in the HIRT group and the bisphosphonate group were analysed separately 
throughout. Bisphosphonates are indicated as treatment of manifest osteoporosis, 
whereas the HIRT drugs and tibolone raloxifene are likely to be prescribed as 
osteoporosis prevention. These cohorts are likely to differ in terms of prior 
susceptibility to fracture and comparing fracture risk between these cohorts would 
therefore be inappropriate. To simplicity analysis the controls of the tibolone 
patients were grouped with those of the HIRT therapies. Importantly however, 
tibolone have different pharmacological effects, side effects and clinical benefits 
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than the HRTs. (Royal College of Physicians 1999) The control patients were 
grouped in one control cohort matched with the HRT patients (including tibolone) 
and one control group matched with the bisphosphonate patients. 
Baseline charactefistics 
The Read code system by which clinical conditions are recorded in Medipluse was 
used to develop definitions for a number of baseline characteristics. A set of Read 
codes to indicate selected conditions was developed by the researcher (HU) and a 
researcher at IMS Health UK (see appendix 5.2). The patient records were 
screened for the presence of a number of clinical conditions recorded until 9 
months prior to the date at which the first prescription of the study medication was 
issued. These were Asthma, Pulmonary disease, Respiratory system disease, 
Rheumatism, Arthritis and Gastrointestinal (GI) disease. Some chronic conditions 
were searched 5 years back in the patient records. These were recording of 
Osteoporosis, Hysterectomy, Breast cancer, Ovarian cancer, CHID, Stroke, MI, 
Cerebrovascular disease and Hypertension. 
Follow-up 
Follow up was 1,2 or 3 years depending on which time the first prescription was 
issued. If the prescription was issued in 1996 the follow-up time was 3 years, if the 
prescription was issued in 1997 the follow-up time was 2 years and similarly the 
follow-up time was 1 year for those included in 1998. 
Outcomes 
Definition of clinical outcome 
A set of Read codes to categorise clinical outcome was developed by the 
researcher (HU) and an analyst at IMS Health (UK) (See appendix 5.2). The 
patient records were searched for the recording of either of the indicators for each 
clinical outcome. 
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17 ip fracture 
A set of clinical Read codes was developed to identify the recording of hip fractures 
in the database. These are provided in appendix 5.2. Occurrence of hip fracture 
was recorded in the original datafile as number of fractures recorded in the patient 
records and date at which the fracture was recordej. If the code occurred at 
several dates then this was extracted into the datafile as a new fracture. If two 
dates recording the same code for outcome were within 3 months of each other 
they were considered duplicate recording of the same fracture and only counted 
once. 
Treahnent pattern 
The day at which the first prescription was issued was assigned the 'Index date'. 
This date indicates inclusion in the study. "Stop date" was defined as the date at 
which no further study drug issued in the 6 months following the end date of the 
duration of the last prescription of drug. A sensitivity analysis was undertaken to 
assess the impact of changing the definition of "stop date" to a drug-free time period 
of 3 months. 
Resource consumption 
The preliminary exploring of the Mediplus@ database described in section 5.1 
indicated that it may be possible to generate resource consumption data on GP 
visits, drug acquisition costs and cost of concomitant medication relevant to the 
therapy. Furthermore, items that were collected to describe the resources 
consumed in secondary care were referral rates to hospital and referral to various 
specialists. Two alternative ways of expressing GP activity at patient level were 
extracted from the database: 
" The number of GP visits computed by the providers of the database 
" The number of dates entered in the patient records 
These two indicators were compared in an attempt to identify whether the database 
providers' definition is an appropriate estimator of GP activity. The results of this 
comparison indicated the plausibility of the computed measure of GP activity, and 
therefore the reliability with which GP visits can be estimated in Mediplus@. 
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The cost of drug treatment was extracted directly from the database. The ATC 
code for the relevant study medications were identified. The cost for the quantity of 
drug that was issued to the patients in the 6 months period before the first 
prescription of study medication was extracted. Similarly, the cost of the quantity of 
study medication in the first, second and third year after the first prescription of 
study medication was extracted. 
The costs of prescriptions issued for other medications were extracted in a similar 
manner to the acquisition cost of study medication. Information was extracted on 
the following drugs: antacids, H2 antagonists, proton pump inhibitors, multivitamins 
and minerals (ATC Al 1A and Al 1B only), mineral supplements (Calcium, vitamin C 
and D), laxatives, sex hormones, corticosteroids, antirheumatic agents, non- 
narcotic analgesics (N02A and N02B only) and bronchodilators. 
Referrals to the specialists listed below were identified through the Read code 
system and quantified by the number of dates entered for each referral type. 
Referrals to hospital were identified and quantified the same way. The referrals 
recorded were hospital referral (A&E) gynaecologist, orthopaedic, rheumatologist, 
gastrointestinal investigation, physiotherapist and radiologist. 
Statistical analysis 
All analysis was conducted using SAS for windows release 6.12 and 8.0 (SAS 
Institute, Cary, NC). A number of simple checks of the data were done prior to 
analysis to investigate the presence of outliers, implausible values and missing 
values. This included creation of frequency tables of class variables and calculation 
of means, standard deviation and range of numeric variables. The datasets were 
also viewed on screen for assessment of face validity. The design protocol was 
compared with the dataf iles to confirm the presence of all variables. It was not 
possible to undertake source verification of the occurrence of outcomes such as hip 
fracture through access to written patient records. The Mediplus@ system does not 
enable such checks. 
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Modelling hip fracture risk 
The primary outcome of the pilot study was hip fracture. Overall time to hip fracture 
was defined as 
Date of fracture - Date of inclusion in the study (Index date) 
An important feature of the data resulting from this design is the fact that patients 
have varying follow-up time during which hip fracture may occur. The timing of 
fractures after initiating therapy was therefore of interest, as well as the frequency 
of fractures. The observations for those patients that do not experience outcome by 
the end of follow-up are censored. 
This censorship was the key reason why Cox regression is the most appropriate 
model structure in this evaluation (see section 5.2.1). The analysis of data that 
describes the time from an origin to the occurrence of a particular event is called 
survival analysis, or Cox proportional hazards regression analysis (Altman 1997). 
The hazard ratio provided by is Cox regression analogous to the relative risk, 
however it incorporates the aspect of time. A strong assumption underlying this 
analysis is that of proportional hazards, which means that the impact of the different 
variables on outcome is constant over time. No particular distribution is assumed 
for the survival times in Cox regression. (Altman 1997) 
A number of factors that practically and intuitively were considered to be plausible 
predictors of outcome were explored on their own and in combination, and those 
factors that came out significant were included in the final model. Powerful 
explanatory variables may be distributed unevenly across the patient cohorts 
because of the non-random treatment assignment. The impact of the medication is 
therefore at risk of being outweighed by other risk factors for fracture. It was 
essential to analyse the association of medication effect on fracture risk in the 
presence of such potential covariates on fracture risk. The patient records were 
screened for the presence of the following variables, which a priori were considered 
to be plausible risk factors for fracture: smoking status, previous hip fracture, 
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previous wrist fracture, previous vertebral fracture, previous other fracture, history 
of osteoporosis and age. Patient age was divided into two strata: <75 and ý: 75. 
Those variables that were deemed to have prognostic value (at conventional 
significance level 0.05) were used in a model selection analysis to assess their 
importance in the presence of other variables. The combination of those factors 
that were significant in the univariate analysis was explored through creating 
interaction terms and that were fitted into the Cox models. Drug exposure (index 
drug) was finally added to the model to assess the impact of osteoporosis drug on 
the risk of hip fracture in the presence of observed covariates. Patients in the 
bisphosphonate treatments (etidronate and alendronate) was analysed and 
compared separately from the patients receiving the HRTs, raloxifene and tibolone. 
The cumulative hazard of hip fracture was plotted using the Kaplan-Meyer method. 
The goodness-of-fit of the Cox regression model was assessed through the plotting 
and examination of the residuals. Examining that the curves in the Kaplan-Meyer 
plots did not cross tested whether the assumption of proportional hazards was 
violated. 
Modelling attrition rate 
A secondary outcome of the analysis was the patients' duration of therapy in clinical 
practice. Of particular interest was whether or not there was a difference in 
duration of treatment between the cohorts of women initiating therapy on the 
various intervention drugs. 
Attrition rate is the rate at which the GPs cease to issue prescriptions of the study 
drug. Overall time to stop was defined as 
Stop date - Date of inclusion in the study (Index date) 
The proportion of patients remaining at each quarter after index date was compared 
using chi-square test. The estimated time to stop was compared between the 
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treatments using Cox regression. Kaplan Meyer plot was used to present 
graphically the rate at which GPs cease to issue prescriptions of the study drugs. 
Analysing resource consumption data 
Unit costs for the resource items were published by Personal Social Services 
Research Unit, University of Kent (see table 5.3). (PSSRU 2000) 
Table 5.3. Unit costs of resource consumption in secondary healthcare (source 
PPSRU 2000). 
Item 
GP consultation 
Unit cos 
218 
Practice nurse E9 
Hospital referral (A&E) 2282 
Rheumatologist 278 
G1 investigation E 73 
Physiotherapist E 21 
Radiologist 9-23 
The intention was to cost GP visits and analyse average cost increase prior to and 
after exposure to index drug between appropriate pairs of study drugs. The 
assumption of normality underlying generalised linear modelling techniques of 
continuous data, is frequently violated in the case of economic evaluations. Cost 
data are frequently positively skewed, many patients often incur no cost and a small 
proportion of patients may account for a large proportion of the resource use and 
hence costs. Comparison of distributions on a log scale data provides a comparison 
of geometric means of the sample. Geometric means are however always less 
than the arithmetic mean (average) and therefore the comparison of geometric 
mean through log-transformation of the data may be inappropriate. (Thompson and 
Barber 2000) Using non-parametric Mann-Whitney U test is also inappropriate as 
this is based on the comparison of medians rather than means and the results are 
difficult to interpret in the context of pound value. (Thompson and Barber 2000) 
The non-parametric bootstrap procedure (Efron and Tibshirani 1986) has been 
proposed as an alternative to investigating differences in costs between groups as it 
does not make parametric assumptions about normality or symmetry on the 
distribution of cost the difference. (Briggs and Gray 1999) The method involves re- 
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sampling with replacement from the study sample and computing of cost 
differences in each of the multiple samples. In this analysis the non-parametric 
bootstrap procedure with 10.000 repetitions was used to compare the difference in 
arithmetic mean costs between treatment and control groups. To express 
uncertainty in the cost difference estimate the 25" and 75 th percentiles of the 
ranked bootstrapped cost differences represent the boundaries for the 95% 
confidence interval (i. e. the 251s'and 9.750th ranked differences). The difference 
between costs in the groups is significant if the 95% confidence interval does not 
include 1 at conventional level of significance (p<0.05). 
The drug class non-steroid anti-inflammatory drugs (NSAIDs) are known to induce 
gastrointestinal side effects similar to those experienced with bisphosphonates. 
The change in average cost of gastrointestinal (GI) drug use associated with the 
use of bisphosphonates was assessed by comparing the costs incurred before 
initiation of study medication with those incurred after first use of bisphosphonate. 
This analysis assessed whether the observed association between 
bisphosphonates and GI drugs could be explained by an inter-relationship between 
GI drug use (outcome) and NSAID. The analysis of GI drug costs was therefore 
carried out incorporating both variables (bisphosphonate and NSAIDs). The use of 
NSAID was defined as a binary variable. 
Referrals and admissions were tabulated and compared between the cohorts. In 
those cases were the difference in absolute number of referrals differ significantly 
between the cohorts between year 0 and 1 the referral rates were costed and 
analysed by using bootstrap Mest. 
Cost-effectiveness analysis 
The aim of cost effectiveness analysis is to compare the costs and effects of one 
treatment compared to some relevant alternative. Known costs and effects of 
treatment versus control interventions may therefore be summarised in a cost- 
effectiveness ratio. The incremental cost-effectiveness ratio (ICER) provides a 
summary of the cost-effectiveness of one intervention relative to a comparison 
therapy or no therapy by dividing the difference in the mean costs of the two 
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alternatives by the difference in mean effects of the alternatives. The ICER of one 
treatment compared to an alternative is therefore given by: 
ICER = 
Ct - Cc 
Ec - Et 
WhereCTis the aggregate cost of treatment, Cc is the aggregate cost of control, ET 
is the effectiveness of the therapy, and Ec is the effectiveness of the control 
therapy. Incremental cost effectiveness ratios are relevant in situations where one 
intervention is more costly and produce greater health benefits than the intervention 
being compared. In such situations the ICER facilitates a judgement of about 
whether the additional costs of the more expensive therapy is justified by the 
additional effects associated with that therapy. In situations where one intervention 
is more costly and produces less health benefits than the other, one intervention is 
said to dominate the other, and the recommendation from the economic analysis 
would be to adopt the less costly and more effective therapy. 
The analysis of this study planned to aggregate the costs incurred in each 
intervention group and estimate a mean total cost per patient. The main analysis 
would take the perspective of the primary care sector and therefore include the 
following cost items: GP visits, acquisition costs and cost of concomitant 
medication. Where relevant, an ICER would be calculated for those study drugs 
that were more costly and produced greater effects than the no-intervention 
alternative in the age-matched control groups. 
The non-parametric bootstrap method would be used to calculate 95% confidence 
intervals around the estimates of cost differences. Cox regression analysis was 
used to analyse adjusted hip fracture risk difference and 95% confidence intervals 
for hip fracture. Unit of analysis for effectiveness was patients with hip fracture. 
The cost effectiveness would therefore be expressed as "cost per patient avoiding 
hip fracture". Number of patients avoiding hip fracture would be modelled from the 
adjusted fracture risk reduction. Both methods of confidence interval estimation are 
restricted to handling uncertainty related to the sampling variation. 
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5.4.2 Design of second study: Raloxifene and bisphosphonates in Mediplus@ 
This second study was designed with the purpose of replicating those aspects of 
the Mediplus@ database that were judged feasible through the evaluation of data 
from the pilot study outlined in chapter 5.4.1. As will become apparent in section 
5.5.1, the evaluation of drug use patterns and costs associated with medication use 
appeared feasible in the database. This second study evaluated raloxifene and the 
bisphosphonates (etidronate and alendronate) in UK clinical practice. 
Data extraction 
An analyst at IMS Health (UK) conducted the data extraction from the Mediplus@ 
database onto an analytical file according to a design protocol. Thestatistical 
variables for the second study are provided in appendix 5.6. 
Patients 
Patient inclusion was based on the following criteria: 
e Patients received a first prescription (index prescription) of any of the exposure 
drugs (index drug) during the period of ls'August 1998 to 31" January 2000. 
o Practice was active in the database in December 1999. 
9 Patients were active in the database 6 months prior to the index prescription. 
Patients were excluded based on the following criterion: 
e Patients who had a prescription of two different study drugs on the index date. 
The only demographic characteristics collected were age and the history of 
osteoporosis in the patient records. 
Table 5.4 lists the interventions included in the study. GPs record drug 
prescriptions in the Mediplus@ database either by product trade name, generic 
name or by chemical substance. Selections from the database were therefore 
based on both product name and substance name. Drug dose and form of 
administration was not considered. 
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Two control patients were identified for each study patient and matched by age. 
Follow-up was 6 months. 
Outcomes 
Concomitant drug use 
A record was made of the use of the following drug therapies 6 months before and 
6 months after the index date (i. e. date of inclusion in the study): 
0 GI Drugs (H2 blockers and proton pump inhibitors) 
0 Analgesics 
e NSAIDs 
Treatment pattern 
5 The day at which the first prescription was issued was assigned the 'Index date. 
This date indicates inclusion in the study. "Stop date" was defined as the date at 
which no further study drug issued in the 6 months following the end date of the 
duration of the last prescription of drug. A sensitivity analysis was undertaken to 
assess the impact of changing the definition of "stop date" to a drug-f ree time period 
of 3 months. 
Statistical analysis 
Modelling attrition rate 
A secondary outcome of the analysis was the duration of patients' therapy in clinical 
practice. Of particular interest was the existence of a difference in duration of 
treatment between the cohorts of women initiating therapy on the various 
intervention drugs. 
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Table 5.4. Study drugs considered 
Overall time to stop was defined as: 
Stop date - Date of inclusion in the study (Index date) 
The proportion of patients remaining at each quarter after index date was compared 
using the chi-square test. Estimated time to stop between the treatments was 
compared using Cox regression and Kaplan Meyer plotting was used to give a 
graphic presentation of the rate at which GPs cease to issue prescriptions of the 
study drugs. 
Cost of gastrointestinal drugs 
The change in average cost of gastrointestinal (GI) drug use associated with the 
use of the bisphosphonates was assessed by comparing the costs incurred before 
initiation of study medication with those incurred after first use of bisphosphonate, 
using the non-parametric bootstrap procedure with 10.000 replications (see section 
5.4.1). The drug class Non-Steroidal Anti-Inflammatory drugs (NSAID) is known to 
induce gastrointestinal side effects similar to those experienced with 
bisphosphonates, so the analysis assessed whether the observed association 
between bisphosphonates and GI drugs could be explained by an inter-relationship 
between G1 drug use (outcome) and NSAID. The analysis of GI drug costs 
incorporated both variables (bisphosphonate and NSAIDs), with the use of NSAID 
defined as a binary variable (i. e. NSAID use or no NSAID use). 
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5.4.3 Summary of design differences between the two studies 
The studies diff ered on several parameters. Table 5.5 summarises the main design 
differences of the studies. 
Table 5.5 Study aspects that differed between the first and the second study 
designed to evaluate the feasibility of the MediplusO database for economic 
evaluation. 
Study aspect First study Second study 
Interventions Alendronate Raloxifene 
Etidronate Alenronate 
Tibolone Efidronate 
HRT(P) 
HRT(N) 
Study period January 1s' 1996 to December 31st August 1s' 1998 to January 31s' 
1998 2000. 
Follow-up 12 months to 3 years 6 months 
Costs GP visits Drug acquisition costs 
Referrals to secondary care Concomitant medication costs (GI 
Accident and emergency drugs only) 
admissions 
Drug acquisition costs 
Concomitant medication costs 
Clinical Hip fracture Attrition rate 
outcomes Other clinical events (e. g. other 
fractures and cancer) 
Attrition rate 
129 
5.5 Results 
Section 5.3.1 reports the results of the first study of HRTs, bishosphonates and 
raloxifene in clinical practice, exploring the feasibility of the database to provide 
variables for analysis of the cost-effectiveness of drugs in clinical practice. Section 
5.3.2 reports the results of the second study, reiterating the feasible aspects of the 
first study, but including bisphosphonates and raloxifene only. The purpose of the 
second study was to reiterate the first, focusing on those variables of the first study 
that provided plausible results and applying those to a subset of patients using 
raloxifene and the bisphosphonates. During analysis it became apparent that the 
results of the overlapping variables differed substantially. Section 5.3.3 highlights 
these differences in the findings of the two studies. 
5.5.1 Results of the First study 
Patients 
Overall, 8463 patients were included in the first study (Table 5.6). A total of 2838 
patients were observed over three years, 2877 over two years and 2748 over one 
year. Two thirds of these patients were age-matched control patients. The number 
of patients exposed to each therapy in each year was similar; only etidronate 
differed, with a doubling of patient numbers from 1996 to 1998. 
The indications for the prescription of drugs included prevention or treatment of 
osteoporosis. (BNF 2000) The prescription of study drug was issued under a 
problem heading (i. e. diagnosis) of osteoporosis for an average of 18.5% of 
patients included in the study (Table 5-7). Alendronate and etidronate users had 
the highest proportion of prescriptions issued for diagnosis of osteoporosis with 
57.3% and 46.3%, respectively. 
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Table 5.6. Number of patients included in the study in study drug cohort by year 
Study drug 1996 1997 1998 Total Total years 
(3 years (2 years (I yea r number of of follow- 
follow-up) follow-up) follow-up) patients up 
HRT(P)' 249 286 274 809 1593 
HRT(N)' 358 290 236 884 1890 
Tibolone 151 167 144 462 931 
Etidronate 34 60 68 162 290 
Alendronate 154 156 194 504 968 
HIRT Control Group 1516 1486 1308 4310 8828 
Bisphosphonate Control 376 432 524 1332 2516 
Group 
Total 
- 
2838 2877 2748 8463 17016 
T Conjugated oestrogen and medroxyprogesterone (PrerniqueTM) 
2 Oestrogen and norethisterone (KliofeMTM) 
Table 5.7, Percent of the prescription of study drug that was linked to a diagnosis of 
osteoporosis by study drug. 
Study drug Diagnosi 
Efidronate 
s of Osteoporosis 
46.3 (n=75) 
Other diagnosis or diagnosis 
missing 
53.7 (n=87 
Total number 
of patients 
162 
Alendronate 57.3 ( n=289) 42.7 (n=215) 504 
HRT(N) 7.9 (n=70) 92.1 (n=814) 884 
Tibolone 7.8 (n=36) 92.2 (n=426) 462 
HRT(P) 6.2 (n=50) 93.8 (n=759) 809 
Total 18.5 ( n=520) 81.5 (n=2301) 
Patient characteristics of age, height body mass index (BMI) and smoking status 
were recorded. Patient height was not routinely recorded in the database - indeed, 
was missing for between 70% and 90 % of the patients. Extreme values were 
recorded, for example, one patient had a height of 1.20 meters recorded and one 
patient had a height of 1.90 meters recorded. The mean heights were between 1.58 
metres and 1.62 metres (Table 5.8). Age was negatively skewed for the patients 
using hormone replacement therapies (HRTs) and their corresponding control 
group (Figure 5.2). Patient age was symmetrically distributed around the mean in 
the bisphosphonate cohorts and their corresponding control group. The age 
distribution was similar between the bisphosphonates as a group and between the 
different HRTs. 
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Figure 5.2 Age distribution for the patients included in the study by study drug cohort. 
Control group (bisphosphonates) 
Etidronate 
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0 
,, Alendronate 
Age (Years) 
Patients that initiated therapy with the bisphosphonates (etidronate and 
alendronate) were more likely to have clinical conditions recorded in their patient 
records than those that initiated on HRT therapy (Table 5.9). For example, 
between 34.5 % and 38.3 % of women on bisphosphonates suffered from arthritis, 
while between 16.9 % and 19.5 % of women on the HRT drugs suffered from the 
same condition. The presence of gastrointestinal (GI) disease was an exception, 
as it had similar frequency in all study drug cohorts, with between 9.3% and 13.0% 
for the bisphosphonates and between 5.7% and 14.3% in the HIRT cohorts. 
Osteoporosis was recorded as a clinical condition in 59.9% of the patients receiving 
etidronate and in 73.4% of patients receiving alendronate (table 5.10). In 
comparison, osteoporosis was recorded in only 1.8% of the patients in the 
bisphosphonate control group. Between 9.9 % and 12.3% of the HIRT patients had 
a recording of osteoporosis in their patient records. 
Table 5,11 reports the number of patients, by drug cohort, that had a fracture 
history prior to inclusion. The patient records were searched for the 5-year period 
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prior to the prescription of study drug for the presence of various fractures. Overall, 
63 women had a previous fracture recorded in their patient records, representing 
0.7% of the total number of women included in the study. Of the etidronate 
patients, 2.5% and of the alendronate patients 4.4 % had hip fractures recorded in 
their clinical records prior to being prescribed a bisphosphonate for the first time. 
Only about 0.2% - 0.7% of the women initiating HRT therapy had previously 
experienced a hip fracture. 
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Risk of Fractures 
The variables describing the presence of fractures were defined as the number of 
fractures recorded on each patient. Six patients had two hip fractures recorded, 
three patients had four hip fractures recorded and one patient had six hip fractures 
recorded in her record. Similarly, one patient had four wrist fractures and one had 
four vertebral fractures recorded. This is likely to have been repeated recording of 
the same injury, so the fracture data was analysed according to the number of 
patients experiencing a fracture rather than by number of fractures which occurred 
(Table 5.12). 
A total of 49 patients experienced a fracture after the index date in the whole 
sample of 8463 patients, representing 0.6% of the population, or about 6 per 1000. 
More patients in the bisphosphonate treatment groups experienced a hip fracture 
after index date compared to those receiving HRT therapies (Table 5.13). 
Table 5.13. Frequency of hip fracture in the index drug cohorts after index date. 
Drug cohort 
Bisphosphonate group Efidronate 
Patients with 
fracture 
2 
Frequency (%) 
1.2 
Alendronate 18 3.6 
Bisphosphonate Control Group 14 1.1 
HRT group HRT(N) 1 0.1 
HRT(P) 3 0.4 
Tibolone 1 0.2 
HRT Control Group 10 0.2 
Total 49 0.61 
A number of clinical conditions were, a priori, considered to be likely predictors of 
the risk of fracture, and the predictive power of the following variables was 
explored: smoking status, previous hip fracture, previous wrist fracture, previous 
vertebral fracture, previous other fracture, history of osteoporosis and age>75. The 
prevalence of these attributes differed by study drug cohort (Table 5.14). When 
analysed individually, the predictive value of previous hip fracture, previous wrist 
fracture, previous other fracture, history of osteoporosis and patient age (> 75) were 
significant, at p<0.05 (Table 5.15). 
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The significant variables were tested in the presence of each other. Recording of 
wrist and other fracture and of osteoporosis in the patient records were insignificant 
in the presence of age>75 and previous hip fracture (Table 5.16). First order 
interactions between the significant variables were not considered clinically 
plausible, and so were not explored. The final model contained previous hip 
fracture and age>75 (see Table 5.17). 
Table 5.15. Cox proportional hazards analyses of time to hip fracture among patients 
with clinical conditions potentially having predictive power. 
Variable Property Number of hip p-value Hazard ratio (95% Cl) 
fractures by (SE) 
variable 
Smoking Status Non smoker 4177264 
(0.56%) 0.650 1.19 
Smoker 8/1157 (0.39) (0.56 to 2.54) 
(0.69%) 
Previous Hip Fracture No fracture 26/8381 
(0.31%) 0.0001 171.84 
Fracture 23/63 (0.29) (97.66 to 302.35) 
(36.51%) 
Previous Wrist Fracture No fracture 45/8208 
(0.55%) 0.020 3.365 
Fracture 4/213 (0.52) (1.21 to 9.36) 
(1.84%) 
Previous Vertebral No fracture 49/8373 
Fracture (0.58%) 1 0.00 
Fracture 0/48 (774.84) 
(0%) 
Previous Other Fracture No fracture 43/8054 
(0.53%) 0.0099 3.077 
Fracture 6/367 (0.44) (1.31 to 7.23) 
(1.61%) 
History of Osteoporosis Diagnosis 43/8054 
(0.53%) 0.0313 2.213 
No diagnosis 6/367 (0.37) (1.07 to 4.56) 
(1.61%) 
Patient age (> 75) <70 25/7474 
(0.33) 0.0001 7.816 
75 24/947 (0-29) (4,46 - 13.69) 
(2.47%) 
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Table 5.16. Cox proportional hazards analyses of time to hip fracture among patients 
with clinical conditions having predictive power individually. 
Variable 
rev ous wrist f ractu re 
p-value 
0.694 
SE 
0.59 
Hazard ratio (95% Cl) 
0.8 (0.3 to 2.5) 
Previous hip fracture <0.0001 0.32 104.7 (55.9 to 197.4) 
History of osteoporosis 0.950 0.39 1.0 (0.5 to 2.1) 
Previous other fracture 0.142 0.50 2.1 (0.8 to 5.4) 
Age >75 <0.0001 0.31 3.7 (2.0 to 6.8) 
Table 5.17. Final Cox proportional hazards model of time to hip fracture* 
Finally, the index drugs were included in the model to investigate drug impact in the 
presence of the explanatory model of prognostic variables. None of the drugs 
produced a significant reduction in the relative risk of hip fracture compared with the 
control groups. Indeed, the analysis indicated that alendronate compared to the 
bisphosphonate control group actually increased the likelihood of experiencing a 
fracture compared with the age matched control groups (Table 5.18). 
Further analysis to compare fracture rates between the HRTs was not considered 
meaningful, as patient numbers and recorded fractures were low in these groups. 
Table 5.18. Adjusted Cox proportional hazards analyses of time to hip fracture among 
patients using bisphosphonates and HRTs. 
Comparison 
Efidronate vs Bisphosphonate control group 
Hazard ratio (95% Cl) 
0.77 (0.17 to 5.49) 
P-value 
0.74 
-2 Log L 
187.45 
Alendronate vs Bisphosphonate control group 1.95 (0.94 to 4.07) 0.07 371.37 
Efidronate vs Alendronate 0.42 (0.10 to 1.82) 0.25 199.69 
HRT(N) vs. HRT control group 0.23 (0.03 to 2.03) 0.18 104.60 
Tibolone vs. HRT control group 0.91 (0.11 to 7.59) 0.93 101.78 
HRT(P) vs. HRT control group 1 . 
07 (0-27 to 4.28) 0.93 137.58 
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Treatment pattern 
The attrition rate for those patients who initiated therapy with the bisphosphonates 
was analysed separately from those initiating therapy with the HRTs, raloxifene and 
tibolone. The proportion of patients remaining on etidronate was significantly lower 
than that of alendronate takers at every point in time for the main analysis using the 
3-month definition of stop date (Table 5.19, Figure 5.4). Using the 6-month 
definition of stop date provided a different result (Table 5.20 and Figure 5.3). 
Table 5,19. Proportion of patients retaining treatment with the bisphosphonates at 
quarterly intervals of the first year* 
0 months 
Etidronate 
100 
Alendronate 
100 
p-value' 
NA 
3 months 69.8 94.1 <0.05 
6 months 61.1 92.9 <0.05 
9 months 54.9 91.5 <0.05 
12 months 51.9 89.9 <0.05 
*The 3-month of drug free period was used as def inition of stop date. 
Table 5.20. Proportion of patients retaining treatment with the bisphosphonates at 
quarterly intervals of the first year* 
0 months 
Oldronate 
100 
Alendronate 
100 
p-value, 
N 
3 months 90.7 97.0 <0.05 
6 months 88.3 96.4 <0.05 
9 months 85.2 96.23 <0.05 
12 months 84.0 95.4 <0.05 
The 6-month of drug free period was used as definition of stop date. 
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Figure 5.3 Attrition rates for the study drugs at one year using 6 month definition for 
stop date. 
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The hazard of stopping therapy with etidronate was 5.3 (3-8 to 7.4) times the 
hazard of stopping therapy with alendronate when using the 3-month definition of 
stop date (Table 5.21). This difference was highly significant (p<O. oOOj). When 
using the 6-month therapy stop definition the hazard estimate differed substantially, 
as the hazard of stopping therapy with etidronate was 2.1 (1.7 to 2.6) times that of 
stopping therapy with alendronate - still a highly significant difference (p<0.0001). 
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Table 5.21. Cox proportional hazards analyses of average time to therapy Stop in the first 
year among patients using the bisphosphonates. 
There was no statistically significant difference between any of the remaining 
proportions of women initiating therapy with the HRTs at any point in time (Table 
5.22). The pattern was confirmed when using the 6-month definition of stop date, 
so Cox proportional hazards analyses for the HRTs was not pursued. 
Table 5.22. Proportion of patients retaining treatment with HRTs at quarterly intervals of 
the first year* 
Interval 
0 months 
HRT(N) 
100 
HRT(P) 
100 
Raloxifene 
100 
Tibolone 
100 
3 months 97.4 96.4 100 95.5 
6 months 95.5 94.1 85.7 93.1 
9 months 94.5 92.3 85.7 91.6 
12 months 93.6 91.6 85.7 90.9 
IThe 3-month of drug free period was used as definition of st op date. 
Resource consumption 
Table 5.23 illustrates the average number of GP consultations as reported by the 
formula inherent in the Mediplus@ database to calculate GP visits from number of 
dates in the patient record. The average number of GP visits was between 9 and 
26 per year in the patient cohorts, according to the calculation by this formula. 
Standard deviations were large and the reported range was exceptionally high, with 
extreme values of estimated 132 GP visits per year. In comparison, the number of 
dates entered in the patient records was remarkably similar to the number of GP 
visits as estimated by the Mediplus@ system (Table 5.24). The Medipluse formula 
does not seem to provide a realistic estimate of GP visits, so further analysis of cost 
of GP activity was not pursued. 
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Average costs of the study drugs are reported in Table 5.25. These were 
accumulated over the period of time that patients took medication, whether they 
stopped prematurely or whether they continued until the end of follow-up. The 
average cost of etidronate was about P-106, and of alendronate E340. The standard 
deviation was very large in the etidronate group, and the maximum observed cost 
was, indeed, more than E300 higher than that of alendronate. The HIRT drugs 
were, on average, less costly than the bisphosphonates. Tibolone differed from the 
HIRT drugs in that the average cost was higher and the maximum observed cost 
higher. 
Table 5.25. Acquisition costs for study drugs by drug cohort. 
Costs are in UK f Sterling (1999). 
The costs of gastrointestinal (GI) drugs in the year prior to index date differed 
between the bisphosphonate group and the corresponding control group. The 
average cost in the previous year for 1-12-antagonists was E5.12 in the control group 
and El 1.94 in the bisphosphonate group, and similarly P-1 0.08 and E30.1 0 for 
proton pump inhibitors (Figure 5.5). During the first year of bisphosphonate use, 
the average cost of H2 antagonists increased by EO. 96 (95% Cl -1.45 to 3.38) 
when compared to the controls (Table 5.26). In comparison, the average cost of 
proton pump inhibitors increased significantly by E10.29 during the first year (95% 
Cl 4.47 to 16.46) when compared to controls. Similar increases were observed in 
subsequent years. The relative magnitude of the difference in the use of H2 
antagonists and proton pump inhibitors was similar, at about 30%, though the 
absolute difference was greater in the case of the proton pump inhibitors, as these 
are more expensive drugs. 
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Increase in the average cost of GI drugs between previous year and first Fioure 5.5. 
year after inclusion in the study 
Table 5.26. Increase in GI drug costs for patients using the bisphosphonates between 
prior and first year, and the subsequent follow-up years. The results are stable in the 
presence of GI condition and NSAID use. 
Drug 
H2 antagonists 
Year 
0-1 
Mean difference from 
control group (C) 
0.96 
95% Cl 
-1.45 to 3.38 
1-2 3.11 0.31 to 6.04 
2-3 3.30 0.72 to 6.27 
Proton pump inhibitors 0-1 10.29 4.47 to 16.46 
1-2 11.48 4.01 to 19.25 
2-3 9.47 3.71 to 15.48 
H2 antagonists and Proton pump inhibitors 0-1 11.26 5.25 to 17.51 
grouped 1-2 14.62 6.78 to 22.93 
2-3 12.73 _ 6.36 to 19.34 
Both concomitant NSAID use and the presence of a GI condition in the patient 
records individually influenced the cost of GI drug use. The interaction effect 
between treatment and GI condition and treatment and NSAID use respectively, 
was small and the effect of treatment on GI costs was stable in the presence of 
both factors. 
The absolute number of people taking GI drugs increased between the prior and 
the first year of treatment with the bisphosphonates (Table 5.27). H2 antagonists 
were issued to 35 (5.3%) new patients and proton pump inhibitors to 49 (7.3%) new 
patients after treatment with alendronate and etidronate. In the same time period, 
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30 patients stopped taking GI drugs after initiating bisphosphonate therapy. In 
subsequent years the increase was not remarkable, in spite of the fact that the 
average cost of GI drugs continued to increase. 
Table 5.27. The number of patients on bisphosphonates that take GI drugs and patients 
that stop and how many of those that initiate therapy on GI drugs in the follow-up years. 
N 
interval 
Year 0-1 
Patients 
Using GI drug prior to study 
Patients using 
H2 antagonists 
78(11.7) 
Patients using 
Proton Pump inhibitors 
82(12.3) 
(666 patients) Using GI drug in first year 94(14.1) 102(15.3) 
Stop taking therapy 19 11 
Initiate therapy 35 49 
Year 1-2* Using GI drug in first year 66(16.3) 72(17.8) 
(404 patients) Using GI drug in second year 52(12.9) 79(19.5) 
Stop taking therapy 33 12 
Initiate therapy 19 24 
Year 2-3* Using GI drug in second year 28(14.9) 37(19.7) 
(188 patients) Using GI drug in third year 22(11.7) 39(20.7) 
Stop taking therapy 13 7 
Initiate therapy 7 9 
The baseline number of patients having accumulated follow-up times of more than a year is 
reduced by year. That is why the absolute number of patients using GI drug in first year is reduced 
when comparing to use in second year. Similar for year 2-3. 
The difference in GI costs for etidronate and alendronate were also analysed 
separately (Table 5.28 and Table 5.29). Significant changes observed in GI costs 
before and after therapy differed in direction and magnitude. 
Table 5.28. Increase in GI drug costs for patients using Etidronate between prior and first 
year, and the subsequent follow-up years. 
Drug 
H2 antagonists 
Year 
0-1 
Mean difference to 
control group (C) 
-1.09 
95% Cl 
-5.70 to 3.17 
1-2 7.91 1.83 to 14.78 
2-3 2.67 -1.79 to 7.53 
Proton pump inhibitors 0-1 12.51 0.05 to 24.95 
1-2 16.65 -0.49 to 32.70 
2-3 16.64 3.62 to 29.69 
H2 antagonists and Proton pump inhibitors 0-1 13.49 -1.08 to 26.30- 
grouped 1-2 24.45 6.64 to 42.00 
2-3 19.50 6.05 to 33.16 
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Table 5.29. Increase in GI drug costs for patients using Alendronate between prior and 
first year, and the subsequent follow-up years. 
Drug 
H2 antagonists 
Year 
0-1 
Mean difference to 
control group (C) 
-0.93 
95% Cl 
-3.71 to 1.79 
1-2 1.59 -1.49 to 4.82 
2-3 3.43 0.53 to 7.10 
Proton pump inhibitors 0-1 9.63 3.28 to 16.33 
1-2 10.02 1.81 to 18.54 
2-3 7.05 1.00 to 13.52 
H2 antagonists and Proton pump inhibitors grouped 0-1 10.54 - 4.18 to 17.43 
1-2 11.65 2.77 to 20.29 
2-3 10.58 3.62 to 17.61 
Table 5.30 contains the recording of referrals and admissions within each cohort. 
Overall, 11.3% (n=982) of patients had two or more accident and emergency (A&E) 
admissions in the six months before treatment and 21 % (n=l 777) had two or more 
A&E admissions recorded in the first year after treatment. Eighty-six patients had 
10 or more A&E referrals recorded in their first year. Similar proportions were seen 
in subsequent years, with many patients having 10 or more admissions in their 
record. Recording generally seems to overestimate the number of referrals, so 
further costing and analysis of these data was not pursued. 
The recording of referrals to specialists such as physiotherapist, radiologist and 
gastrointestinal (GI) investigation seemed more realistic than that of A&E 
admissions (not shown). One to three GI investigations were recorded for 33 
patients in the 6 months prior to initiating the study drug, and 69 patients had one to 
three GI investigations in the first year after treatment. No patient had more than 
four investigations in any year. Recording of referrals to physiotherapist was more 
frequent, with an overall 0.48% (41) of patients having two or more referrals 
recorded in the previous six months. Of these, one patient had 10 admissions 
recorded in six months. Seventy-eight patients (0.92%) had two or more referrals 
recorded in the first year after initiating the study drug and of these, 13 patients had 
between 5 and 15 referrals in the first year. Referrals to radiologist were recorded 
for 27 patients (0.04%) who had two to three radiologist referrals in the six months 
prior to treatment, and 37 (0.05%) patients had two to four referrals in the first year 
after initiating treatment. The proportion of patients in each cohort with referrals 
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recorded was very similar over all categories in each year, so formal analysis of the 
average difference in cost was not pursued. 
Incremental cost-effectiveness ratio 
An analysis of incremental cost effectiveness ratio was planned for the first study 
for each study drug compared to the control group. This would have been 
appropriate in those circumstances where the study drug was more costly and 
produced greater effects than the no-treatment alternative (see section 5.4.1). The 
costs comprised estimates of GP visits, drug acquisition costs and costs associated 
with increased use of concomitant medication. Hip fracture was primary endpoint 
intended for the economic evaluation. 
The results presented in this section did however show that the analysis of the data 
from the first study did not provide plausible estimates of neither resource use nor 
clinical effectiveness. Realistic estimates of GP visits were not obtainable, and in 
spite of the use of multivariate techniques, the analysis of hip fracture did not arrive 
at unbiased estimates of hip fracture risk reduction associated with treatments. 
This negated the calculating of incremental cost effectiveness ratios for the 
interventions under study. 
The results of the second study are reported in the next section. Due to the 
revelations of shortcomings of the first study of the Mediplus@ data to provide 
plausible and valid information on GP visits, referral rates and clinical outcomes, the 
recording of these outcomes were not pursued in the second study. 
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5.5.2 Results of the second study 
The second study was developed to replicate those components of an economic 
evaluation that the first (pilot) study indicated was feasible for the purpose. Therefore 
the second study had a more limited scope, and was not designed with the objective 
of arriving at a full cost-effectiveness analysis. The study evaluated patients using 
raloxifene, etidronate and alendronate according to the outcomes of attrition rate and 
cost of concomitant GI medication. 
Patients 
Two-thirds of the 2076 patients included in the second study belonged to the age- 
matched control group (see Table 5.31). By design, all patients had a follow-up time 
of six months. None of the patients in the study drug cohorts had a clinical history of 
osteoporosis recorded in their patient records in the six months prior to inclusion in 
the study, but 22 patients (1.59 %) in the control group had this history. 
Table 5.31. Number of patients and average patient age in each cohort (sd) 
Alendronate 
Number of patients 
409 
Average age (sd) 
69.22 (12.1) 
Etidronate 59 68.22 (12.4) 
Raloxifene 224 61.79(9.8) 
Control 
Igroup 
1384 
I 
66.73 (11.9) 
Treatment pattern 
The proportion of patients remaining on alendronate six months after first prescription 
was 56%, significantly lower than the 71 % remaining on therapy with etidronate 
(Table 5.32, Figure 5.6). The risk of stopping therapy with alendronate was 38% (-7 
% to 63%) higher than that of raloxifene, though this difference was not significant at 
a conventional level. 
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Table 5.32. Cox proportional hazards analyses of time to stop among patients using 
raloxifene or bosphosphonates. * 
Ficiure 5.6 Attrition rates for the stud drugs at six months using 3-month y 
definition for stop date. 
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Resource consumption 
The average costs of gastrointestinal (GI) drugs in the six months prior to index date 
were somewhat higher in the bisphosphonate group compared with the 
corresponding control group (table 5.33). The average cost in the previous six 
months for H2-antagonists was P-46.50 in the control group, 9-66.50 in the 
alendronate group and F-77.35 in the etidronate group. The average cost in the 
previous six months for proton pump inhibitors was 2118.37 in the control group, 
E137.37 in the alendronate group and F-128.87 in the etidronate group. 
During the first six months of bisphosphonate use, the average cost of H2 
antagonists increased by 9-1.48 (95% CI 0.13 to 3.01) when compared with the 
controls. The average cost of proton pump inhibitors saw a significant increase of 
E5.48 during the first year (95% Cl 2.15 to 8.79) when compared with controls. 
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Figure 5.7 Costs for concomitant medication with GI drugs. 
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Table 5.33. Increase in GI drug costs for patients using the bisphosphonates between 
prior 6 months and following 6 months. 
The differences in GI costs for etidronate and alendronate were also analysed 
separately (Table 5.34 and Table 5.35). No significant changes in GI costs could be 
observed between the six months before patients initiated either of the 
bisphosphonates. 
Table 5.34. Increase in GI drug costs for patients using Etidronate between prior and 
first year, and the subsequent follow-up years. 
Table 5.35. Increase in GI drug costs for patients using Alendronate between prior and 
first year, and the subsequent follow-up years. 
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The average acquisition costs of the study drugs are reported in Table 5.36. The 
costs were based on all patients, whether they stopped prematurely or whether they 
continued until the end of follow-up. The average cost of etidronate was about E81, 
and of alendronate P-126. Standard deviation was very large in both groups. Patients 
initiating therapy with raloxif ene generated an average cost of therapy of about F-1 08. 
Table 5.36. Average acquisition costs for the study drugs. 
5.5.3 Summary of differences between the two studies 
The studies reported in section 5.3.1 and 5.3.2 included patients over two different 
time periods. The study period of the pilot study (the first study) was January 1s' 1996 
to December 31 st 1998 and the study period of the second study was August 1 s' 1998 
to January 31s'2000. The data extraction for the first study was done in March 2000, 
and the extraction for the second study was done in September 2000. The second 
study was undertaken in order to analyse patients on raloxifene according to aspects 
of the Mediplus@ database that proved of value in the first (pilot) study. The aspects 
included in the second study were treatment pattern and cost of concomitant 
gastrointestinal (GI) medication for the treatment of suspected side effects. Patients 
initiating therapy on raloxifene, etidronate and alendronate were included in the 
second study. By design, patient inclusion criteria were virtually identical. The 
outcomes investigated in the two studies overlapped, so the results of the analysis of 
patients on bisphosphonates were expected to be comparable, within a reasonable 
range of variation due to chance. 
However, the findings from the studies outlined above revealed large discrepancies. 
Firstly, the estimate of the degree to which GlPs ceased to issue prescriptions of the 
bisphosphonates (attrition rate) differed profoundly between the studies. Figures 5.3 
and 5.6 highlight this finding. The proportion of patients remaining on therapy with 
etidronate was 6 1.1 % after six months in the first study and 71.2% in the second 
study, both when using the 'three month' definition of stop date in the first study. In 
contrast however, the proportion of patients remaining on therapy with alendronate 
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was as high as 92.9% in the first study, but dropped to 56.0% in the second study. 
Secondly, the estimate of cost of GI drugs differed between the studies, both at 
baseline and in terms of change over the period during which patients had been 
exposed to the study medications. Figures 5.5 and 5.7 highlight these differences. 
For example, the estimated average cost of GI drugs in the 12 months prior to 
prescription of etidronate in the first study was E51.92, whereas the estimated 
average cost of GI drugs in the six months prior to prescription of etidronate was 
El 10.75. The estimated baseline level differed by more than 300% -a difference that 
was unlikely to be attributable to chance. 
Action was taken to verify the origin of these unexplained discrepancies. A 
comprehensive description of the datafiles, analysis and results was presented to 
IMS Health in March 2001. Upon presentation of the discrepancies, the consultancy 
attempted to compare the SAS code that was used for the two extractions. Two 
different analysts at IMS Health had conducted the data extraction from Mediplus@ 
for the datafiles for the first and the second study. The analyst that conducted the 
first data extraction had since left the company and the remaining staff was unable to 
verify the SAS code that had been developed by that individual. After reviewing their 
internal data extraction notes, the counsultancy confirmed that the data for the first 
study was faulty (oral communication with Mary Thompson at IMS Health on August 
21st 2001). The consequences of this finding are discussed in the next section. 
5.6 Discussion 
Health care systems increasingly aspire to provide cost-effective health care to its 
populations. A challenge for researchers is to develop methodologies for adoption by 
health economists wishing to undertake economic evaluations where the findings 
have a high external validity. Retrospective observational databases score in theory 
highly on speed and convenience of conduct and external validity of the results. 
Such studies can therefore be carried out quickly compared to the time it takes to set 
up a prospective study or a trial. However, the use of observational data for the 
purpose of economic evaluation introduces a series of challenges. Specifically these 
include provision of relevant clinical and resource variables, provision of valid 
recording of clinical events and resource use, and enabling the use of appropriate 
analysis methods to arrive at unbiased estimates of costs and effectiveness. 
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This study set out to evaluate a patient record database for its feasibility to providing 
data for a full economic evaluation in primary care setting. This aim was met through 
the development of design and evaluation of two studies of therapies in osteoporosis 
using the UK Primary Care Database (UK Mediplus@). Specific objectives of the first 
study described in section 5.2.1 were to assess the risk of hip fracture, 
discontinuation rate and primary care resource use amongst women in general 
practice setting in the UK who initiated therapy on individual osteoporosis drugs. The 
objective of second study was described in section 5.2.2 and this sought to evaluate 
a second subset of patients by outcomes deemed feasible by the first study. 
Section 5.4.1 reviews whether the Mediplus@ database in its current form fulfilled 
basic data requirements for a full economic evaluation study design. Section 5.4.2 
discusses the study results in view of whether they provide plausible and valid 
information on costs and outcomes of medication use in clinical practice. Finally, the 
discussion turns to answer the bigger question of overall feasibility of Medipluse for 
economic evaluation. The results of the two studies, the first pilot study and the 
second replication study, are discussed parallel throughout, and implications are 
drawn of the fact that the data for first study was flawed on delivery from IMS Health. 
5.6.1 The merits of the database for economic evaluation study design 
The first phase in the evaluation of Mediplus@ involved an assessment of whether 
the database fulfils data requirements to economic evaluation. For the conduct of a 
relevant and comprehensive economic evaluation in a database, the GPs and 
patients need to be representative of the general population; patient level resource 
consumption in the sectors relevant to the perspective of the analysis must be 
identified, measured and valued; clinical consequences at patient level must be 
identified and measured; and finally, it must be possible to identify an appropriate 
control group. 
There were no substantial demographic differences between the GP panel and the 
general UK population of GPs. (IMS Health 1998) At first glance this may indicate 
that the database is representative of the general pool of GlPs. However, there may 
be reasons that the GPs on the panel are not typical of UK GlPs after all. Firstly, the 
155 
panel was initially set up based on practices that found the transition to a 
computerised record keeping acceptable. Before entering the panel supplying data 
to Mediplus@ the GPs undertook a trial period. The GP practices were then selected 
on the basis of their adherence to the entry regulations of the database. (IMS Health 
1998) Secondly, the GPs contributing to the Mediplus@ database are younger than 
the average GP population. There may be reason to believe that the practice of 
younger GPs deviate from that of more senior colleagues. Perhaps these would pick 
up new therapy traditions more easily and may also be more computer skilled. 
Finally, GPs on the Mediplus@ panel are regularly monitored and subject to regular 
quality audits. This may increase completeness of the data, but it introduces a 
selection bias in that only those GPs participate that are likely to be compliant, 
computer skilled and younger than average. Taken together, these factors suggest 
that the recorded information in Mediplus@ may systematically differ from the care 
that is provided to the general population. Whether this influences the content and 
quality of care is unsure, but it may limit the scope for extrapolation of study results. 
The designs of the feasibility studies were based on patient inclusion by drug 
exposure, age and gender. The database enabled collection of patient-level 
information on variables covering relevant clinical conditions at baseline, incidence of 
relevant clinical outcomes and indicators for use of resources such as GP visits, 
referral rates and cost of medication. The database enabled valuation of resource 
use directly by providing wholesale prices for issued prescriptions. 
In the context of an observational study, where exposure is assigned through non- 
random selection, it is essential to match by certain features of adjust for the 
presence of explanatory factors that may impact the effect of treatment. In a study of 
osteoporosis drugs it would be desirable to identify a control group by matching with 
the clinical condition of osteoporosis. In preliminary exploring of the Mediplus@ data 
it became apparent that very few patients had the diagnosis of osteoporosis recorded 
if they were not treated for the condition. This may not necessarily be a shortcoming 
of the database as such but may rather be a result of clinical practice being 'activity 
driven'. For example, why would a GP record the presence of osteoporosis if the 
patient does not receive treatment for it? In addition, findings of the first study 
indicated that relevant clinical conditions may indeed not be routinely recorded even 
when action towards the condition is taken. For example, only 46.3% of the 
prescriptions of etidronate and 57.3 of the prescriptions of alendronate were linked to 
a problem of osteoporosis in spite of the indication for these drugs are prevention 
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and treatment of osteoporosis. For etidronate and alendronate patients, only 59.9 % 
and 73.4 % respectively, had a diagnosis of osteoporosis in their records. Studies 
undertaken in a database where recording is activity driven, and where relevant 
clinical information may be omitted, there is a risk that the measurable is made 
important rather than the important being measured. 
In summary, the database may present a biased GP population, it enabled 
identification of key clinical and resource use indicators in the patient records, but 
activity-driven patient records may result in the data being less comprehensive than 
anticipated. This latter point had particular consequences for the identification of 
covariates for the modelling of effect estimate, as discussed in the next section. 
5.6.2 Assessment of the study findings 
The further analysis of the individual data components in the first study indicated that 
some aspects of the data seemed implausible and therefore limited the scope for a 
full economic evaluation. This was particularly evident for the evaluation of clinical 
outcomes, such as hip fractures. Therefore, only concomitant medication and 
attrition rates were reiterated in the second study. 
Evident from the results of the analysis of the two studies was the profound 
differences between the two studies on those outcome variables that were common 
to the studies. Both the attrition rates and cost of gastrointestinal (GI) drugs differed 
by more than should be expected by chance and they were considered sufficiently 
large to contact IMS Health for verification of the findings. IMS Health, who 
undertook the data extraction for both studies from the Medipluse system, assigned 
these differences to problems in the extraction of the first study, and it was confirmed 
that the extraction of the datafile according to design of the first study may have 
been flawed. The consultancy was however unable to confirm exactly which aspects 
of the study was flawed, as the SAS code that was used to extract the first dataset 
had been produced by a researcher who had left the organisation since. It was 
emphasised that the contents of the second study were reliable. 
All data from the first study had been analysed and written up at this stage, and parts 
of the data had been presented. (Urdahl et al 2000, appendix 6) The second study 
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had been undertaken to reiterate feasible aspects of the first study. In addition to 
providing information on a second subset of patients, the second study served to 
highlight shortcomings in the procedures to ensure the quality of the data extraction 
from the Mediplus@ database. The discrepancies between the studies and the 
implications are discussed parallel to the assessment of the study findings in this 
section. 
Fracture risk and effect estimate 
During the analysis of the first study, multiple recording manifested itself as a 
problem with the database. This was documented by the fact that six patients had 
two hip fractures recorded, three patients had four hip fractures recorded and one 
patient had six hip fractures recorded in her record. In an attempt to overcome this 
problem, the number of patients with a hip fracture rather than number of fractures in 
the sample was used as unit of analysis. Overall, 49 patients experienced a fracture 
after the index date in the whole sample of 8470 patients, this was 0.6% of the 
population, or about 6 per 1000. 
Fracture was more frequently recorded in the records of those patients in the 
bisphosphonate group, where 3.6% of alendronate patients and 1.2% of etidronate 
patients had hip fracture recorded in their records. In comparison, 2.5% of the 
women on etidronate have hip fracture prior to inclusion in the study, and prior 
fracture was present in 4.4% of the women on alendronate. Hip fracture was less 
frequently recorded for those patients receiving the HIRT therapies, with proportions 
of recorded fractures between 0.2% and 0.3% prior to index date and between 0.11% 
to 0.37% after index date. The indications for these drugs may to some extent 
explain these differences, as bisphosphonates are indicated for both treatment and 
prevention of osteoporosis, whereas hormone replacement therapies are indicated 
for osteoporosis prevention. 
In clinical practice, one would expect treated patients to differ from untreated 
patients, as the former would have an explicit indication for the treatment. To the 
extent that the indication is related to the outcome variable as well, the indication can 
function as a confounding variable. Matching by indication and stratification may be 
used in observational studies to control for this confounding by indication. This was 
however impossible in this study due to the 'activity driven' recording resulting in 
diagnosis having a higher likelihood of being recorded in the database when action is 
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taken on the condition. The absence of an appropriate control groups against which 
to demonstrate the impact of the treatments limited the validity of the analysis of 
clinical outcome. For example, only 1.1%to 1.8% of the control group had 
osteoporosis recorded in their patient records and 0.3% to 1-1% had a previous hip 
fracture recorded in their records. From the outset this provides indication that the 
susceptibility of fracture in the control group may have been lower than that in the 
treatment groups. 
Recognising that observational studies inherently are susceptible to bias and 
confounding factors, which are the major threats to study validity, the design 
incorporated collection of information on factors that may have influenced the validity 
of the effect estimates. Age has previously been identified as a covariate of hip 
fracture. (Dennison and Cooper 2001) For the purpose of arriving at an unbiased 
estimate of treatment effect, several other variables were tested for their predictive 
power of hip fracture. Only age and the recording of a previous fracture featured in 
the final model of time to fracture between the groups. Previous hip fracture 
increased the relative risk of having a hip fracture recorded by a spectacular amount 
(Hazard ratio 108.3,95% Cl from 58.4 to 200.8), and age above 75 increased the 
relative risk of having a hip fracture by nearly 300% (Hazard ratio 3.5,95% Cl from 
1.9 to 6.5). 
These implausible results indicate that it was impossible to arrive at an unbiased 
estimate of fracture risk in the cohorts. When the treatments were added to the final 
model and compared to controls, none of the drug treatments reduced the incidence 
of fracture significantly. In fact, the analysis estimated that alendronate increased the 
risk of hip fracture significantly by as much as 95%. This should merely be seen as a 
result of the non-randomised design of the study and selection of high-risk women 
into the alendronate group rather than indication that alendronate actually is a risk 
factor for hip fractures in women. In comparison, randomised clinical trials of 
alendronate have estimated a hip fracture risk reduction of about 49%. (Black et al 
1996) No randomised clinical trials of etidronate, tibolone or the HRTs have been 
powered to show efficacy on hip fracture as primary endpoint. (Royal college of 
Physicians 1999) 
In summary, the analysis of clinical effectiveness in terms of risk reduction of hip 
fracture was unfeasible in the Mediplus@ database for two main reasons. Firstly, it 
was not possible to compare fracture risk to a matched control group and therefore 
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the effect estimates are biased. Secondly, multiple recording of the same fracture 
was a problem, and analysis of hip fracture was undertaken based on the number of 
women experiencing a fracture rather than the absolute number of fractures. This 
did however not control for the artefact that would be created if a fracture was 
experienced before index date and then re-recorded after index date, a situation that 
would be picked up by this study design as a new fracture after initiation of drug 
therapy. This phenomenon may undermine the predictive value of previous fracture 
in the models by resulting in the prediction of a fracture with a previous record of the 
same event. 
Two papers published in the BMJ in the autumn of 2000 illustrated similar key issues 
in observational studies undertaken in routinely collected patient record databases. 
Both studies, Farmer et al (2000) and Jick et al (2000) analysed the incidence of 
venous thromboembolism before and after the warning from the UK Committee on 
Safety of Medicines about third generation oral contraceptives using the 
computerised patient record database General Practitioners Research Database 
(GPRD). Conducting a time-series analysis Farmer et al (2000) found that the 
incidence among pill users had not dropped. By means of a cohort analysis with a 
nested case-control Jick et al (2000) found that, both before and after the warning in 
October 1995, the risk of venous thromboembolism in women using third generation 
oral contraceptives was about twice that in users of preparations using 
levonorgestrel. Moreover fewer cases occurred after the warning than would have 
been expected if the prescribing of oral contraceptives had not changed. 
These two studies arrived at opposite conclusions on the same research question 
using the same database, and the incidence provides important learning points for 
database studies. (Skegg 2000) The study undertaken in the Mediplus@ database is 
no exception. It was not possible to review individually all cases. It was not possible 
to provide any details of validity and specificity of the diagnoses of the hip fracture or 
any other clinical diagnosis. Compute r- recorded diagnosis of hip fracture and other 
clinical conditions were used, without documentation from clinical records or hospital 
data. The potential for misclassification bias is substantial. The analysis of clinical 
endpoints was therefore not pursued in the second study of raloxifene and the 
bisphosphonates. 
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Drug therapy pattern 
Compliance with therapy is generally higher within the context of controlled clinical 
trials than in usual care settings, and as such can be a contributing factor to the cost- 
effectiveness of a drug when used in a clinical practice setting. (Hughes et al. 2001) 
Clinical guidelines in osteoporosis recommend long-term treatment in order to 
experience the full preventive effect of the prescribed drugs. (Royal college of 
Physicians 1999) 
The impact of discontinuation on the cost effectiveness ratio is likely to be greatest 
where the effect of discontinuation is that the costs increase and the benefits 
decrease. When treatment is not taken for long enough to experience preventive 
effect of treatment resources are lost to society without benefits gained. This may be 
the case with preventive treatments in osteoporosis, where long-term adherence is 
key to experience preventive effect from treatment. Unfortunately, failure to persist 
with therapy is particularly prevalent with asymptornatic diseases. For example, 
Jones et al (1995) estimated that a third of patients discontinue anti hypertensive 
drugs during the first year of treatment, and between 40% and 50% of the patients 
may change or discontinue therapy after 6 months. It should be noted that in those 
cases where the patients experienced side effects from treatment discontinuation 
might in fact be clinically appropriate and cost saving in the long run. 
Cessation of therapy is not routinely recorded in the Mediplus@ database. It was 
therefore essential to develop a set of definitions to estimate the date at which a 
patient stopped taking the medication. The imputed date at which the patient was 
anticipated to stop therapy was based on the duration of the last prescription of study 
medication and the date at which a new prescription should have been issued. Two 
assumptions were used to derive two definitions of stop date in the first study. The 
first stop date definition assumed that patients who had a new prescription issued 
within three months of the last day of therapy was a continuous user. In other words, 
those patients for whom a new prescription was not issued within three months of 
last prescription qualified as having stopped therapy. In order to assess the 
sensitivity of this assumption, the second stop date definition assumed that patients 
who had a new prescription issued within six months of the last day of therapy was a 
continuous user. 
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Both studies evaluated attrition rate as an outcome. The first study revealed that the 
estimate of attrition rate was very sensitive to the definition of Stop date. For 
example, by using the main indicator of stop date (three months drug free period 
allowed), 48.1 % of women initiating therapy on etidronate and 10.1 % of the women 
initiating therapy on alendronate stopped taking the drug within the first 12 months. 
The risk of stopping therapy with etidronate was 5.31 (3.84 to 7.36) times that of 
stopping therapy with alendronate. The results of using the 3-month stop date 
strongly suggested that patients using etidronate seemed to tolerate treatment less 
than those initiating therapy on alendronate resulting in a very poor real-life 
adherence with etidronate. In comparison, by allowing a six-month drug free period 
before a stop date was imputed, the analysis showed that 16.0% of the etidronate 
patients and 4.6% of the alendronate patients stopped therapy within the first year. 
The average time to stop was significantly shorter for etidronate patients than that of 
alendronate patients also with this definition of stop date. The attrition rate for the 
hormone replacement therapies and tibolone remained similar between the two stop 
date definitions. The second study provided different results. By using the main 
indicator of stop date (three month drug-free period) the second study indicated a 
drop out rate of 29.3% after 6 months for patients initiating therapy with etidronate 
and 44.0% for patients initiating therapy with alendronate. 
A limitation of this analysis is the fact that Mediplus@ is only recording issued 
prescriptions, and provides no insight as to whether the prescriptions are dispensed 
at the pharmacy or not. Beardon et al (1993) found that 5% of 20.000 prescriptions 
issued from a large UK general practice were never actually redeemed at the 
pharmacy. Approximately 80% of the unredeemed prescriptions were for 
asymptomatic conditions, and the remainder for prophylactic drugs. Furthermore, 
once the prescription has been redeemed from the pharmacy and the acquisition 
cost to society has occurred there is no guarantee that the medication is actually 
taken by the patient. 
Resource consumption 
The first study attempted to identify resource use indicators for GP visits, drug 
acquisition costs, costs of concomitant medication and indicators for referrals to 
secondary care. Analysis of these variables provided mixed results. Medication 
costs derived from the database seemed plausible and enabled analysis. This 
aspect was therefore pursued in the second analysis. The analysis of the other 
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resource indicators, such as GP visits and referral rates, did not encourage faith in 
the data and they were therefore not included in the second study. 
The Mediplus@ database does not record directly whether the patient is present in 
the surgery or not when an activity is undertaken that results in information entry to 
the patient record, and only a series of dates at which an action was taken is 
recorded in the patient records. For that reason, one date can be recorded several 
times, and activity not directly involving the GP, such as recording of laboratory 
results and repeat prescriptions, receive equal weight. IMS Health has developed a 
formula in the database to estimate number of GP visits from the number of dates. In 
order to evaluate this formula, both the number of dates recorded in the records as 
well as the estimated number of GP visits was analysed. The results revealed high 
similarity between the dates and estimated GP visits, resulting in implausibly high 
estimates of GP activity. It was therefore not possible to make meaningful 
assessment of the number of GP visits by the patients in the observation period, and 
this resource consumption item was not reiterated in the second study. 
The cost of treatment was recorded in both studies to estimate the cost of acquisition 
drug. The recording of prescriptions for medications is close to 100% and the system 
provides a calculation of cost of the prescribed amount directly based on MIMS. (IMS 
Health 1998) During analysis of this outcome it became apparent that the cost 
estimate not necessarily is informative. The acquisition cost varied hugely within 
each study group, for the reason that follow-up time and attrition rate varied within 
the cohorts. Therefore, this analysis was unable to estimate treatment costs relative 
to each other. This illustrates difficulties in developing appropriate variables for 
censored cost data rather than revealing a shortcoming of the database. 
Concomitant medication costs may be an important consideration when undertaking 
an economic evaluation for osteoporosis in primary care. The costs of treating 
gastrointestinal side effects associated with the use of the bisphosphonates were 
analysed using appropriate methodology for the analysis of highly skewed cost data. 
The bisphosphonates were grouped in the main analysis of the cost of 
gastrointestinal (GI) side effects. The average costs of H2 antagonistis and proton 
pump inhibitors (GI drugs) were E44.4 in the bisphsphonate group and E15.2 in the 
control group. During the first year of bisphosphonate use the average cost of GI 
drugs increased by El 1.3 (95% Cl 5.3 to 17-5) when compared to the difference in 
the control group over the same time period. Similar increases were observed in the 
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subsequent years. The analysis therefore provides indication that the 
bisphosphonates are associated with a 20-25% increase in the cost of GI drugs in 
the first year after initiating therapy, however when analysed separately this increase 
was not significant. 
The absolute number of women taking GI drugs increased between the prior and the 
first year of treatment with the bisphosphonates, but this increase was not significant. 
In the subsequent years the increase is not that remarkable in spite of the fact that 
the average cost of G1 drugs increase, also in these years. This may indicate that 
those women who already taking the GI medication when initiating therapy with the 
bisphosphonates increased on average their use of the drugs. This may provide 
indication that caution should be exercised when prescribing bisphoshonates to 
those women that are already taking GI drugs, and consequently are susceptible to 
GI problems. These findings confirm those of other observational studies. (Ettinger 
1998) The findings of van Staa et al (1997) indicate that etidronate does not induce 
GI side effects. This is also confirmed in the separate analysis of the 
bisphosphonates. 
The second study provided a very different picture of GI drug costs altogether. 
Firstly, the baseline costs of GI drugs was substantially higher in the second study, 
with an average cost of GI drugs in the prior six months of E94.2 and 9-110.8 and 
El 10.2 for the control group, etidronate takers and alendronate takers, respectively. 
In comparison, the corresponding estimates were P-15.2, E51.9 and E42.0 in the first 
study. There was no significant difference between GI drug use in the prior period 
and the first six months after initiating therapy, neither when the bisphosphonates 
were analysed grouped nor separately. 
The same limitations to the use of prescriptions as a measure of treatment 
discontinuation apply in the analysis of concomitant medication. There is no 
information about whether the issued prescriptions are collected at the pharmacy and 
drugs collected at the pharmacy may not be used in the last instance. An additional 
limitation of the analysis of the first study is the fact that time period prior during 
which resource consumption was quantified prior to index date was only six months, 
whereas the costs in subsequent years were accumulated over intervals of 12 
months. The costs in the prior six months were multiplied by two in the first analysis 
in order to escalate costs to a full year. It is not clear whether this could have biased 
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the analysis in any systematic manner and in that case which direction the results 
were skewed. 
Finally, the analysis revealed some limitations of the meaningful assessment of 
referral and admissions to secondary care. Multiple recording seemed to be a 
problem with accident and emergency admissions, and for example as much as 86 
patients had 10 or more referrals in their first year. The database therefore failed to 
provide plausible data for assessment of costs in other sectors than primary care. 
In summary, it was not feasible to analyse indicators of GP visits, referral rates or to 
provide a relevant presentation of acquisition costs for study medication. This 
prevented inclusion of these variables in the second study. The first study did on the 
other hand suggest that analysis of resource use associated with treatment of side 
effects seemed feasible. When comparing the results of the studies however, 
discrepancies emerged, which questioned the validity of the first evaluation 
altogether. 
5.6.3 Feasibility of Mediplus@ for economic evaluation 
Specific research objectives in the two pilot studies presented in this Chapter were 
linked to the study of fracture risk reduction and resource consumption associated to 
use of osteoporosis, drugs in the UK clinical practice setting. Problems with the data 
became apparent during analysis, and these prevented answering of the specific 
research questions set at the outset of the study. Did the two studies presented in 
this chapter enable answering the bigger question of whether the Mediplus@ system 
is a feasible vehicle for the clinical and economic evaluation of pharmaceuticals? 
The first study was comprehensive and included variables that may have enabled 
economic evaluation and resulted in a series of cost-effectiveness estimates for the 
study drugs. However, the analysis of the individual resource consumption 
components and the clinical effectiveness estimates provided implausible results. 
Similar comprehensive data extraction for the second study was not pursued due to 
the discouraging results of the first study, and the second study was not designed to 
enable full economic study. Therefore, the confirmation from IMS Health on August 
21s'2001 that the first study was flawed provided a dilemma. Would an economic 
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evaluation have been possible if the second study had been comprehensive? Would 
an economic evaluation have been possible if the first study had been un-flawed? 
Three main aspects that discourage the use of Mediplus@ for economic evaluation 
are summarised below. 
Firstly, the fact that unreliable data could be released from IMS indicated a 
shortcoming in the internal quality assurance procedures for researchers at IMS. 
The problem turned out to be that one analyst did all the data extraction on his own 
and wrote SAS code that was unreadable to the other IMS researchers. A second 
researcher did the data extraction for the second study. The result was two datafiles 
that differed profoundly in spite of the fact that they were meant to measure the same 
outcomes. The problem detected by comparison of the two studies was not primarily 
an issue with the data, but rather revealed flaws in the data management process. 
Secondly, it was not possible to derive estimates of cost-effectiveness of 
pharmaceuticals from the database because of the failure to provide valid estimates 
of clinical effectiveness, and comprehensive estimates of costs. The issue of 
multiple recording of clinical events and administrative activity such as referrals and 
admissions disclosed in the first study were not likely to be due to faulty data 
extraction of these variables. The gathering of observational data for study can be 
flawed by bias at many stages, including subject selection, data recording, accuracy 
in data entry, data construct and definition of analytical variables. The findings 
therefore cast doubt about whether the data recording is complete and sufficiently 
structured to enable valid economic evaluation. The development of quality audits in 
routinely collected datasets may provide opportunity to minimise the vulnerability of 
observational studies to bias resulting from non-random assignment of patients to 
therapy. (Black 1999) 
Finally, the scope for using statistical methods to control for bias and confounding to 
evaluate costs and clinical outcome was restricted. In clinical research there is a 
need to demonstrate that changes in costs and outcomes are caused by, rather than 
merely associated with, the intervention under investigation. The database did not 
provide sufficient level of data quality to enable the use of modelling techniques 
methodologies to control for observed and unobserved confounding variables. 
Statistical methods to control for observed and unobserved biases can only be 
applied if the data are collected and managed at a certain quality level ensuring valid 
recording. No amount of sophisticated modelling is able to counteract invalid data. 
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Methods such as the use of instrumental variables and propensity scores have 
added value to other analyses of observational data. (Radford et al. 2001, 
McClelland et al 1994) In this study however, statistical methods could not have 
minimised the bias introduced by lack of randomisation, simply because the 
recording of outcomes and covariates was unreliable. 
The advantages of using data reflective of clinical practice for the purpose of 
economic evaluation have been outlined elsewhere in this thesis. In spite of the fact 
that the potential advantages of study in the Mediplus@ database for economic 
evaluation may not exist in reality, the studies outlined in this chapter made the best 
possible use of available observational data. The two studies illustrated ways in 
which an observational patient record database can be used to study aspects of cost 
effectiveness in clinical practice. The second study provided plausible indicators of 
attrition rate and cost of concomitant medication. Some aspects of the database may 
therefore have value in economic evaluation. 
5.7 Conclusions and recommendations 
This feasibility study in the Mediplus@ database was limited to the therapy area of 
osteoporosis. Therefore, generalisation to other therapy areas may be restricted. 
Replication of the study is therefore encouraged in other therapy areas that are 
considered different from osteoporosis on key clinical aspects. 
The (first) pilot study did not produce unbiased estimates of clinical effectiveness and 
resource use and failed to provide a full economic evaluation. Importantly, however, 
the aim was to assess whether the Mediplus@ database is feasible for the economic 
evaluation of pharmaceuticals in UK clinical practice, and this aim was met. 
Conclusions 
Health economic researchers need to explore ways in which the needs and 
requirements of decision-makers can be satisfied. The choice of methodologies is 
made in a time and money constrained environment. The approach taken requires a 
series of choices and compromises on the part of the researcher. One challenge is 
to select a strategy that is capable of generating information that have an acceptable 
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balance between internal and external validity, between immediate solutions and 
long-term study and between local information and broader policy setting. 
Observational databases provide vast amounts of real-life data that may have a 
potential value for determining whether the benefits expected from the evidence 
provided by RCTs are achieved then new pharmaceuticals are adopted in the wider 
context of clinical practice. 
A design in the Mediplus @database was successfully developed that aimed to 
demonstrate benefits of pharmaceutical treatments in osteoporosis outside of clinical 
trials. Findings in the second, reliable, study indicated that concomitant medication 
use and attrition rates may be evaluated using the data. Provided that research 
questions and variables are developed with caution, the database may be a valuable 
source of input for example to economic models. It is important that the question of 
the potential of routine data should not be dismissed because of the inadequacies of 
circumstances of this study. 
The Mediplus@ data are stored in a complex manner, and it is a specialised task to 
access and extract data. The findings of this study indicated that checks and quality 
assurance procedures have been inadequate. In this particular case, the 
individual(s) that was responsible for the data extraction according to design was 
(were) 'the weakest link', and the fact that the data not reproducible throws doubt on 
the validity of the studies. This is not to suggest that the database were infeasible for 
all aspects of economic evaluation. Rather, it has emphasised the importance of 
having appropriate quality assurance steps in place to prevent unscientific data 
management processes. It would be premature to recommend wide use of the 
database for components of economic evaluation analysis before steps are taken by 
the database providers to ensure valid data extraction. 
It would not be relevant to argue that observational data in any sense should - or can 
- replace randomised controlled trial (RCT) estimates of drug efficacy. RCTs are the 
appropriate vehicle for assessing outcomes of treatments in ail stages in the life cycle 
of a drug. However, it is time to question the consistent use of randomised data only 
for the effect estimate within economic evaluation. Rigidly designed studies in good- 
quality comprehensive observational databases can be a useful supplement for trial- 
based estimates of cost-effectiveness. 
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Recommendations 
Some barriers would need to be overcome if more studies were to be undertaken 
using data from the Mediplus@ database. The primary issue for further consideration 
is that of data quality and management. The experience generated through this 
research may provide constructive guidance on the use of observational data. How 
could problems of this sort be avoided in the future? 
A carefully written protocol should describe the extraction of data from the 
database. This could require that two people independently conduct the data 
extraction according to the protocol. The same subset of patients and variables 
should result from the two extractions and comparison would provide a quality- 
check. The introduction of this quality step could be implemented at a marginal 
cost to the database providers, and it would in the long run contribute to 
increasing the faith in observational data, a faith that this study has jeopardised. 
To guide the conduct of clinical trials, the good clinical practice (GCP) regulations 
apply to all commercially sponsored clinical trials and provide guidance to the 
data entry process, subject monitoring, and source verification. (ICH 1996) 
These could aid the development of quality assurance step for data management 
systems. 
e In order that the Mediplus@ database could be used on a larger scale for full 
economic evaluation, procedures for valid recording of clinical events 
implemented across the whole panel of information suppliers (GPs) should be in 
place. Multiple recording was a problem in the pilot study of this chapter, as was 
lack of recording of relevant clinical conditions (for example osteoporosis in 
patients receiving osteoporosis treatment). 
9 The recording of clinical outcomes in Mediplus@ needs to be validated 
comprehensively in a rigorously designed validation study. Furthermore, 
researchers using the data should have the opportunity to go back to the original 
patient record once the dataset has been extracted to source verify clinical 
events of major importance to the study results. 
At a more general level the findings from the studies presented in this chapter 
highlight the following: 
0 None of the current guidelines for cost-effectiveness analysis of pharmaceuticals 
explicitly state whether observational study designs are an acceptable source for 
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economic evaluation studies. Such guidelines should take an active standpoint 
as to when a pharmaceutical evaluation should be based on investigation under 
ideal conditions (randomised clinical trials) or under conditions of normal practice 
(observational data). 
The likelihood of poor adherence to therapy in clinical practice should be studied 
and incorporated in economic models of pharmaceutical interventions. 
Multivariate techniques can be adopted for reducing bias and issues with 
confounding factors. Such methodologies are making important contribution to 
epidemiological studies in general and have the potential to add significant value 
to the use of observational data for economic evaluation. Techniques such as 
instrumental variables methods and imputing techniques for missing data should 
be developed to increase the ability to deal with issues of non-random allocation 
of treatment in observational studies. 
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CHAPTER 6 
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
The aim of this thesis was to assess and further develop research methods to increase 
the general isabi I ity of economic evaluation studies of pharmaceuticals. Factors that limit 
the general isab i lity of economic evaluations across locations include clinical practice 
patterns, incentive structures for healthcare providers, relative price levels and 
demographic profile of disease (O'Brien 1997). Empirical studies have provided 
evidence that these differences may be important. (Willke et al 1998) The sensitivity of 
cost and clinical estimates to factors that vary by location raises methodological 
questions on the design and conduct of economic evaluation studies. The objectives of 
the research presented here were framed in the context of the increasing need to 
transfer economic evaluation data across settings and the scarcity of empirical and 
methodological research into the limiting factors and methods to overcome them. 
Availability of clinical research designs able to reflect context-specific data ranged from 
controlled pivotal trials through to observational studies, with the methodology of 
pragmatic trials providing an intermediate degree of clinical practice data through 
maintaining randomisation but relaxing other design features. The principal focus has 
been on economic evaluation throughout the thesis. 
This chapter considers the extent to which the research objectives were achieved. The 
first section outlines the empirical findings from the three source projects that constitute 
the thesis and review the methodological contribution of the source projects in light of 
the research context outlined in Chapter 2. The second section compares the methods 
and provides an assessment of the relative merits of each. Finally, some implications of 
this work are outlined and accompanied by specific recommendations for future research 
and policy. 
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6.1 Contribution to methodological development 
The projects in this thesis explored aspects of three complementary methods for 
generalising economic evaluations. Firstly, effect sizes from pragmatic trials were 
examined to assess whether external validity was achieved at the cost of internal 
validity. Secondly, economic models were assessed according to how well they 
accommodated contextual differences in resource use and clinical assumptions. Finally 
the feasibility of an observational database was explored in an attempt to further develop 
a method for the conduct of economic evaluations with externally valid results. 
6.1.1 Pragmatic or explanatory design? 
Concerns about the generalisability of randomised controlled trials have been raised in 
the context of clinical evaluation. (Altman and Bland 1998) In pivotal RCTs, the 
'laboratory' environment of the experiment provides atypical conditions that may limit 
external validity of findings, with the result that pharmaceutical interventions are often 
evaluated under one set of circumstances but implemented in clinical practice under 
another. Reliance on clinical trial data for economic evaluation has led health 
economists to investigate the problems of general isabil ity of economic evaluations 
undertaken alongside randomised controlled trials. (Drummond and Davies 1991, Coyle 
et al 1998) These authors have advocated the use of trials adopting a more pragmatic 
design, through which external validity may be increased by reflecting clinical practice 
circumstances. It was emphasised in the introduction that a binary concept of 
6 pragmatic' versus 'explanatory' trials may not be appropriate. Rather, we may consider 
a continuum of pragmatism versus explanatory trials, in which investigators adopt design 
features rendering the trial more, or less, pragmatic (section 2.1.1). 
In the first source project, a checklist of 'pragmatic' design features was developed and 
applied to the randomised clinical trials from 318 randomised controlled trials in two 
therapy areas. Generalised linear models were fitted to assess whether key 
components of trial design predict the estimate of outcome. The models included a 
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specified hierarchical factor reflecting the structure of the data, and the final model only 
included items that predicted outcome at conventional levels of statistical significance. 
The study provided empirical evidence that on average, 'pragmatic' design features do 
not systematically impact effect size estimate. The findings favour the hypothesis that 
pragmatic trials do not jeopardise internal validity when seeking to maximise external 
validity to a particular setting. These features may safely be adopted in economic 
evaluation research, without the fear that the effect size may be biased by design. 
In spite of reflecting clinical practice to a larger extent, trials adopting pragmatic features 
are still specific to the specific heaithcare contexts within which it was conducted. The 
results of pragmatic trials may still be context-specific to the extent that they add limited 
value to healthcare decisions in other settings. 
Because of the way in which economic evaluation incorporates assessment of relative 
costs and collapses this with an estimate of clinical effectiveness into one outcome 
measure, the cost-effectiveness ratio, economic evaluations may be particularly 
sensitive to factors in the study environment that may limit the gene ralisabi lity of the 
results. A limitation of this project was that it only examined the clinical effect estimate 
from pragmatic trials and paid little attention to the numerator (costs) in the cost- 
effectiveness ratio. Examination of resource consumption collected alongside pragmatic 
trials would have provided more insight into how resource-use varies between settings. 
6.1.2 To model or not to model? 
Economic models are simulation experiments evaluating cost-effectiveness based on a 
series of parameter estimates. These individual parameter estimates are likely to be 
influenced by the setting in which the input data were derived, and the setting which 
these parameter estimates are based on do to an extent limit the generalisability of the 
results of a model. In the second source project, a checklist was devised for 
assessment of generalisability of economic models that incorporated both clinical and 
resource consumption estimates. The checklist was intended to facilitate critical 
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assessment of the generalisability of economic models to judge the study's adaptability 
to a specific context. The framework may provide guidance to those conducting 
economic evaluation models on how they can increase the generalisability of their 
results. 
The checklist was applied to economic models published in the area of osteoporosis, 
with the critical review revealing that very few models attempt to generalise findings to 
settings outside of one specific context regarding economic assumptions. None of the 
models published prior to June 1999 assessed a range of unit costs relevant to different 
settings or countries and most assumed 100% compliance with treatment over 
substantial periods of time. A few models accommodated for clinical differences such as 
case-mix in patient population and baseline risks. So in addition to providing a 
framework for the assessment of models, this project provided empirical evidence that 
few models actually employ sensitivity analysis to explore the impact of the therapy 
under evaluation in different sets of circumstances. 
The generic framework enables assessment across a range of models in different areas 
of therapy. Applying the checklist to models in one therapy area facilitated between- 
study comparison. A limitation of this project was that it was unable to study differences 
across study results that may have been explained by location, or to study difference in 
cost-effect estimates over time. The models in this therapy area presented cost- 
effectiveness ratios by a variety of outcomes, e. g. cost per vertebral fracture avoided, 
cost per hip fracture avoided and cost per quality adjusted life year. The patient 
subgroup studied differed across models, as did currency and choice of incremental 
versus average cost-effectiveness ratio. In order to provide empirical data on how cost- 
effectiveness ratios travel between settings and across time, the checklist could be 
applied to models in other areas and regression analysis attempted on a larger and 
more homogeneous data set. Insight into whether models in other therapy areas have 
accommodated for variation in setting to a larger extent than models in osteoporosis 
would test the merits of models as a tool for generalising economic evaluations. 
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6.1.3 To randomise or to observe? 
The need for economic evaluation data of relevance to clinical practice settings led to 
the investigation of the potential contribution of electronic patient record databases. The 
aim of the third source project was to evaluate the feasibility of the Medipluse database 
to provide data for a full economic evaluation. The therapy area of osteoporosis was 
used as a model and the study objectives were to combine resource consumption 
attributable to osteoporosis drugs with real-life fracture data in clinical practice, in an 
analysis of incremental cost-effectiveness. An observational, retrospective cohort study 
was designed, including women over 55 using bisphosphonates, HRTs and tibolone. 
Fractures, hospital referrals, GP visits, concomitant medication and attrition rate over a 
3-year long follow-up time were recorded outcomes. A second study was designed, 
reiterating those aspects of the first design that seemed feasible after analysis, however 
the second study included patients using bisphosphonates and raloxifene in a different 
timeframe. 
Analysis from the first study revealed limitations with the data in terms of availability of 
information required for economic evaluation, limitations that negated a full analysis of 
cost-effectiveness of the study drugs. For example, clinical diagnosis and resource 
consumption data were difficult to obtain, and a problem with multiple recording became 
apparent. The first study was, nevertheless, able to generate some data of relevance to 
economic evaluation, and these were the use of concomitant medication and patient 
attrition rate in clinical practice. These aspects were therefore reiterated in a second 
study, extracting a different subset of patients. In spite of similarities in design and 
inclusion criteria, comparison of the results from the two studies identified major 
discrepancies, revealing shortcomings with the consultancy's data management 
procedures. 
The observational database was pursued for it's prospect of providing two potential 
practical advantages. Firstly, administration, funding, quality control and considerable 
infrastructure are necessary for the conduct of RCTs. In economic evaluation, the drugs 
under scrutiny should be compared to that of alternative treatments representing the 
current best practice. Over the course of a trial of long duration, the opinion of what is 
considered 'current best practice' may change. A database study compared to the trial 
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approach is appealing, as it would enable head-to head comparisons as well as a 
comparison to 'no intervention', according to what is relevant to a given decision-maker 
at any time. Secondly, in a clinical trial, observations are recorded on a case report form 
(CRF). Investigators would seek to reduce the size of the CRF to simplify the process 
for the physician enrolled, minimise interference and patient burden and increase trial 
participation. Routinely collected data, in contrast, may contain vast amounts of patient 
information. The first observational study of this thesis collected information on 180 
variables, equating to a clinical trial with a CRF of 180 questions and numerous pages. 
The richness of the information and the potential volumes of observational studies in 
longitudinal databases may offer a distinct advantage to clinical trials. 
Substantial disadvantages do however discourage use of observational databases for 
the purpose of economic evaluation. Observational data are susceptible to the influence 
of known and unknown factors that may systematically bias the effect estimates. The 
basic function of randomised clinical research designs is to provide a fair and unbiased 
comparison of outcomes between patient cohorts with and without an exposure that 
impacts the outcome. (Piantadosi 1997, Pocock 1984) Fundamentally, though, an 
observational study shifts the focus of the analysis from attributing a causal relationship 
between intervention and outcome to identifying associations between the intervention 
and changes in costs and outcomes. It is true for observational studies as well as 
clinical trials, that estimates from any evaluation study are only as good as the data 
themselves. The prospective nature of randomised trials enables special care to be 
taken to maximise valid, complete and reliable recording of information, (ICH 1996) 
whereas the recording in observational databases is subject to less restrictive 
monitoring. The studies undertaken and reported in this thesis provide empirical 
evidence of poor data recording management procedures that flawed the results. Lack 
of transparency in procedures meant that this was not detected until a second study was 
undertaken, and data from the first study had already been presented. (Urdahl et al 
2000) 
Strategies adopted in the statistical analysis of the observational study of this thesis 
were primarily generalised linear modelling. However, strategies such as instrumental 
variables have made valuable contribution to the analysis of observational data, a 
methodology that was developed responding to the fact that important aspects of health 
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status cannot be observed. (McLelland and Newhouse 1997) Such unobserved patient 
factors may include underlying severity of disease, patient preferences, compliance, and 
physician prescribing preferences. These all are potentially strong predictors of the 
treatment outcome. A possible instrumental variable in the Medipluse database may 
have been GP identity, but instrumental variables analysis was not pursued here, 
principally because the Mediplus@ study was exploratory and the issues to be explored 
ranged from appropriate design of the study to availability and validity of the data. In the 
light of the inconsistent findings, it is doubtf ul whether such sophisticated statistical 
techniques would have provided a more reliable result given the nature of and lack of 
sophistication of the data collected in the studies. 
An additional observation that was made throughout the design, conduct and analysis of 
the Mediplus@ studies was the fact that in spite of the fundamental difference between 
observational and randomised study designs the processes of undertaking the research 
have key features in common. Time and cost constraints and issues of data quality 
needing consideration in a trial are also important to the conduct of an observational 
study. The initial time investment to acquire the skills and insight to conduct an analysis 
in an observational database are substantial, and may result in a time-lag between the 
inception of the idea readiness for dissemination. The cost per patient is lower in an 
observational study of this kind than in a clinical trial, yet there are still substantial costs 
involved and in the case of Mediplus@, these are calculated on the basis of patient 
numbers included in the study. 
Well-designed observational studies conducted in valid, reliable and accurate 
databases, and the concomitant use of statistical methodology developed over the last 
few years to control for both observed and unobserved bias in observational studies, 
may be valuable when assessing cost-effectiveness in clinical practice. Despite the rigid 
design and appropriate methodology, the database that was explored in this thesis failed 
to meet the data requirements for economic analysis, and problems with data 
management planted seeds of doubt about the scientific contents of files extracted. 
In conclusion, the feasibility of the Mediplus@ database in its current format was found to 
infeasible for full economic evaluation. Both the lack of relevant variables and the invalid 
data extraction encountered, provide limitations for the database. The project did not 
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however reject the hypothesis that observational data in general may be used in 
economic evaluation. The second study indicated that the database may be of value in 
studying aspects of drug use such as likelihood estimates of compliance rates, cost of 
treatment for side-effects as well as a description of patient population in real life. 
6.2 Relative merits of alternative approaches; Conclusions 
Three methods were evaluated individually in the thesis in spite of not being mutually 
exclusive. In fact, all study design approaches evaluated in this thesis are less than 
perfect for the purpose of increasing generalisability of economic evaluations and may 
therefore be combined in one or more ways in order to generalise cost-effectiveness 
estimates across settings. Estimates of effect derived in a clinical trial are based on a 
series of assumptions incorporated in the design of the trial and may not be reflective of 
clinical practice, (Coyle et al 1998) but estimates based on pragmatic trials can be 
'contaminated by reality'. (Freemantle and Drummond 1997) Economic models may be 
'black boxes' and difficult to quality assess, (Sculpher at al 2000, Hill et al 2000) but 
evaluations based on epidemiological studies can be flawed by poor data management 
and invalid estimates (Chapter 5). Table 6.1 outlines the relative merits of the methods 
assessed in this thesis to generalise economic evaluation results. 
The first source project evaluating pragmatic trials provided evidence that trial features 
do not, on average, provide systematically different effect estimates from those adopting 
explanatory features. Pragmatic trials complement late phase III drug development, 
where aspects of generalisability in terms of cost-effectiveness from clinical trial to 
clinical practice and from country to country could be assessed. Their use is limited in 
generalising economic evaluation analyses as they are conducted in one particular 
setting, and so could be generalised only to this setting. For example, pragmatic trials 
frequently use 'current practice' as comparator to the therapy under evaluation, but 
6 current practice' may vary between healthcare systems and settings. (O'Brien 1997) 
The extent to which this is a problem will depend on whether the data is to be used by a 
specific decision-maker faced by context-specific set of financial and practical 
constraints, or whether it is to inform a broader debate surrounding resource allocation. 
(Murray et al 2000) 
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Table 6.1 Relative merits of different methodological approaches to generafising economic 
evaluations 
Advantages 
Pragmatic trials 
Random allocation 
ensures good basis for 
group comparison 
Data reflect clinical 
practice without, on 
average, jeopardising 
internal validity 
Economic modelling 
Sensitivity analysis 
enables testing of 
general isability using 
context-specific 
parameters 
Enables combination of 
randomised and non- 
randomised data 
Observational study 
(patient records) 
Data reflect clinical 
practice 
Large patient numbers 
increases power and may 
enable study of final 
outcomes 
Time and financial 
constraints may be 
overcome 
Dis- Results are context- Dependent on availability Non-randomised 
advantages specific of context-specific data approach jeopardises 
for parameter estimates study validity 
Choice of comparator or 
unit costs may not Presentation of results Inability to demonstrate 
translate beyond the complicated and space- causal relationships 
setting of the trial consuming 
Constraints in real-life 
limits quality of recording 
Activity-driven records 
limits availability of 
factors relevant to the 
analysis 
Potential Clinical trial to context- Early phase drug Clinical trial to context- 
uses specific clinical practice development to explore specific clinical practice 
impact of real-life 
Phase III of drug scenarios on cost- Input to economic models 
development effectiveness ratio 
Late phase cross-national 
extrapolations 
The synthesis of results 
from trial data with 
observational data on 
resource use and 
baseline risks 
The choice of an appropriate method or combination of methods to generalise the 
results of an economic evaluation depends critically on the use of the results. For an 
evaluation targeted at a specific decision-making body facing a known budget and a 
given set of options, the pragmatic trials and observational study approaches offer 
advantages over the pivotal trial-based, and even the model-based, evaluation because 
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of their context-specific properties. Based on such evaluations, the decision-maker 
faced with limiting factors such as human resources and healthcare provision 
infrastructure, may decide to reallocate resources or indeed allocate a budget increase. 
However, for the provision of general information on the relative costs and benefits of 
selected healthcare interventions, models may be more appropriate, as they enable 
testing of relative cost-effectiveness under different set of assumptions. Indeed, relative 
estimate of clinical effectiveness from a pragmatic trial may be combined with baseline 
risks and resource consumption data derived from an observational study within the 
framework of a computerised model. 
Patient-level analyses such as pragmatic trials and observational studies do not provide 
scope for an overall sectoral perspective in which costs and effectiveness of all possible 
interventions could be compared, enabling identification of the mix that maximises 
healthcare under given resource constraints. By default, patient-level studies are 
context-specific, even if that context is more reflective of clinical practice patterns than 
clinical trial setting through adoption of observational or pragmatic design. An implicit 
assumption of analyses presenting cost-effectiveness of a single proposed new 
intervention as compared with an alternative intervention, or with a fixed cut-off point 
representing an assumed societal 'willingness to pay' for an additional unit of benefit is 
that, to improve overall efficiency, resources would need to be transferred to the more 
efficient intervention or from another sector. Broadly, cost-effectiveness analyses based 
on models may be seen as a tool to allocate a fixed health budget in order to maximise a 
society's health (Garber et al 1996) 
The second source project indicated that models are feasible vehicles for generalising 
trial to practice estimates, for example through exploring different compliance rates and 
country to country unit costs estimates. They may represent a method that, in theory, 
could be used for the broader remit of maximising resource allocation within different 
fixed healthcare budgets under different sets of circumstances. Economic models 
seeking to present results in a generalised fashion may risk being criticised of 
insensitivity and inaccuracy when trying to present cost-effectiveness across a span of 
healthcare contexts. Also, space- restriction in scientific journals and concerns voiced 
about the quality of reporting of economic models (Hill et al 2000) limits the degree to 
which models may make use of the opportunity to explore ranges of scenarios. 
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However sophisticated a model is, some issues are unlikely to be solved by more 
modeling, and some may only be solved by collecting new clinical data. Data input to 
economic models should reflect clinical practice and conventions in order to increase the 
merits of the model for providing generalisable results. 
The various approaches evaluated in this research may be appropriate methodologies at 
different phases of product development. Modelling may be appropriate in an early 
phase of clinical development, to moderate explanatory trial features to reflect clinical 
practice. Pragmatic trials may be appropriate for an intermediate phase. Valid 
observational studies may be relevant in a late phase where the intervention in question 
has been in routine use for some time. Then a return to modelling at a more advanced 
phase may facilitate transferability of cost-effectiveness results between countries. 
Importantly, models may at any stage in the drug lifecycle provide a valuable tool to 
combine trial data with observational studies or population-based data. 
There is little value in searching for a universal methodology to increase general isabi lity 
of economic evaluation. The research team would need to decide which approach to 
apply in a given circumstance, as it would depend on the nature of the intervention, drug 
development phase, target patient population and the decision to be informed. The 
methods reviewed in this thesis may all be feasible approaches across different stages 
in the development of a drug and across different settings either individually or in 
combination. Experimentation and observation can be complementary tools to improve 
external validity of economic evaluations. 
The emphasis here is that, as yet, there is no perfect approach to generalisability. Only 
through insight into the strengths and weaknesses of each approach, can researchers 
establish the one that satisfies the information need. The methods reviewed in this 
thesis are not mutually exclusive, but complementary tools for researchers and decision- 
makers wishing to throw light on these issues. When used by themselves or in 
combination they may increase understanding of how technologies change across 
settings and provide deeper insight into cost-effectiveness for clinical decision-makers in 
particular healthcare environments. 
181 
6.3 Recommendations 
There is a prevailing need for methodologies to evaluate generalisability of economic 
evaluation and empirical research to assess how economic and clinical data travel 
across settings. Research presented in this thesis has added to the current knowledge 
base of methods to generalise economic evaluation results and provided empirical data 
demonstrating relative merits of three alternative methods. The findings may have 
implications for research and policy agenda: 
1. The examination of internal versus external validity of pragmatic trials did not 
evaluate resource aspects of cost-effectiveness analyses alongside pragmatic trials. 
The project concluded that effect estimates from pragmatic trials do not jeopardise 
internal validity at the expense of externally valid estimates. However, a key 
component of economic evaluation is the identification of unit costs. Further 
research should explore the resource-side of this and provide insight into 
transferability of context-specific resource information. 
2. Empirical data demonstrating the use of modelling to enhance the generalisability of 
context-specific evaluations is scarce. The way that models can be used to explore 
cost-effectiveness under different scenarios should be applied to increase 
understanding of cost-effectiveness ratios across settings. 
3. Those undertaking economic modelling should, to a larger extent, explore alternative 
assumptions relating to context. Trial-based probabilities should be subject to 
sensitivity analysis reflecting assumptions about practice patterns in clinical practice. 
Similarly, those that commission studies must be prepared to explore a range of 
scenarios relevant to the transfer of a therapy between settings. They must be 
prepared to justify the values chosen with respect to general isabi lity. 
4. The feasibility study of the Mediplus@ database revealed limitations relating to data 
quality and data management. Firstly, formal validation studies should be 
undertaken to assess whether current recording is reliable. Secondly, quality control 
mechanisms should be introduced to ensure validity of recording in the Medipluse 
database. Finally, scientific method should be adopted in future extractions of data 
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from Mediplus@ for similar studies, for example through dual data extraction and 
introduction of procedures to document the data extraction steps. 
5. Further research should seek to evaluate the influence of context specific factors on 
cost-effectiveness estimates, and assess which characteristics an economic 
evaluation should encompass, in terms of overall design, data collection, analysis 
and presentation, in order to optimise the generalisability of the results. 
6. The research presented in this thesis has focused on methods that can be adopted 
to increase and explore generalisability across settings and locations. Limitations to 
generalisability can occur over time, for example through changes in demography, 
treatment patterns and available interventions, illustrating the need for empirical 
research to explore how cost-effectiveness profiles of interventions change over 
time. This has specific implications in those jurisdictions where economic evaluation 
systematically contributes to decision-making such as in Australia, Canada and the 
UK, where reimbursement decisions may be reassessed. 
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Title: Age specific prevalences do not suggest association with in utero exposure 
Type of article: Letter 
Author: Lawrenson RA, Farmer R 
Publication: BMJ. 1998; 316(7146): 1746 
IMS Database: UK MediPlus"' 
Title: Postmarketing surveillance of adverse drug reactions: a correlational study 
approach using multiple data sources 
Type of article: Scientific study results 
Author: Rathmann W, Haastert B, Delling B, Gries FA, Giani G 
Publication: Pharmacoepidemiol Drug Safety. 1998; 7: 51-7 
IMS database: German MediPlus 
Title: Assessment of effectiveness of therapy using retrospective population data 
Type of article: Poster 
Author: Sverdlov LS, Jones JK, Dixon RB 
Publication: Presented at ASCPT conference (New Orleans) March 1998 
IMS database: UK MediPlus' 
Title: Impact of potassium chloride on renal function in hypertensive patients 
Type of article: Poster 
Author: Jones A Sverdlov LS, Carlile OL, Dixon RB, Shannon MW, Hou EW 
Publication: Presented at ASCPT conference (New Orleans) March 1998 
IMS database: UK MediPlus"' 
Title: Neuroleptic use and indications in UK primary care database 
Type of article: Poster 
Author: Jones JK, Miwa LJ, Staffa JA, Pathiyal A, Schwamlein C 
Publication: Presented at ASCPT conference (New Orleans) March 1998 
IMS database: UK MediPluso 
Title: The risks of venous thromboembolic disease among German women using 
oral contraceptives: a database study 
Type of article: Scientific study results 
Author: Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ 
Publication: Contraception. 1998 Feb; 57(2): 67-70 
IMS database: German MediPlus 
Title: Oral contraception was not associated with venous thromboembolic disease 
in recent study 
Type of article: Letter 
Author: Farmer RDT, Todd J-C, MacRae KID, Williams TJ, Lewis MA 
Publication: BMJ. 1998; 316: 1090-1 
IMS database: German MediPlus 
Title: Do women with diabetes receive hormone replacement therapy? 
Type of article: Scientific study results 
Author: Lawrenson RA, Newson RB, Feher MD 
Publication: Pract Diabetes Int. 1998 Mar; 15: 71-2 
IMS database: UK MediPlus"' 
Title: Characteristics of practices contributing to the MediPlus database and the 
implications for its use in epidemiological research 
Type of article: Scientific study results 
Author: Lawrenson RA, Coles G, Walton K, Farmer RDT 
Publication: J Informatics in Prim Care 1998 May; 14-8 
IMS database: UK MediPlus"' 
Title: The pivotal role of post-licensing activities 
Type of article: Data citation 
Author: Wood S, Harman RJ 
Publication: The Regulatory Review, July. 1998 May; 1: 3-8 
IMS database: UK MediPluse 
Title: New drug introductions-The issues raised by Viagra 
Type of article: Data citation 
Author: Stephens P 
Publication: Medi-Pharm Opportunities. June 1998; 8 
IMS database: UK MediPlus"' 
Title: Prescription drug use and costs among diabetic patients in primary health 
care practices in Germany 
Type of article: Scientific study results 
Author: Rathmann W, Haastert B, Roseman J, Gries FA, Giani G 
Publication: Diabetes Care. 1998 Mar; 21: 389-97 
IMS database: German MediPluso 
Title: Population-based study of risk of venous thromboembolism associated with 
various oral contraceptives 
Type of article: Scientific study results 
Author: Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR 
Publication: Lancet. 1997 Jan 11; 349(9045): 83-8 
IMS database: UK MediPlusg 
Title: Oral contraceptives and venous thromboembolism 
Type of article: Letter 
Authoffarmer RDT, Lawrenson RA 
Publication: Lancet. 1997; 349: 733 
IMS database: UK MediPluso 
Title: Oral contraceptives and venous thromboembolism 
Type of article: Letter 
Author: Lawrenson R, Farmer R 
Publication: NZ Med J. 1997; 110: 63 
IMS database: UK MediPluso 
Title: Examining the management of depression in primary care using the 
MediPlus"' database in the Netherlands 
Type of article: Abstract 
Author: Pathiyal A, Hylan T, Quick R, Jones JK 
Publication: Pharmacoepidemiol Drug Safety. 1997; 6(Suppl 2): S88 
IMS Database: Netherlands MediPlus 
Title: Examining the management of depression in primary care using the MediPlus 
database in the Netherlands 
Type of article: Scientific study results 
Author: Pathiyal A, Hylan TR, Quick R, Jones JK 
Publication: Clin Ther. 1997 Jul-Aug; 19(4): 798-810 
IMS Database: Netherlands MediPlus 
Title: Antidepressant use patterns in the naturalistic GP setting in the Netherlands 
Type of article: Poster 
Author: Pathiyal A, Hylan TR, Quick R, Jones JK 
Publication: Presented at ECNP Conference (Vienna) 1997 
IMS Database: Netherlands MediPlus 
Title: Pregnancy following oral contraception 
Type of article: Poster 
Author: Farmer RIDT, Todd J-C 
Publication: Poster abstract Number 317.13 th Intl Conf Pharmacoepiderniology, 
(Orlando) August 1997 
IMS database: UK MediPluse 
Title: The validity of general practice computer data 
Type of article: Poster 
Author: Farmer RDT, Lawrenson RA, Coles GLA 
Publication: Poster abstract Number 318.13 th Intl Conf Pharmacoepiderniology, 
(Orlando) August 1997 
IMS database: UK MediPluse 
Title: Hormone replacement therapy prescriptions for women with diabetes 
Type of article: Abstract 
Author: Lawrenson RA, Feher M 
Publication: Diabet Med. 1997; 14(Suppl): S40 
IMS database: UK MediPlus") 
Title Antibacterial prescribing for respiratory symptoms in health care. Time to put 
the brakes on 
Type of article: Abstract 
Author: Malik F, Gaskin M, Davey PG 
Publication: Pharmacoepiderniol Drug Safety. 1996; 5(Suppl 1): S34 
IMS database: UK MediPluso 
Title: The cost of treatment of uncomplicated cystitis: transfer of data from a clinical 
trial in the USA based on an epidemiological study in the UK 
Type of article: Abstract 
Author: Malik F, Gaskin M, Davey PG 
Publication: Pharmacoepidemiol Drug Safety. 1996; 5(Suppi 1): S34 
IMS Database: UK MediPlus`ý) 
Title: The scale of repeat prescribing 
Type of article: Scientific study results 
Author: Harris CM, Dajda R 
Publication: Br J Gen Pract. 1996 Nov; 46(412): 649-53 
IMS database: UK MediPluso 
Title: Cough due to ACE inhibitors: a case-control study using automated general 
practice data 
Type of article: Scientific study results 
Author: Visser LE, Vlug AE, van der Lei J, Stricker BH Ch 
Publication: Eur J Clin Pharmacol. 1996 Jun; 49: 439-44 
IMS database: Netherlands MediPlus 
Title: Specific therapeutic group age-sex related prescribing units (STAR-PUs): 
weightings for analysing general practices' prescribing in England 
Type of article: Scientific study results 
Author: Lloyd DC, Harris CM, Roberts DJ 
Publication: BMJ. 1995 Oct 14; 311(7011): 991-4 
IMS database: UK MediPluso 
Title: Discontinuation of, and changes in treatment after start of new courses of 
antihypertensive drugs: a study of United Kingdom population 
Type of article: Scientific study results 
Author: Jones JK, Gorkin J, Lian JF, Staffa JA, Fletcher AP 
Publication: BMJ. 1995 Jul 29; 311(7000): 293-5 
IMS database: UK MediPluso 
Title: Treating menorrhagia in primary care. An overview of drug trials and a survey 
of prescribing practice 
Type of article: Data citation 
Author: Coulter A, Kelland J, Peto V, Rees M 
Publication: Int J Technol Assess Health Care. 1995 Summer; 1 1(3): 456-71 
IMS database: UK MediPlusg' 
Title: Approaching a century after: morbidity and potentially drug induced disease 
Type of article: Review 
Author: Fletcher AP 
Publication: Adverse Drug React Toxicol Rev. 1995 Spring; 1 4(l): 45-64 
IMS database: UK MediPlusc" 
APPENDIX 5 
ANALYTICAL VARIABLES TO THE OBSERVATIONAL STUDY 
APPENDIX 5.1 
DEFINITION OF STATISTICAL VARIABLES 
The data extracted according to the study design document will be exported into 
five data files. The first file will contain information on demographic details, the 
second on therapy pattern of the intervention drugs, the third on resources 
consumed through concomitant medication, the fourth on administrative activities 
undertaken and the fifth file will contain information on the clinical events of the 
patients. Each datafile will contain 1 record per patient. 
General and demographic variables (FILE 1, "PDEMOG") 
A datafile containing patient age, marital status, previous co-morbidity etc. This will 
include clinical Problem and Notes (ICD 10 level 1 and 2 and Read codes) and date 
on which a problem was entered. Previous clinical events, such as occurrence of 
fractures, cancers and cardiovascular events and the various forms of fractures will 
be included in this file. 
Var. name Label Definition and creation 
PATNR Patient ID Unique identifier for a study subject as given in the source data. Will be used to link 
source data files. 
PATCO Study cohort 1996,1997 or 1998 
INXDRG Index drug The study drug prescribed to a study subject on the index date. The variable 
categories will be named as following: 
EVISTA, FOSAMAX, KLIOFEM, LIVIAL, DIDRONEL, PREMIQUE, BISCNTR, 
HRTCNTR 
INXDIAG Diagnosis for The diagnosis under which the index drugs was prescribed. 
index drug Osteoporosis: OSTEO 
Other: OTHER 
It no diagnosis recorded, then missing value. 
PATAGE Patient age in The age of a patient as of the year of the index date, computed from patient's age as 
index year of December 1999 
PATRES Patient 17 areas in the source data set according to the former indexing of Regional Health I 
residential area Authorities. 
Var. name 
RI 
Label 
Practice ID number 
Definition and creation 
Unique identifier for a practice given in the source data. 
PRXPAT Number of patients in the 
practice 
Number of patients enrolled in the practice 
PRXGP Practice size Size of the practice in terms of number of GPs 
GPNUM GP's ID number The sequential number in MediPlus database, unique for each GP* 
GPSEX GP's gender MALE / FEMALE The gender of the GP who issued the index prescription 
GPAGE GP's age Doctor's age in the index year 
PRXFUND Practice previous 
fundholding 
FUND = The practice was previously a fundholding practice, NOFUND 
The practice was not previously a fundholding practice. 
In those cases where two GPs inder)end entiv issued two r)rescrii)tions of the same drua at the same dav. and 
one of the prescriptions was linked to a problem of osteoporosis, then the prescription linked to osteoporosis will 
have priority. If neither of the two prescriptions were issued in osteoporosis then the patients GP will be selected 
randomly from the two. 
Data on the following clinical status entered in the patient records within five years 
prior to index prescription will be recorded. In those cases where these details are 
recorded repeatedly, the value entered closer to the index date will be included in 
the file. If BIVII is recorded in the database then use this direct recording for the 
variable PATBIVIL If BMD is not given directly but weight and height is given, then 
MBD will be derived from these two. 
Var. name 
PATHE 
Label 
Patient's height 
Definition and creation 
height (it recorded) in centimetres 
PATWE ___ Patient's weight Patient's weight (if recorded) in kilograms 
PATBMI BMI Patients BM I Patient's body mass index (when recorded) 
PATSMOK Smoking status _ Patient registered as smoker =1 
Patient registered as non-smoker =0 
PATBMD Bone Mass Density Patients Bone Mass Density 
The following clinical events may affect outcome variables in this study and 
therefore this information will be collected on the patients. The recording of these 
will allow controlling for such confounders in the analysis. Information prevalent in 
the Problem Headings or in the Notes in the patient records 5 years before or at the 
index date will be recorded. 
The four variables concerning fractures are a special case in that GlPs may record a 
fracture on more than one occasion. Therefore the following rule was developed: If 
a new fracture is recorded in Read within a3 month period following another 
recording, then it is likely that the second fracture is the same as the first and this 
will consequently be ignored. Counting for new fractures will start after month 3. 
This rule does not apply to hip, wrist or vertebral fractures, as the recording of these 
is likely to be site-specific. Lists of the detailed Read codes characterising each 
clinical state can be found in appendix 1 B. 
Var. name Label Definition and creation 
PRHIP Previous hip fracture Note or problem of hip fracture entered in patient record before index date. 
1 =yes, O=no 
PRWRIST 1 Previous wrist fracture Note or problem of wrist fracture entered in patient record before index 
date. 1 =yes, O=no 
PRVERT Previous vertebral Note or problem of vertebral fracture entered in patient record before index 
fracture date. 1 =yes, O=no 
PROTH Previous other fracture Note or problem of any other fracture entered in patient record before index 
date. 1 =yes, O=no 
PRANY Any f ractu re Any of the above fractures. 1 =yes, O=no 
PRHIPN Number of previous hip Number of hip fractures 
fractures 
PRWRISTN Number of previous Number of wrist fractures 
wrist fractures 
PRVERTN Number of previous Number of vertebral fractures 
vertebral fractures 
PROTHN Number of any other Total number of fractures 
previous fractures 
PRAWN Number of total The total of the above fractures, i. e. all fractures recorded in the patient 
fractures record 
HOST History of osteoporosis There is mentioning of an osteoporosis-related diagnosis in the patient 
record prior to index date (Including problem or note of family history) as 
defined in appendix 1D 
PRHYST Previous hysterectomy Note or problem of hysterectomy entered in patient record before index 
date. 1= yes, 0= no 
HBRCAN History of breast cancer There is mentioning of a breast cancer related diagnosis in the patient 
record prior to index date (Including problem or note of family history). 1 
yes, 0= no 
HOVCAN History of ovarian There is mentioning of an ovarian cancer-related diagnosis in the patient 
cancer record prior to index date (including problem or note of family history). 1 
yes, 0= no 
HCHD History of coronary There is mentioning of coronary heart disease in the patient record prior to 
heart disease index date (including problem or note of family history). 1= yes, 0= no 
HSTROKE History of stroke There is mentioning of stroke in the patient record prior to index date 
(Including problem or note of family history). 1= yes, 0= no 
HSTROKEN Number of strokes There is mentioning of stroke in the patient record prior to index date 
(Including problem or note of family history). Entered in the file as number 
of stroke diagnoses 
HMI History of myocardial There is mentioning of a myocardial infarction -related diagnosis in the 
infarction patient record prior to index date (Including problem or note of family 
history). 1= yes, 0= no 
HYP Prior Hypertension There is mentioning of a Hypertensive disease related diagnosis in the 
patient record prior to index date (Including problem or note of family 
history). 1 yes, 0= no 
HCEREBR Prior Cerebrovascular There is mentioning of a Cerebrovascular disease related diagnosis in the 
disease atient record prior to index date. 1= yes, 0= no 
Information on the following conditions prevalent in the Problem Headings or in the 
Notes in the patient records 9 months before or at the index date will be recorded. 
Var. name Label Definition and creation 
HVCS Prior vertebral column There is mentioning of vertebral column syndrome in the patient record prior 
syndrome to index date 
HRESP Prior Respiratory system There is mentioning of any Respiratory system disease related diagnosis in 
disease the patient record prior to index date 
HPULM Prior Pulmonary disease There is mentioning of Chronic obstructive pulmonary disease in the patient 
record prior to index date. 
HARTH Prior Arthritis There is mentioning of Rheumatiod Arthritis / arthrosis related diagnosis in 
the patient record prior to index date. 
HRHEUM Prior Rheumatism There is mentioning of Nonarticular rheumatism related diagnosis in the 
patient record prior to index date. 
HASTHMA Prior Asthma There is mentioning of Asthma or Asthma-related diagnosis in the patient 
record prior to index date. 
HOES Prior GI disease There is mentioning of Oesophag / stomach / duoden disease diagnosis in 
the patient record prior to index date. 
Therapy progress (FILE 2, "THPROGR99) 
This file contains information on the progress of osteoporosis drug therapy. A 
decision-tree that shows the flow of patients initiating therapy on study drugs and 
then moving on to stopping therapy, swapping therapy or continuing therapy will be 
developed. The variables will enable the analysis of treatment patterns such as 
attrition rates, rate of swapping in the different cohorts and therapy cost incurred 
over the course of the treatment. The data are recorded on patient level and will 
enable the development of attrition curves and potential migration towards other 
any drugs in particular. Definitions were: 
Therapy Stop: No further study drug issued in the 6 months following the end date 
of the duration of the last prescription of drug. 
Switch: New study drug (or other drug in osteoporosis) issued within the time from 
the period covered by the last prescription of the study drug to the end of a6 month 
period following the coverage of the last prescription. 
Failure: Switch or stop 
Therapy Break: A new prescription issued within 6 months after the duration of the 
last prescription of the study drug. Will be computed from the variables in the 
dataset. 
Var. name Label Definition and creation 
INDEXDAT Index date Date of the initial prescription of index drug 
STOPDAT Last day of index Date at which the coverage of the last prescription of the first treatment 
therapy episode with index drug ended 
INXCOST Cost of index therapy Total cost of the index therapy until failure date 
FOSDATE Date, Fosamax second Date at which the patients initiates therapy with Fosamax as second drug 
drug 
FOSCOST Cost of Foxamax Total cost of Fosamax as second drug 
second drug 
_ DIDDATE Date, Didronel second Date at which the patients initiates therapy with Didronel as second drug 
drug 
Cost of Didronel second Total cost of Didronel as second drug 
DIDCOST drug 
LIVDATE Date, Livial second drug Date at which the patients initiates therapy with Livial as second drug 
LIVCOST Cost of Livial second Total cost of Livial as second drug 
drug 
KLIDATE Date, Kliofem second Date at which the patients initiates therapy with Kliofem as second drug 
drug 
KLICOST Cost of Kliotem second Total cost of Kliofem as second drug 
drug 
PREDATE Date, Premique second 
drug Date at which the patients initiates therapy with Prernique as second drug 
PRECOST Cost of Premique Total cost of Premique as second drug 
second drug 
HRTDATE Date, other HRT Date at which the patients initiates therapy with other HRT as second drug 
second drug (see appendix 1 D) 
HRTCOST Cost of other HRT Total cost of other HRT as second drug 
second drug 
BISDATE Date, other Date at which the patients initiates therapy with other bisphosphonate 
Bisphosphonate second therapy as second drug (see appendix 1 D) 
drug 
BISCOST Cost of Bisphosphonate Total cost of other bisphosphonate as second drug 
second drug 
EVIDATE Date, Evista second Date at which the patients initiate therapy with Evista 
drug 
EVICOST Cost of Evista second Total cost of Evista as second drug 
drug 
OSTDATE Date, other Date at which the patients initiate therapy with other drug with an impact in 
osteoporosis drug as osteoporosis 
second drug 
OSTCOST Cost of other Total cost of other drug in osteoporosis as second drug 
osteoporosis drug as 
second drug 
Concomitant medication (FILE 3, "CONCOM") 
This file includes concomitant prescribing over the 1st, 2 nd and 3 rd year, respectively, 
following index prescription as well as patient-level data on prescriptions issued to 
the patients in the 6 months period before the index date. The file will include 
variables indicating whether each prescription was linked to an osteoporosis - 
related problem or not (appendix 1 D), and the cost of the concomitant prescriptions. 
Variables have a -0_5,1,2, or 
3 added to identify the period of 6 months prior, 1,2, 
or 3 years after the index clate. 
'ýVar. nam 
A02A-0_ 
e 
5 
Definition and creation 
Cost of prescriptions of antacids issued in the six months prior to inclusion in the study. 
A02A1 Cost of prescriptions of antacids issued in the first year after inclusion in the study. 
A02A2 Cost of prescriptions of antacids issued in the second year after inclusion in the study. 
A02A3 Cost of prescriptions of antacids issued in the third year after inclusion in the study. 
A02130 5 Cost of prescriptions of H2 antagonists and proton pump inhibitors issued in the six months prior to 
inclusion in the study 
A02B1 Cost of prescriptions of H2 antagonists and proton pump inhibitors issued in the first year after inclusion 
in the study 
A02132 Cost of prescriptions of H2 antagonists and proton pump inhibitors issued in the second year after 
inclusion in the study 
A02133 Cost of prescriptions of H2 antagonists and proton pump inhibitors issued in the third year after inclusion 
in the study 
A2131 0 5 Cost of prescriptions of H2 antagonists issued in the six months prior to inclusion in the study. 
A2131 1 Cost of prescriptions of H2 antagonists issued in the first year after inclusion in the study. 
A21312 Cost of prescriptions of H2 antagonists issued in the second year after inclusion in the study. 
A2BI3 Cost of prescriptions of H2 antagonists issued in the third year after inclusion in the study. 
A2B2 0 5 Cost of prescriptions of Proton pump inhibitors issued in the six months prior to inclusion in the study. 
A2B21 Cost of prescriptions of Proton pump inhibitors issued in the first year after inclusion in the study. 
A2B22 Cost of prescriptions of Proton pump inhibitors issued in the second year after inclusion in the study. 
A21323 Cost of prescriptions of Proton pump inhibitors issued in the third year after inclusion in the study. 
Al 105 Cost of prescriptions of Multivitamins and minerals (ATC Al 1A and Al IB only) issued in the six months 
pr . or to inclusion in the study. 
A111 , Cost of prescriptions of Multivitamins and minerals issued in the first year after inclusion in the study. 
Al 12 Cost of prescriptions of Multivitamins and minerals issued in the second year after inclusion in the study. 
Al 13 Cost of prescriptions of Multivitamins and minerals issued in the third year after inclusion in the study. 
A1 2A-0- 5 Cost of prescriptions of Mineral supplements (Calcium, vitamin C and D) issued in the six months prior to 
inclusion in the study. 
A12A1 Cost of prescriptions of Mineral supplements issued in the first year after inclusion in the study. 
A12A2 Cost of prescriptions of Mineral supplements issued in the second year after inclusion in the study. 
Al 2A3 Cost of prescriptions of Mineral supplements issued in the third year after inclusion in the study. 
A06A 0 5 Cost of prescriptions of Laxatives issued in the six months prior to inclusion in the study. 
A06A1 Cost of prescriptions of Laxatives issued in the first year after inclusion in the study. 
A06A2 Cost of prescriptions of Laxatives issued in the second year after inclusion in the study. 
A06A3 Cost of prescriptions of Laxatives issued in the third year after inclusion in the study. 
G03 05 Cost of prescriptions of Sex hormones issued in the six months prior to inclusion in the study. 
G031 Cost of prescriptions of Sex hormones issued in the first year after inclusion in the study. 
G032 Cost of prescriptions of Sex hormones issued in the second year after inclusion in the study. 
G033 Cost of prescriptions of 
_Sex 
hormones issued in the third year after inclusion in the study. 
H02A 0 5 Cost of prescriptions of Corticosteroids issued in thesix months prior to inclusion in the study. 
H02A1 Cost of prescro tions of Corticosteroids issued in the first year after inclusion in the study. 
H02A2 Cost of prescriptions of Corticosteroids issued in the second year after inclusion in the study. 
H02A3 Cost of prescrip tions of Corticosteroids issued in the third year after inclusion in the study. 
M01 05 Cost of prescri ptions of Antiffieurnatic agents issued in the six months prior to inclusion in the study. 
M01 1 Cost of pre cri ptions of Antirheumatic agents issued in the first year after inclusion in the study. 
M012 Cost of prescri ptions of Antirheumatic agents issued in the second year after inclusion in the study. 
M013 Cost of prescri ptions of Antirheumatic agents issued in the third year after inclusion in the study. 
N0205 Cost of prescriptions of Non-narcotic analgesics (N02A and N02B only) issued in the six months prior to 
inclusion in the study. 
N021 Cost of prescri ptions of Non-narcotic analgesics issued in the first year after inclusion in the study. 
N022 Cost of prescri ptions of Non-narcotic analgesics issued in the second year after inclusion in the study. 
N023 Cost of prescri ptions of Non-narcotic analgesics issued in the third year after inclusion in the study. 
R03 05 Cost of pre cri ptions of Bronchodilators issued in the six months prior to inclusion in the study. 
R031 Cost of prescri ptions of Bronchodilators issued in the first year after inclusion in the study. 
R032 Cost of prescri ptions of Bronchodilators issued in the second year after inclusion in the study. 
R033 Cost of prescri ptions of Bronchodilators issued in the third year after inclusion in the study. 
Administrative activity (FILE 4, "ADMIN") 
Administrative Read codes indicating GP activity (dates entered in patient record) 
and referrals to secondary health care. 
Variables have a _0_5,1,2, or 
3 added to identify the period of 6 months prior, 1,2, 
or 3 years after the index date. 
Var. name 
GPVS 05- 
Definition and creation 
GP visits as estimated at the MediPlus terminal in the six months prior to in3lusion in the 
GPVS1 GP visits as estimated at the MediPlus terminal in the first year after inclusion in the study. 
GPVS2 GP visits as estimated at the MediPlus terminal in the second year after inclusion in the study. 
GPVS3 GP visits as estimated at the MediPlus terminal in the third year after inclusion in the study. 
ENTN 05 Number of dates of entries in the patient record in the six months prior to inclusion in the study. 
ENTN1 Number of dates of entries in the patient record in the first year after inclusion in the study. 
ENTN2 Number of dates of entries in the patient record in the second year after inclusion in the study. 
ENTN3 Number of dates of entries in the patient record in the third year after inclusion in the study. 
NURS_0-5 Number of recordings of patients seen by practice nurse in the six months prior to inclusion in the 
study. 
NURS1 Number of recordings of patients seen by practice nurse in the first year after inclusion in the study. 
NURS2 Number of recordings of patients seen by practice nurse in the second year after inclusion in the 
study. 
NURS3 Number of recordings of patients Seen by practice nurse in the third year after inclusion in the study. 
Var. nam 
HREF-0- 
e 
5 
Definition and creation 
Number of referrals to hospital in the six months prior to inclusion in the study. 
HIRER in the first year after inclusion in the study. 
HREF2 in the second year after inclusion in the study. 
HREF3 in the third year after inclusion in the study. 
HADM-0 
-5 
Number of accident and emergency admissions to hospital in the six months prior to inclusion in the 
study. 
HADIV11 Number of accident and emergency admissions to hospital in the first year after inclusion in the stuýL 
HAM Number of accident and emergency admissions to hospital in the second year after inclusion in the 
study. 
HADM3 Number of accident and emergency admissions to hospital in the third year after inclusion in the 
study. 
GYNE 0 5 Number of referrals to Gynaecologist in the six months prior to inclusion in the study. 
GYNE1 Number of referrals to Gynaecologist in the first year after inclusion in the study. 
GYNE2 Number of referrals to Gynaecologist in the second year after inclusion in the study. 
GYNE3 Number of referrals to Gynaecologist in the third year after inclusion in the study. 
ORTO 0 5 Number of referrals to Orthopaedic in the six months prior to inclusion in the study. 
ORT01 Number of referrals to Orthopaedic in the first year after inclusion in the study. 
ORT02 Number of referrals to Orthopaedic in the second year after inclusion in the study. 
ORT03 Number of referrals to Orthopaedic in the third year after inclusion in the study. 
RHEU 0 5 Number of referrals to Rheumatologist in the six months prior to inclusion in the study. 
RHEW Number of referrals to Rheumatologist in the first year after inclusion in the study. 
RHEU2 Number of referrals to Rheumatologist in the second year after inclusion in the study. 
RHEL13 Number of referrals to Rheumatologist in the third year after inclusion in the study. 
GIIN 05 Number of referrals to GI investigation in the six months prior to inclusion in the study. 
GlIN1 Number of referrals to GI investigation in the first year after inclusion in the study. 
G112 Number of referrals to GI investigation in the second year after inclusion in the study. 
G113 Number of referrals to GI investigation in the third year after inclusion in the study. 
PHYS 0 5 Number of referrals to Physiotherapist in the six months prior to inclusion in the study. 
PHYS1 Number of referrals to Physiotherapist in the first year after inclusion in the study. 
PHYS2 Number of referrals to Physiotherapist in the second year after inclusion in the study. 
PHYS3 Number of referrals to Physiotherapist in the third year after inclusion in the study. 
RADI 05 Number of referrals to Radiologist in the six months prior to inclusion in the study. 
RAD11 Number of referrals to Radiologist in the first year after inclusion in the study. 
RAD12 Number of referrals to Radiologist in the second year after inclusion in the study. 
RAD13 Number of referrals to Radiologist in the third year after inclusion in the study. 
Clinical events (FILE 5, "CLINEV") 
This file will contain information on incident clinical events such as fractures, 
cancers and cardiovascular events recorded in Problem or Note over the three 
years period of follow-up. The file will also contain information on when the first of 
these diagnoses were recorded after index date. The Read codes used to define 
the clinical events are outlined in appendix 1 B. 
The rule that was developed in datafile 1 applies in this datafile as well: If a new 
fracture is recorded in Read within a3 month period following another recording, 
then it is likely that the second fracture is the same as the first and this will 
consequently be ignored. Counting for new fractures will start after month 3. This 
rule does not apply to hip, wrist or vertebral fractures, as the recording of these is 
likely to be site-specific. 
Var. name 
HIPFN 
Definition and creation 
Number of hip fractures noted in patient records after index date 
DHIPF Date of first hip fracture experienced after index date 
YHIPF Year of hip fracture 
WRISTFN Number of wrist fractures after index date 
DWRISTF Date of first wrist fracture experienced after index date 
YWRISTF Year of wrist fracture 
VERTFN Number of vertebral fractures after index date 
DVERTF Date of first vertebral fracture experienced after index date 
YVERTF Year of vertebral fracture 
OTHFN Number of other fractures 
DOTHF Date of first other fracture experienced after index date 
YOTHF Year of other fracture 
ANYFN Number of any fracture after index date 
DANYF Date of any fracture first experienced after index date 
YANYF Year of any fracture 
BRCAN Diagnosis of breast cancer 
DBRCAN Date of breast cancer experienced after index date 
YBRCAN Year of breast cancer 
OVCAN Diagnosis of ovarian cancer 
DOVCAN Date of ovarian cancer experienced after index date 
YOVCAN Year of ovarian cancer 
STROKE Diagnosis of stroke after index date 
DSTROKE Date of first stroke experienced after index date 
YSTROKE Year of stroke 
MI Diagnosis of myocardial infarction after index date 
DMI Date of first MI experienced after index date 
YMI Year of MI 
CEREBR Diagnosis of Cerebrovascular disease after index date 
DCEREBR Date of Cerebrovascular disease experienced after index date 
YCEREBR Year of Cerebrovascular disease 
CHD Diagnosis of coronary heart disease (CHD) 
DCHD Date of first recording of CHD experienced after index date 
IYCHD Year of CHD 
APPENDIX 5.2 
READ CODES FOR THE CLASSIFICATION OF CLINICAL EVENTS 
Osteoporosis 
. M61. Osteoporosis 
. 1268 FH: Osteoporosis 
Asthma 
. 14134 H/O: asthma 
.1 73A Exercise-induced asthma 
. 663N Asthma disturbing sleep 
. 6630 Asthma not disturbing sleep 
. 663P Asthma limiting activities 
. 663Q Asthma not limiting activities 
. 663U Asthma management plan given 
. 663V Asthma severity 
. 663W Asthma prophylaxis used 
. 663d Emerg asthm adm since 1 st appt 
. 663e Asthma restricts exercise 
. 663f Asthma never restricts exercise 
. 663h Asthma - currently 
dormant 
. 663j Asthma - currently active 
. 8791 Further asthma - 
drug prevent. 
. 8793 Asthma control step 
0 
. 8794 Asthma control step 
1 
. 8795 Asthma control step 
2 
. 8796 Asthma control step 
3 
. 8797 Asthma control step 
4 
. 8798 Asthma control step 5 
. 81-12P Emergency admission asthma 
. 9N1d Seen 
in asthma clinic 
. 90J. Asthma monitoring admin. 
. 90,11 Attends asthma monitoring 
. 90J2 Refuses asthma monitoring 
. 90,13 Asthma monitor offer 
default 
. 90,14 Asthma monitor 
1 st letter 
. 90J5 Asthma monitor 
2nd letter 
. 90J6 Asthma monitor 
3rd letter 
. 90,17 Asthma monitor verbal 
invite 
. 90J8 Asthma monitor phone 
invite 
. 90,19 Asthma monitoring 
deleted 
. 90JA Asthma monitoring check 
done 
. 90jz Asthma monitoring admin. 
NOS 
. 9Q21 
Patient in Asthma study 
. H43. Asthma 
. 1-1431 Extrinsic asthma - atopy 
. 1-1432 Extrinsic asthma 
. 1-1433 Status asthmaticus 
. 1-1434 Asthma attack NOS 
. H43Z Asthma NOS 
. c7.. ASTHMA PROPHYLAXIS 
Cervica]Vuterine cancer 
. 685C Ca cervix screen abnormal 
. 131 E. Carcinoma cervix uteri 
. 131 El Ca cervix uteri - endocervix 
. 131 E2 Ca cervix uteri - exocervix 
. 131 EZ Ca cervix uteri NOS 
. 131 F. Carcinoma body of uterus 
. 131 G. Ca ovary/other uterine adnexa 
. B1GZ Ca ovary/uterine adnexa NOS 
. B1N1 Ca uterus NOS 
. 13312 Carcinoma in situ cervix uteri 
Breast cancer 
. B1 D. Carcinoma breast 
. 131 D1 Ca breast - nipple central 
. 131 D2 Ca breast-upper, inner quadrant 
. B1D3 Ca breast-lower, inner quadrant 
. 61 D4 Ca b reast-upper, outer quadrant 
. 131 D5 Ca breast-lowe r, inner quadrant 
. 131 D6 Ca breast - axillary tail 
. 131 DZ Ca breast - NOS 
. 13311 Carcinoma in situ breast 
Bronchitis and COPD 
. 12D1 FH: Bronchitis/COAD 
. 1-116. Acute bronchitis/bronchiolitis 
. 1-1161 Acute bronchitis 
. H16Z Acute bronchitis NOS 
. H4.. Chronic obstructive pulm. 
dis. 
. 1-141. Chronic bronchitis 
. 1-1411 Simple chronic 
bronchitis 
. 1-1412 Mucopurulent chr. bronchitis 
. 1-1413 
Obstructive chronic bronchitis 
. 1-1414 
Chronic bronchitis, acute exac 
. 1-1415 
Acute exacerbation COAD 
. H41Z 
Chronic bronchitis NOS 
. H4Z. 
Chronic obst. pulm. dis. NOS 
. 1-1512 
Acute chemical bronchitis 
-H6Z1 Bronchitis NOS 
. 1-146. Mild chron obstr pulm disease 
-H47. Mod chron obstr pulm disease 
. 1-148. Sev chron obstr pulm disease 
Stroke 
.1 4A7 H/O: CVA/stroke 
.1 4AK H/O: Stroke in last year 
. 662M Stroke monitoring 
. G75. Stroke/CVA - undefined 
Cerebrovascular disease 
. 1477 H/O: cerebrovascular disease 
. 17366 Cerebral oedema 
. G7.. Cerebrovascular disease 
. G71. Cerebral 
haemorrhage 
. G712 Intracerebral haemorrhage 
. G71Z Cerebral 
haemorrhage NOS 
. G72. Precerebral arterial occlusion 
. G72Z Precerebral A. occlusion 
NOS 
. G73. Cerebral arterial occlusion 
. G731 Cerebral thrombosis 
. G732 Cerebral embolism 
. G73Z Cerebral 
A. occlusion NOS 
. G74. Transient cerebral ischaemia 
. G76. Other cerebrovascular 
disease 
. G761 Cerebral arteriosclerosis 
. G763 Cerebral aneurysm-non ruptured 
. G71Z Cerebral 
hemorrage 
. G72. Precerebral arterial occlusion 
. G72Z Precerebral A. occlusion 
NOS 
. G73. Cerebral arterial occlusion 
. G731 Cerebral thrombosis 
. G732 Cerebral embolism 
. G73Z Cerebral 
A. occlusion NOS 
. G74. Transient cerebral 
ischernia 
. G76. Other cerebrovascular 
disease 
. G761 Cerebral arteriosclerosis 
. G763 Cerebral aneurysm-non ruptured 
. G76Z Other cerebrovascular 
dis. NOS 
. G77. Cerebrovasc. 
dis. late effects 
. G7Z. 
Cerebrovascular disease NOS 
. P312 Cerebral 
lacteration/contusion 
. P31Z 
Intracerebral injury NOS 
Myocardial infarction (MI) 
. 14A3 H/O: myocardial infarct<60 
.1 4A4 H/O: myocardial infarct >60 
. 323. ECG: myocardial infarction 
. 3232 ECG: old myocardial infarction 
. 323Z ECG: myocardial infarct NOS 
. G41. Acute myocardial infarction 
. G43. Old myocardial infarction 
Hysterectomy 
. 1599 H/O: hysterectomy 
.1 5A9 H/O: myectomy/hysterotomy 
. 685H No smear - benign hysterectomy 
. 81-70 Hysterectomy planned 
. 7CB. Hysterectomy 
. 7CB1 Subtotal abdom. hysterectomy 
. 7CB2 Total abdominal hysterectomy 
. 7CB3 Vaginal hysterectomy 
. 7CB4 Radical abdominal hysterectomy 
. 7CB5 Radical vaginal hysterectomy 
. 7CB7 Total hysterectomy & B. S. O. 
. 7CBZ Hysterectomy NOS 
. 7CD2 Uterine FB -vaginal remove NOS 
. 7CF1 Hysterectomy 
Hip fractures 
. M626 Pathological fracture - pelvis/thigh 
. M656 Fracture malunion-pelvis/thigh 
. P1 E. #Femur 
. P1 El #Neck of femur 
. P1 E2 #Shaft of femur 
. P1 E3 #Lower end of femur 
. P1 EZ #Fernur NOS 
Wrist fractures 
, 
M624 Pathological fracture - fore arm 
. M625 Pathological 
fracture - hand 
. M654 Fracture malunion 
fore arm 
. PlA. #Radius/ulna 
. P1A1 #Radius/ulna - upper end 
. P1A2 #Radius/ulna -shaft 
. P1A3 #Radius/ulna-lower end-colles 
. P1AZ #Radius/ulna 
NOS 
Vertebral fractures 
. P13. #Spine - no cord lesion 
. P131 #Cervical spine-no cord lesion 
. P132 #Thoracic spine-no cord lesion 
. P133 #Lumbar spine - no cord lesion 
. P134 #Sacrum/coccyx-no cord lesion 
. P13Z #Spine NOS - no cord lesion 
. P1 4. #Spine + cord lesion 
. P141 #Cervical spine + cord lesion 
. P142 #Thoracic spine + cord lesion P143 #Lumbar spine + cord lesion 
. P144 #Sacrum/coccyx + cord lesion 
. P14Z #Spine NOS + cord lesion 
Non-specific fractures 
. 8F86 Convalesc. after fracture Rx 
. 8HB9 Fracture therapy follow-up 
. 9NOX Seen in 
fracture clinic 
. M62. Pathological fracture 
. M621 Path. fracture - multiple 
. M62Z Path. fracture - 
NOS 
. M65. 
Malunion/nonunion of fracture 
. M65Z Fracture malunion - 
NOS 
. P1 K. 
Multiple fractures 
. P1z. Fracture NOS 
. P1.. Fractures 
Other specific fractures 
. M623 Path. fracture - upper arm M624 Path. fracture - fore arm 
. M625 Path. fracture - 
hand 
. M627 Path. 
fracture - lower leg 
. M652 Fracture malunion - shoulder 
. M654 Fracture malunion - 
fore arm 
. M655 Fracture malunion - 
hand 
. M658 Fracture malunion - ankle/foot 
. 0213 Fracture of clavicle - 
birth 
. P1 1. #Skull 
. P111 #Frontal 
bone 
. P1 12 #Parietal 
bone 
. P1 13 #Base of skull 
. P1 14 #Skull - multiple 
. PIIZ #Skull 
NOS 
. P1 2. #Facial 
bones 
. P121 #Nasal 
bones 
. P122 Wandible 
. P123 #Maxilla 
. P124 #Zygoma 
. P125 #Orbital floor (blow-out) 
. P12Z #Facial bones NOS 
. P15. #Rib/sternum/larynx/trachea 
. P151 #Rib 
. P152 #Sternum 
. P153 #Flail chest 
. P154 #Larynx/trachea 
. P16. #Pelvis 
. P161 #Acetabulum of pelvis 
. P162 #Pubis of pelvis 
. P16Z #Pelvis NOS 
. P17. #Clavicle 
. P18. #Scapula 
. P19. #Humerus 
. P191 #Humerus - upper end 
. P192 #Humerus - shaft 
. P193 #Humerus - lower end 
. P19Z #Humerus NOS 
. P1 B. #Carpal bones 
. P1B1 #Scaphoid 
. P1BZ #Carpal 
bones NOS 
. P1 C. #Metacarpal bones 
. P1C1 #Bennett's 
fracture 
. P1Cz #Metacarpal 
bone NOS 
. P1 D. #Phalanx of 
finger/thumb 
. P1 D1 #Phalanx of 
finger 
. P1 D2 #Phalanx of thumb 
. P1 DZ #Phalanx of 
finger/thumb NOS 
. P1 F. #Patella 
. P1 G. #Tibia/fibula 
. P1G1 #Tibia alone 
. P1G2 #Fibula alone 
. P1G3 #Tibia/fibula - upper end 
. P1G4 #Tibia/fibula - shaft 
. P1GZ #Tibia/fibula 
NOS 
. P1H. #Ankle 
. P1H1 #Ankle - medial malleolus 
. P1 H2 #Ankle - lateral malleolus 
. P1H3 #Ankle - 
bimalleolar - Potts # 
. P1H4 #Ankle - trimalleolar 
. P1 HZ #Ankle - 
NOS 
. P1 1. #Tarsal/metatarsal 
bones 
. P111 #Calcaneus - 
heel 
. P1 IZ #Tarsal/metatarsal 
bone NOS 
. P1j. #Phalanges of 
foot - toe 
Hypertension 
.1 4A2 H/O: hypertension 
. 6624 Borderline hyperten: yearly obs 
. 6628 Poor hypertension control 
. 6629 Hypertension: follow-up default 
. 662F Hypertension treatm. started 
. 662G Hypertensive treatm. changed 
. 662H Hypertension treatm. stopped 
. 68B1 Hypertension screen 
. 68B4 Hypertension risk 
. 8B26 Anti hypertensive therapy 
. 90D. Hypertension screen admin. 
. 90DZ Hypertension screen admin. NOS 
. 901. Hypertension monitoring admin. 
. 9011 Attends hypertension monitor. 
. 9012 Refuses hypertension monnitor 
. 9013 Hyperten. monitor offer default 
. 9014 Hypertens. monitor. 1st letter 
. 9015 Hypertens. monitor 2nd letter 
. 9017 Hypertens. monitor verbal inv. 
. 9018 Hypertens. monitor phone inv. 
. 9019 Hypertension monitor 
. 901A Hypertension monitor. chck done 
. 901Z Hypertens. monitoring admin. NOS F363 Benign intracranial hyperten. 
F522 Hypertensive retinopathy 
. G3.. Hypertensive disease 
. G31. Essential hypertension 
. G32. Hypertensive heart disease 
. G33. Hypertensive renal disease 
. G34. Hypertensive renal + heart dis 
. G35. Secondary hypertension 
. G36. Malignant hypertension 
. G3Z. Hypertensive disease NOS 
. G521 Primary pulmonary hypertension 
. G762 Hypertensive encephalopathy 
. 1734 Portal hypertension X24. Preg. + pre-existing hypertensn 
IHD/CHD 
.1 4A. H/O: cardiovascular 
disease 
.1 4A6 H/O: heart 
failure 
.1 4AA H/O: 
heart disease NOS 
.1 4AL H/O: 
Treatmen ischaem heart dis 
. 1407 At risk of 
heart disease 
. 14S3 
H/O: heart recipient 
. 14S4 
H/O: heart valve recipient 
.1 4T3 
H/O: artificial heart valve 
. 18.. Cardiovascular symptoms 
. 329. ECG: heart block 
. 329Z ECG: heart block NOS 
. 5533 Angiocardiography abnormal 
. 68133 Heart disease screen - risk 
. 77.. Cardiovascular operations 
. 771. Heart valve operations 
. 7711 Closed heart valvotomy 
. 7712 Open heart valvotomy 
. 7713 Heart valve replace rn ent-g raft 
. 7714 Heart valve replace-prosthesis 
. 7715 Heart valvuloplasty 
. 7716 Heart valve replacement NOS 
. 771 Z Heart valve operation NOS 
. 772. Heart septum operations 
. 7723 
Close heart septal defect 
. 772Z Heart septum operation NOS 
. 777. Heart repair 
. 778. Heart transplant 
. 77Z. 
Cardiovascular operations NOS 
. 7931 Cardioplasty 
. 8H20 Admit cardiothoracic emergency 
. 9022 Patient in heart disease study 
. 
G4.. Ischaemic heart disease 
. G45. Chr. ischaernic heart dis. NOS 
. G452 Aneurysm of heart 
. 
G45Z Chr. ischaemic heart dis. NOS 
. 
G4Z. Ischaemic heart disease NOS 
. 
G5.. Pulmonary heart disease 
. 
G52. Chronic pulmonary heart dis. 
. 
G52Z Pulmonary heart disease NOS 
. G5Z. Other pulmonary heart disease 
. 
G6.. Other heart disease 
. G64. Cardiomyopathy 
. G64Z Cardiomyopathy NOS 
. G655 Heart block NOS 
. 
G6A. Heart failure 
. 
G6AZ Heart failure NOS 
. 
G613. Other heart disease 
. 
G6135 Cardiomegaly 
. 
G613Z Heart disease NOS 
. 
G6Z. Other heart disease NOS 
. 
N21. Bulbus/septum heart anomalies 
. 
N22. Congenital heart anomaly NOS 
. 
N22Z Congenital heart anomaly NOS 
. 
RD20 Echocardiogram abnormal [D] 
. 
RD21 X-ray heart shadow abnormal[D] 
. RD22 
Ultrasound cardiogram abn. [D] 
. 
RE3. Cardiovascular function abn[D] 
. RE31 
ECG electrocardiogram abn. [D] 
. 
RJ10 Cardiorespiratory failure [D] 
.1 4A5 H/O: angina pectoris 
.1 4AJ H/O: Angina in last year 
. 662K Angina control 
. 81327 Antianginal therapy 
. G44. Angina pectoris 
Arthritis 
. M217 Knee joint pain 
. M267 Osteoarthritis - knee joint 
. M261 Osteoarthritis -multiple joint 
. M212 Shoulder joint pain 
. M26. Osteoarthritis 
. M216 Hip joint pain 
. M218 Ankie/foot joint pain 
. M211 Multiple joint pain 
. M2.. Arthritis/arthrosis 
. M266 Osteoarthritis - hip joint 
. M296 Chondromalacia patellae 
. M215 Hand joint pain 
. M214 Wrist joint pain 
. M265 Osteoarthritis - hand joint 
. M21. Pain in joint - coxalgia 
. M268 Osteoarthritis - ankle/foot 
. M29. Internal derangement of knee 
. M22. Rheumatoid arthritis 
. M213 Elbow joint pain 
. M2G7 Effusion - knee joint 
. M28Z Arthropathy NOS 
. M2Z. Joint disorder NOS 
. M221 Rheum. arth. - multiple joint 
. M219 Other joint pain 
. M262 Osteoarthritis -shoulder joint 
. M292 Derangement of medial meniscus 
. M29Z Internal knee derangement NOS 
. M269 Osteoarthritis - other joint 
. M26Z Osteoarthritis - NOS 
. M25. Polyarthropathy NOS -inflammat 
. M264 Osteoarthritis - wrist joint 
. M21Z Joint pain NOS 
. M2L. Difficulty 
in walking 
. M293 Deranged lateral meniscus 
. M28. Arthropathy 
NOS 
. M285 Clicking joint 
. M263 Osteoarthritis - elbow 
joint 
. M284 
Reactive arthropathy unspec 
. M2A. 
Articular cartilage disorder 
. M295 Loose 
body in knee 
. M225 
Rheum. arth. - hand joint 
. M2J1 
Multiple joint stiffness 
. M294 Meniscus derangement NOS 
. M2H7 Haemarthrosis - knee joint 
. M2D2 Recur. disloc. - shoulder joint 
-M2K. Other joint symptoms 
-M2J5 Hand joint stiffness 
. M251 Sero negative polyarthritis 
. M22Z Rheumatoid arthritis NOS 
. M24. Still's disease - juvenile R. A 
. M2J. Joint stiffness NOS 
. M227 Rheum. arth. - knee joint 
. M217 Pyog. arthr. - knee joint 
. M2J7 Knee joint stiffness 
. M2G3 Effusion - elbow joint 
. M2J2 Shoulder joint stiffness 
. M224 Rheum. arth. - wrist joint 
. M2B. Loose body in joint - not knee 
. M2E5 Contracture - hand joint 
. M291 Old bucket handle tear- medial 
. M2D7 Recur. disloc. - knee joint 
. M275 Traumatic arth. - hand joint 
. M2G. Effusion of joint 
. M226 Rheum. arth. - hip joint 
. M277 Traumatic arth. - knee joint 
. M278 Traumatic arth. - ankle/foot 
. M2J9 Other joint stiffness 
. M228 Rheum. arth. - ankle/foot 
. M279 Traumatic arth. - other joint 
. M283 Post-viral arthropathy 
. M2J6 Hip joint stiffness 
. M2J8 Ankle/foot joint stiffness 
. M2G8 Effusion - ankle/foot 
. M216 Pyog. arthr. - hip joint 
. M2H. Haernarthrosis 
. M213 Pyog. arthr. - elbow joint 
. M2J4 Wrist joint stiffness 
. M222 Rheum. arth. - shoulder joint 
. M2D9 Recur. disloc. - other joint 
. M218 Pyog. arthr. - ankle/foot 
. M2E. Contracture of joint 
. M2JZ Joint stiffness NOS 
. M2E9 Contracture - other joint 
. M2G5 Effusion - hand joint 
. M2J3 Elbow joint stiffness 
. M2H3 Haemarthrosis - elbow 
joint 
. M272 Traumatic arth. -shoulder 
joint 
. M2G2 Effusion - shoulder 
joint 
. M27. 
Traumatic arthropathy 
. M282 
Climacteric arthritis 
. M2D. 
Recurrent dislocation of joint 
. M21. 
Pyogenic arthritis 
. M215 
Pyog. arthr. - hand joint 
-M2D5 Recur. disloc. - hand joint M273 Traumatic arth. - elbow joint M274 Traumatic arth. - wrist joint 
. M2D6 Recur. disloc. - hip joint 
. M2E3 Contracture - elbow joint M229 Rheum. arth. - other joint 
. M2H2 Haemarthrosis - shoulder joint M281 Allergic arthritis 
. M2G4 Effusion - wrist joint M212 Pyog. arthr. -shoulder joint 
. M2C2 Path. disloc. - shoulder joint 
. M2G6 Effusion - hip joint M223 Rheum. arth. -elbow joint 
. M2D3 Recur. disloc. - elbow joint 
. M2E7 Contracture - knee joint M276 Traumatic arth. - hip joint 
. M2DZ Recurrent dislocation NOS M23. Felty's syndrome 
. M2D8 Recur. disloc. - ankle/foot M214 Pyog. arthr. - wrist joint 
. M2C5 Path. disloc. - hand joint 
. M2E8 Contracture - ankle/foot 
. M2H5 Haemarthrosis - hand joint M219 Pyog. arthr. - other joint 
. M2C6 Path. disloc. - hip joint 
. M2F6 Ankylosis - hip joint 
. M2G9 Effusion - other joint M21Z Pyogenic arthritis NOS 
. M2C3 Path. disloc. - elbow joint 
. M2C7 Path. disloc. - knee joint 
. M2C9 Path. disloc. - other joint 
. M2E4 Contracture - wrist joint 
. M2E6 Contracture - hip joint 
. M2EZ Contracture of joint NOS 
. M2G1 Effusion -multiple joint 
. M2GZ Effusion of joint NOS 
. M2H8 Haemarthrosis - ankle/foot 
. M211 Pyog. arthr. - multiple joint 
. M27Z Traumatic arthritis NOS 
. M2E1 Contracture - multiple joint 
. M2H4 Haemarthrosis - wrist joint 
. M2H9 Haernarthrosis - other joint M271 Traumatic arth. -multiple joint 
. M2D4 Recur. disloc. - wrist 
joint 
. M2F7 Ankylosis - 
knee joint 
. M2FZ Ankylosis of 
joint NOS 
. M2E2 
Contracture - shoulder joint 
. M2F8 Ankylosis - ankle/foot 
. M2F9 
Ankylosis - other joint 
. M2C- 
Pathological dislocation 
. M2C8 
Path. disloc. - ankle/foot 
. 
M2CZ Pathological dislocation NOS 
. 
M2F. Ankylosis of joint 
. 
M2H1 Haernarthrosis -multiple joint 
. 
M2H6 Haemarthrosis - hip joint 
GI Disease 
.1 2E1 FH: Peptic ulceration 
. 14C1 H/O: peptic ulcer 
. 1956 Peptic ulcer symptoms 
. 1972 Epigastric pain 
. 25C3 O/E - abd. pain - epigastrium 
. 25C9 O/E - abd. pain - hypogastrium 
. 363. Endoscopy: gastrointestinal 
. 7956 Gastric fundusectomy 
. 7981 Perf. peptic ulcer closure 
. 7982 Gastric ulcer suture 
. 7984 Gastric anastomosis revision 
. 122. Gastric ulcer 
. 122Z Gastric ulcer NOS 
. 124. Peptic ulcer NOS = PU 
. 124Z Peptic ulcer NOS 
. 125. Gastritis and duodenitis 
. 1251 Acute gastritis 
. 1252 Chronic (atrophic) gastritis 
. 1253 Alcoholic gastritis 
. 1255 Helicobacter gastritis 
. 125Z Gastritis/duodenitis NOS 
. 1264 Dyspepsia, indigestion NOS 
. P784 Burn - oesophagus 
. P785 Burn - gastrointestinal tract 
. R906 Epigastric pain [D] 
Rheumatism 
. M421 Shoulder syndrome 
. M422 Tennis elbow - epicondylitis 
. M4G. Leg cramps 
. M426 Tendinitis of ankle/tarsus 
. M4A7 Plantar fasciitis 
. M4E4 Pain in left leg 
. M434 Synovitis/tenosyn. - wrist 
. M4E5 Pain in right 
leg 
. M4A8 Muscle 
injury / strain 
. M42Z 
Peripheral enthesopathy NOS 
. M453 Bursitis - elbow 
. M457 
Bursitis - knee 
. M464 
Gang I ion/synov. cyst - wrist 
. M44. 
Bunion 
. M41. Polymyalgia rheumatica 
. M435 Synovitis/tenosyn. - hand 
. M4E2 Pain in left arm 
. M4A6 Dupuytren's contracture 
. M4AZ Muscle/ligament disorder NOS 
. M4E3 Pain in right arm 
. M4CZ Myalgia/myositis - NOS 
. M4E9 Pain in limb NOS 
. M465 Gang I ion/synov. cyst - hand 
. M458 Bursitis - ankle/foot 
. M4E. Pain in limb 
. M4B. Rheumatism/fibrositis NOS 
. M468 Gang lion/synov. cyst-an kle/f oot 
. M46. Gang I ion/synovial cyst 
. M4DZ Neuralgia/neuritis - NOS 
. M4A. Muscle/ligament disorder NOS 
. M4E1 Pain in limb - multiple 
. M4B2 Rheumatism NOS - shoulder 
. M456 Bursitis - hip 
. M43. Synovitis/tenosynovitis 
. M4D. Neuralgia/neuritis NOS 
. M4C. Myalgia/myositis NOS 
. M438 Synovitis/tenosyn. - ankle/foot 
. M477 Rupture of synovium - knee 
. M4BZ Rheumatism/fibrositis NOS 
. M425 Patellar tendinitis 
. M4C1 Myalgia/myositis - multiple 
. M4B1 Rheumatism NOS - multiple 
. M4C2 Myalgia/myositis - shoulder 
. M488 Tendon rupture - ankle/foot 
. M437 Synovitis/tenosyn. - knee 
. M4.. Nonarticular rheumatism 
. M42. Peripheral enthesopathies 
. M45. Bursitis 
. M433 Synovitis/tenosyn. - elbow 
. M467 Gang I ion/synov. cyst - knee 
. M4C6 Myalgia/myositis -pelvis/thigh 
. M4C7 Myalgia/myositis - lower leg 
. M432 Synovitis/tenosyn. - shoulder 
. M485 Tendon rupture - hand 
. M43Z Synovitis/tenosyn. - NOS 
. M46Z Gang lion/synov. cyst - NOS 
. M4A9 Fibromyalgia 
. M4C3 Myalgia/myositis - upper arm 
. M49. Synovial/tendon problem 
NOS 
. M45Z Bursitis 
NOS 
. M423 Periarthritis of wrist 
. M4D8 Neuralgia/neuritis -ankle/foot 
. M4A5 
Hypermobility syndrome 
. M436 
Synovitis/tenosyn. - hip 
. M4D2 
Neuralgia/neuritis - shoulder 
. M4A3 Muscle wasting/atrophy NOS 
. M4D6 Neu ralgia/neu rit. -pelvis/thig h 
. M4F5 F. B. left in hand 
. M48. Tendon rupture - non traumatic 
. M4B5 Rheumatism NOS - hand 
. M4B7 Rheumatism NOS - knee 
. M48Z Tendon rupture - NOS 
. M4D7 Neuralgia/neuritis - lower leg 
. M482 Tendon rupture - shoulder 
. M4A4 Laxity of ligaments 
. M4D3 Neuralgia/neuritis - upper arm 
. M424 Tendinitis of hip region 
. M4B6 Rheumatism NOS - hip 
. M4Z. Nonarticular rheumatism NOS 
. M452 Bursitis - shoulder 
. M463 Gang I ion/synov. cyst - elbow 
. M4D4 Neuralgia/neuritis - fore arm 
. M4B8 Rheumatism NOS - ankle/foot 
. M487 Tendon rupture - knee 
. M4C4 Myalgia/myositis - fore-arm 
. M4D5 Neuralgia/neuritis - hand 
. M431 Synovitis/tenosyn. - multiple 
. M4F8 F. B. left in ankle/foot 
. M461 Gang I ion/synov. cyst - multiple 
. M4A2 Muscle calcific. /ossification 
. M462 Gang I ion/synov. cyst - shoulder 
. M4B3 Rheumatism 
NOS - elbow 
. M4FZ F. B. left in tissue 
NOS 
. M4F. Foreign body left in tissue 
. M4B4 Rheumatism NOS - wrist 
. M484 Tendon rupture - wrist 
. M4A1 Infective myositis 
. M4D1 Neuralgia/neuritis - multiple 
. M483 Tendon rupture - elbow 
. M454 Bursitis - wrist 
. M455 Bursitis - hand 
. M4C5 Myalgia/myositis - hand 
. M4C8 Myalgia/myositis - ankle/foot 
. M4F7 F. B. left in knee 
. M481 Tendon rupture - multiple 
. M451 Bursitis - multiple 
. M4F2 F. B. left in shoulder 
. M4F3 F. B. left 
in elbow 
. M466 Gang lion/synov. cyst - 
hip 
. M486 Tendon rupture - 
hip 
. M47. Rupture of synovium 
. M4F1 F. 
B. left in tissue - multiple 
. M4F4 
F. B. left in wrist 
. M478 Rupture of synovium-ankle/foot 
Vertebral Column Disease 
. M3Z5 Backache NOS 
. M3Z4 Sciatica M342 Cervicalgia 
M321 Cervical spond. - no myelopathy 
M344 Torticollis NOS 
. M3Z3 Lumbago M32. Spondyloses 
M343 Brachial (cervical) neuritis 
. M3Z7 Coccygeal disorder NOS M333 Lumbar disc lesion - displaced 
M323 Lumbosacral spond-no myelopath 
M312 Sacroiliitis 
M322 Cervical spond. with myelopathy 
M33. Intervertebral disc disorders 
M336 Lumbar disc degeneration 
M34. Cervical disorder NOS 
M331 Cervical disc lesion-disp laced 
. M34Z Cervical/neck disorder NOS 
. M311 Ankylosing spondylitis 
. M32Z Spondylosis 
NOS 
. M3.. Vertebral column syndromes M325 Thoracic spondylosis 
M334 Cervical disc degeneration 
. M33Z Intervertebral 
disc lesion NOS 
. M3Z1 Spinal stenosis excl. cervical 
. M3Z2 Pain 
in thoracic spine 
M324 Lumbosacral spond + myelopathy 
. M3ZZ Back disorder/symptom 
NOS 
. M3Z. Back disorders - other M332 Thoracic disc lesion-displaced 
. M3Z6 Sacral disorder 
NOS 
M337 Disc disorder+ myelopathy 
M335 Thoracic disc degeneration 
M338 Post laminectomy syndrome 
M341 Cervical spinal stenosis 
. M31Z Inflam. spondylopathies 
NOS 
. M31. Inflammatory spondylopathies 
APPENDIX 4.3 
READ CODES FOR THE CLASSIFICATION OF ADMINISTRATIVE 
ACTIVITY 
Hospital Admissions 
. 8H1. Admit to intensive care unit 
. 81-111 Admit to cardiac ITU 
. 8H12 Admit to respiratory ITU 
. 81-113 Admit to neurological ITU 
. 81-114 Admit to metabolic ITU 
. 81-115 Admit to burns unit 
. 8H1Z Admit to intensive c. u. NOS 
. 81-12. Emergency hospital admission 
. 81-121 Admit medical emergency unsp. 
. 81-122 Admit surgical emergency unsp. 
. 81-123 Admit psychiatric emergency 
. 8H24 Admit geriatric emergency 
. 81-125 Admit paediatric emergency 
. 81-126 Admit gynaecological emergency 
. 81-127 Admit obstetric emergency 
. 81-128 Admit orthopaedic emergency 
. 81-129 Admit ENT emergency 
. 81-12A Admit trauma emergency 
. 8H2B Admit ophthalmological emerg. 
. 81-12C Admit rheumatology emergency 
. 8H2D Admit 
dermatology emergency 
. 8H2E Admit neurology emergency 
. 8H2F Admit urology emergency 
. 8H2G Admit radiotherapy emergency 
. 8H2H Admit haematology emergency 
. 81-121 Admit plastic surgery emergenc 
. 8H2J Admit 
diabetic emergency 
. 8H2K Admit oral surgical emergency 
. 8H2L Admit psychogeriatric emerg. 
. 81-12M Admit renal medicine emergency 
. 8H2N Admit neurosurgical emergency 
. 81-120 Admit cardiothoracic emergency 
. 8H2P Emergency admission asthma 
. 8H2Z Admit 
hospital emergency NOS 
. 81-13. 
Non-urgent hospital admission 
. 8H31 Non-urgent 
hosp. admission unsp 
. 81-136 
Non-urgent medical admission 
. 81-137 
Non-urgent surgical admission 
. 8H38 
Non-urgent psychiatric admisn. 
. 81-139 
Non-urgent geriatric admission 
. 81-13A Non-urgent paediatric admisn. 
. 8H3B Non-urgent gynaecol. admission 
. 81-13C Non-urgent obstetric admission 
. 81-13D Non-urgent orthopaedic admisn. 
. 8H3E Non-urgent ENT admission 
. 8H3F Non-urgent trauma admission 
. 8H3G Non-urgent ophthalmolog. admisn 
. 8H3H Non-urgent rheumatology admisn 
. 81-131 Non-urgent dermatology admisn. 
. 8H3J Non-urgent neurology admission 
. 8H3K Non-urgent urology admission 
. 8H3L Non-urgent radiotherapy admisn 
. 81-13M Non-urgent haematology admisn. 
. 8H3N Non-urgent plastic surg. admisn 
. 8H30 Non-urgent diabetic admission 
. 81-13P Non-urgent respiratory admis. 
. 81-13S Non-urgent neurosurgical admis 
. 8H3U Non urgent oral surg admission 
. 81-13V Non-urgent cardiolog admission 
. 81-13Z Other hospital admission NOS 
. 8HM. Listed for admission to hosp. 
. 8HM1 Listed for Gen Medicine admiss 
. 8HM2 Listed for Paediatric admiss'n 
. 8HM3 Listed for Dermatology admissn 
. 8HM4 Listed for Cardiology admiss'n 
. 8HM5 Listed for Immunology admiss'n 
. 8HM6 Listed for Neurology admission 
. 8HM7 Listed for Geriatrics admiss'n 
. 8HM8 Listed for Gastroenterol admis 
. 8HM9 Listed for Psychiatric admissn 
. 8HMA Listed for Rheumatology admiss 
. 8HMB Listed for Chest Med admission 
. 8HMC Listed for Psychogeriatr admis 
. 8HMD Listed for Oncology admission 
. 8HME Listed for Diabetology admissn 
. 8HMF Listed for other medical admis 
. 8HMG Listed for Gen 
Surgery admissn 
. 8HMH Listed for Ophthalmology admis 
. 8HMJ Listed for E. 
N. T. admission 
. 8HMK Listed for Orthopaedic admissn 
. 8HML Listed for Neurosurgical admis 
. 8HMMListed for Paed 
Surgery admiss 
. 8HMN Listed for 
Obstetric admission 
. 8HMO Listed 
for Gynae admission 
. 8HMP Listed 
for Plastic Surg admiss 
. 8HMQ Listed 
for Oral Surgery admiss 
. 8HMR Listed 
for Urology admission 
. 8HMZ Listed 
for hosp admission NOS 
. 8HO. 
Admission funding status 
. 8HO1 
Admission f undable procedure 
. 8HO2 
Admission non-fundable proced. 
. 8HOZ Admission funding status NOS 
. 8HX. Admission to hospice 
. 8HXO Urgent admission to hospice 
. 8HX1 Routine admission to hospice 
. 8HX2 Admission to hospice - respite 
Respiratory Diseases 
.1 4B. H/O: respiratory disease 
.1 4B1 HIO: hay fever 
.1 4BZ H/O: respiratory disease NOS 
. 17.. Respiratory symptoms 
.1 7Z. Respiratory symptoms NOS 
.1 7ZZ Respiratory symptom NOS 
. 1827 Painful breathing -pleurodynia 
. 23E. O/E - non-specific resp. lesion 
. 23E5 O/E -fibrosis of lung present 
. 3374 Lung function testing abnormal 
. 3375 Lung function mildly obstruct. 
. 3376 Lung function signific. obstr. 
. 3377 Lung function restrictive 
. 3394 Resp. flow rate abnormal 
. 663B Resp. treatment changed 
. 663C Resp. dis. treatment started 
. 663D Resp. dis. treatment stopped 
. 76.. Respiratory system operations 
. 764. Excision of lung/bronchus 
. 7668 Lung transplant 
. 876Z Respiratory medication 
NOS 
. H... Respiratory system diseases 
. H231 Chronic rhinitis 
. H28. Hay fever 
. H29. Allergic rhinitis 
NOS 
. H6.. Other resp. system diseases 
. 
H6Z. Respiratory disease NOS 
. H6ZZ Respiratory disease NOS 
. HZ.. Respiratory diseases NOS 
. R6.. Respiratory/chest symptoms [D] 
. R60. Respiratory abnormalities [D] 
. R607 Respiratory insufficiency [D] R60Z Respiratory abnormality NOS[D] 
R651 Painful respiration [D] 
. R6Z. 
Respir/chest symptoms NOS [D] 
. 
RD1. Lung x-ray field abnormal [D] 
. RD10 Lung x-ray, coin 
lesion [D] 
. RD1 1 Lung x-ray, shadow 
[D] 
. RD1Z 
Lung x-ray abnormal NOS [D] 
. RE20 
Lung scan abnormal [D] 
. 
RE21 Ventilatory capacity reduc. [D] 
. RJ1. 
Respiratory failure [D] 
. RJ10 Cardiorespiratory failure (D] 
. RJ11 Respiratory arrest (D] 
-RJ1Z Respiratory failure NOS [D] 
Smoking 
. 137. Tobacco consumption 
. 1372 Trivial smoker -<1 cig/day 
. 1373 Light smoker - 1-9 cigs/day 
. 1374 Moderate smoker - 10-19 cigs/d 
. 1375 Heavy smoker - 20-39 cigs/day 
. 1376 Very heavy smoker - 40+cigs/d 
. 1377 Ex-trivial smoker (<1/day) 
. 1378 Ex-light smoker (1-9/day) 
. 1379 Ex-moderate smoker (10-1 9/day) 
.1 37A Ex-heavy smoker (20-39/day) 
.1 37B Ex-very heavy smoker (40+/day) 
.1 37C Keeps trying to stop smoking 
.1 37D Admitted tobacco cons untrue 
.1 37E Tobacco consumption unknown 
.1 37F Ex-smoker - amount unknown 
.1 37G Trying to give up smoking 
.1 37H Pipe smoker 
. 1371 Passive smoker 
.1 37J Cigar smoker 
.1 37K Stopped smoking 
.1 37L Current non-smoker 
.1 37M Rolls own cigarettes 
.1 37N Ex pipe smoker 
. 1370 Ex cigar smoker 
.1 37P Cigarette smoker 
.1 37Q Smoking started 
.1 37R Current smoker 
. 137S Ex smoker 
.1 37T Date ceased smoking 
.1 37Z Tobacco consumption NOS 
. 6791 Health ed. - smoking 
. 67A3 Pregnancy smoking advice 
. 9001 Attends stop smoking monitor. 
. 9002 Refuses stop smoking monitor 
. 9003 Stop smoking monitor default 
. 9004 Stop smoking monitor 1st 
lettr 
. 9005 Stop smoking monitor 2nd 
lettr 
. 9007 Stop smoking monitor verb. 
inv. 
. 9008 Stop smoking monitor phone 
inv 
. 9009 
Stop smoking monitoring delete 
. 900A 
Stop smoking monitor. chck done 
. 90OZ 
Stop smoking monitor admin. NOS 
All Referrals 
. 8H.. Referral for further care 
-81-14. Referral to physician 
. 81-141 General medical referral 
. 8H42 Paediatric referral 
. 81-143 Dermatological referral 
. 81-144 Cardiological referral 
. 81-145 Immunological referral 
. 81-146 Neurological referral 
. 81-147 Geriatric referral 
. 8H48 Gastroenterological referral 
. 8H49 Psychiatric referral 
. 81-14A Referred to venereologist 
. 81-1413 Referred to rheumatologist 
. 81-14C Referred to chest physician 
. 81-14D Referral to psychogeriatrician 
. 81-14E Referral to oncologist 
. 81-14F Referral to diabetologist 
. 81-14G Refer to radiotherapist 
. 81-141-1 Refer to clin pharmacologist 
. 81-141 Refer to geneticist 
. 8H4J Referred to anaesthetist 
. 81-14K Referred to endocrinologist 
. 81-141- Referred to nephrologist 
. 81-14M Ref to community paediatrician 
. 8H4N Ref to paediatric cardiologist 
. 81-140 Ref to paediatric neurologist 
. 81-14Z Referral to physician NOS 
. 81-15. Referral to surgeon 
. 8H51 General surgical referral 
. 8H52 Ophthalmological referral 
. 81-153 ENT referral 
. 81-154 Orthopaedic referral 
. 8H55 Neurosurgical referral 
. 8H56 Paediatric surgical referral 
. 81-157 Obstetric referral 
. 8H58 Gynaecological referral 
. 81-159 Referred to plastic surgeon 
. 81-15A Referred to oral surgeon 
. 81-1513 Referred to urologist 
. 81-15C Referred to thoracic surgeon 
. 81-15D Referred to vascular surgeon 
. 81-15E Burns referral 
. 81-15F Refer to maxillofacial surgeon 
. 81-15G Refer 
Cardiothoracic surgeon 
. 81-15Z Referral 
to surgeon NOS 
. 81-16. Referral 
to other doctor 
. 81-161 
Referral to private doctor 
. 8H62 
Referral to G. P. 
. 81-163 
Refer to casualty officer 
. 81-164 Refer to house officer 
. 81-165 Refer to hospital registrar 
. 81-166 Refer to child medical officer 
. 81-167 Referred for radiotherapy 
. 81-168 Referred to haernatologist 
. 8H69 Refer to pain clinic 
. 8H6A Refer to terminal care consult 
. 8H6B Refer to public health 
. 8H6Z Refer to other doctor NOS 
. 8H7. Other referral 
. 81-171 Refer to practice nurse 
. 81-172 Refer to district nurse 
. 8H73 Refer to health visitor 
. 8H74 Refer to mid-wife 
. 8H75 Refer to social worker 
. 81-176 Refer to dietician 
. 8H77 Refer to physiotherapist 
. 81-178 Refer to counsellor 
. 8H79 Refer to community day centre 
. 81-17A Refer to mental health worker 
. 8H7B Refer to community psych. nurse 
. 81-17C Refer diabetic liaison nurse 
. 8H7D Refer to osteopath 
. 8H7E Refer to chiropractor 
. 81-17F Referred to dentist 
. 8H7G Refer to speech therapist 
. 8H7H Refer to optician 
. 81-171 Refer to partner 
. 8H7J Refer to occupational therap. 
. 8H7K Refer to orthoptist 
. 8H7L Refer for terminal care 
. 8H7M Refer to stoma nurse 
. 8H7N Refer for colposcopy 
. 81-170 Refer to Radiology 
department 
. 81-17P Refer to pathology 
department 
. 8H7Q Refer to surgical 
fitter 
. 8H7R Refer to chiropodist 
. 8H7T Refer to psychologist 
. 8H7U Refer to homeopathist 
. 81-17V Refer to audiologist 
. 8H7W Refer to 
TOP counselling 
. 8H7X Refer to podiatry 
. 81-17Y Refer to acupuncture 
. 8H7Z 
Refer to other health worker 
. 81-17a 
Refer to hospital 
. 8H7b 
Refer to day hospital 
. 8H7c 
Refer to occup health dept 
. 81-17d 
Refer to school nurse 
. 8H7e 
Referral to nurse practitioner 
. 81-17f 
Referral to diabetes nurse 
. 8HA5 
Follow-up refused 
. 8HC. Refer to hospital casualty 
. 8HC1 Refer to A. & E. department 
. 8HC2 Refer to hosp. eye casualty 
. 8HC3 Refer to hosp. paeds casualty 
. 8HCZ Refer to hospital casualty NOS 
. 8HD. Refer to hospital OPD 
. 8HH. Referred - other care 
. 8HH5 Refer domiciliary physio 
. 8HH6 Referral to Macmillan nurse 
. 8HI. Refer - no direct consultation 
. 8HJ. Self-referral to hospital 
. 8HJ1 General medical self-referral 
. 8HJ2 General surgical self-referral 
. 8HJ3 Psychiatric self-referral 
. 8HJ4 Geriatric self-referral 
. 8HJ5 Paediatric self-referral 
. 8HJ6 Gynaecological self-referral 
. 8HJ7 Obstetric self-referral 
. 8HJ8 Orthopaedic self-referral 
. 8HJ9 ENT self-referral 
. 8HJA Trauma self-referral 
. 8HJB Ophthalmology self-referral 
. 8HJC Rheumatology self-referral 
. 8HJD Dermatology self-referral 
. 8HJE Neurology self-referral 
. 8HJF Urology self-referral 
. 8HJG Radiotherapy self-referral 
. 8HJH Haematology self-referral 
. 8HJI Plastic surgery self-referral 
. 8HJZ Self-referral to hospital NOS 
. 8HP. Referral for laboratory tests 
. 8HP1 Referral for haematology test 
. 8HP2 Refer for microbiological test 
. 8HP3 Refer for biochemical test 
. 8HP4 Refer for radio-immune assay 
. 8HP5 Refer for thyroid test 
. 8HP6 Refer for cytological test 
. 8HP7 Refer for 
histology 
. 8HP8 Refer for serological testing 
. 8HP9 Refer for immunological test 
. 8HPZ Referral 
for lab test NOS 
. 8HQ. Refer 
for imaging 
. 8HQ1 Refer 
for X-Ray 
. 8HQ2 Refer 
for ultrasound investign 
. 8HQ3 
Refer for NMR scanning 
. 8HQ4 Refer 
for CAT scanning 
. 8HQ5 
Refer for medical photography 
. 8HQ6 
Refer for angiogram 
. 8HQZ 
Refer for imaging NOS 
. 8HR. 
Refer for physiology investign 
. 8HR1 
Refer for ECG recording 
. 8HR2 Refer for audiometry 
-8HR3 Refer for nerve conduct study 
. 8HR4 Refer for lung function test 
-8HR5 Refer for EEG 
. 8HR6 Refer to Urodynamic studies 
-8HR7 Refer for vascular studies 
. 8HR8 Referral for 24 hour BP 
. 8HR9 Referral for 24 hour ECG 
. 8HRA Referral for exercise ECG 
. 8HRZ Refer for physiology test NOS 
. 8HS. Referral for endoscopy 
. 8HSO Refer for sigmoidoscopy 
. 81-IT. Referral to clinic 
. 8HT1 Referral to lipid clinic 
. 8HT2 Refer to hearing aid clinic 
. 8HT3 Referral to audiology clinic 
. 8HT4 Referral to orthodontic clinic 
. 8HT5 Referral hypertension clinic 
. 8HT8 Referral to mammography clinic 
. 8HT9 Referral to antenatal clinic 
. 8HTA Referral to postnatal clinic 
. 8HTB Referral to fertility clinic 
. 8HTC Referral to well woman clinic 
. 8HTD Referral fam planning clinic 
. 81-ITE Referral to other clinic 
. 8HTF Referral to emergency clinic 
. 8HTG Refer acute chest pain clinic 
. 81-ITH Referral to back pain clinic 
. 81-ITI Referral to breast clinic 
. 8HTZ Referral to clinic NOS 
. 8HU. Referral other investigation 
. 8HUO Referral for bronchoscopy 
. 8HU1 Referral for colonoscopy 
. 8HU2 Referral for sigmiodoscopy 
. 8HV. Private referral 
. 8HVO Private general surg referral 
. 8HV1 Private ophthalmolog referral 
. 8HV2 Private 
ENT referral 
. 8HV3 Private orthopaedic referral 
. 8HV4 Private neurosurgical referral 
. 8HV5 Private paediat surg referral 
. 8HV6 Private obstetric referral 
. 8HV7 Private gynaecologic referral 
. 8HV8 Private referral 
to plast surg 
. 8HV9 
Private referral to oral surg 
. 8HVA 
Private referred to urologist 
. 8HVB 
Privat referral to thorac surg 
. 8HVC 
Private referral to vasc surg 
. 8HVD 
Private referr maxillofac surg 
. 8HVE 
Private referr cardiothor surg 
. 8HVF 
Private referral to physician 
. 8HVG Private general medic referral 
. 8HVH Private referral paediatrician 
. 8HVI Private dermatology referral 
-8HVJ Private cardiological referral 
. 8HVK Private immunological referral 
. 8HVL Private neurological referral 
. 8HVM Private geriatric referral 
. 8HVN Private gastroenterol referral 
. 8HVO Private psychiatric referral 
. 8HVP Private referral to venereolog 
. 8HVQ Private referr rheumatologist 
. 8HVR Private ref to chest physician 
. 8HVT Private referral to oncologist 
. 8HVU Private referral diabetologist 
. 8HVV Private ref to radiotherapist 
. 8HVY Private referral anaesthetist 
. 8HVZ Private ref to endocrinologist 
. 8HW. Referral by nurse 
. 8HY. Referral to hospice 
. 8HZ. Further care referral NOS 
. 8HZO Referral needed 
Osteopath Referrals 
. 8H7D Refer to osteopath 
Physiotherapy Referrals 
. 8HH5 Refer domiciliary physio 
. 8H77 Refer to physiotherapist 
Radiology Referrals 
. 8H4G Refer to radiotherapist 
. 81-167 Referred 
for radiotherapy 
. 81-170 Refer to 
Radiology department 
. 8HJG Radiotherapy self-referral 
. 8HP4 Refer for radio-immune assay 
. 8HQ1 Refer for X-Ray 
. 8HQ3 Refer 
for NIVIR scanning 
. 8HQ4 Refer 
for CAT scanning 
. 8HQZ 
Refer for imaging NOS 
. 8HVV 
Private ref to radiotherapist 
Orthopaedic Referrals 
8H54 Orthopedic referral 
8HJ8 Orthopedic self-referral 
. 8HV3 Private orthopedic referral 
Gynaecological Referrals 
. 81-158 Gynaecological referral 
. 8HJ6 Gynaecological self-referral 
. 8HV7 Private gynaecologic referral 
Gastro -Intestinal Referrals 
. 81-148 Gastroenterological referral 
. 8HU1 Referral for colonoscopy 
. 8HU2 Referral for sigmiocloscopy 
. 8HVN Private gastroenterol referral 
Rheumatology Referrals 
. 8H4B Referred to rheumatologist 
. 8HJC Rheumatology self-referral 
. 8HVQ Private referr rheurnatologist 
Nursing Codes 
. 13F6 Nursing/other home 
. 13GI District nurse attends 
.1 3GA District nurse involv. stopped 
. 6314 Nursing home birth 
. 64Q6 Child ref. to school nurse 
. 66S5 Shared care: district nurse/GP 
. 66S7 Full care: nurse practitioner 
. 66S8 Shared care: practice nurse/GP 
. 6732 Counselled by a nurse 
. 6130. Nurse health promotion 
. 8A31 Head injury - nursing supervis 
. 8C1. Nursing care 
. 8CI I Intensive nursing care 
. 8C12 Nursing supervision 
. 8C1 3 Intermediate nursing care 
. 8C15 Nursing care - dressing 
. 8C1 6 Nursing care - 
irrigation 
. 8C17 Nursing care - 
injections 
. 8C18 Nursing care-enema administrat 
. 8C1 9 
Nursing care - bathing patient 
. 8C1A 
Nursing care - pressure areas 
. 8C1 B 
Nursing care - blood taken 
. 8C1 
C Nursing care operation assist 
. 8C1 
Z Nursing care NOS 
. 8GA. 
Psychological nursing 
-8H71 Refer to practice nurse 
. 81-172 Refer to district nurse 
. 81-1713 Refer to community psych. nurse 
-81-17C Refer diabetic liaison nurse 
. 8H7M Refer to stoma nurse 
. 8H7d Refer to school nurse 
. 81-17e Referral to nurse practitioner 
. 81-17f Referral to diabetes nurse 
. 8HE6 Delayed disch nursing home 
. 81-11-16 Referral to Macmillan nurse 
. 8HW. Referral by nurse 
. 8007 Prov special educ needs nursry 
. 9493 Patient died in nursing home 
. 9N1 G Seen in nursing home 
. 91\122 Seen by practice nurse 
. 91\124 Seen by district nurse 
. 9N2J Seen by hospital nurse 
. 91\12Y Seen by community paed nurse 
. 9N64 Referred by nurse 
. 9NFA District nurse visit 
. 9NFE First annl visit distr nurse 
APPENDIX 5.5. 
DRUGS WITH AN EFFECT IN THE TREATMENT OF OSTEOPOROSIS 
ALLYLESTRENOL 
AREDIA 
BONEFOS 
CLIMAGEST 
CLIMESSE 
CONJ OESTMORGESTR 
CONJUGATED OESTROG 
CRINONE WYE 
CYCLO PROGYNOVA 
CYCLOGEST 
DEPO PROVERA 
DERIVIESTRIL 
DUPHASTON 
DYDROGESTERONE 
ELLESTE DUET 
ELLESTE DUET CONTI 
ELLESTE SOLO 
ELLESTE SOLO MX 
ESTRACOMBI 
ESTRADERM 
ESTRADERM IVIX 
ESTRAPAK 
ETHINYLOESTRADIOL 
EVISTA 
EVOREL 
EVOREL CONTI 
EVORELPAK 
EVORELSEQUI 
FEMAPAK 
FEMATRIX 
FEMOSTON 
FEMSEVEN 
GESTANIN 
GESTONE 
HARMOGEN 
HORIVIONIN 
HYDROXYPROGESTRONE 
IMPROVERA 
KLIOVANCE 
LORON 
MEDROXYPROGESTERON 
MENOPHASE 
MENOREST 
MENZOL 
MICRONOR 
NORETHISTERONE 
NUVELLE 
NUVELLE CONTINUOUS 
NUVELLE TS 
OESTRADIOL 
OESTRADIOUNORETH 
OESTRIOL 
OESTROGEL 
OVESTIN 
PAMIDRONATE 
PIPERAZINE OESTRON 
PREMARIN 
PREMPAK 
PRIMOLUT N 
PROGESTERONE 
PROGYNOVA 
PROGYNOVATS 
PROLUTON DEPOT 
PROVERA 
RALOXIFENE 
SANDRENA 
SKELID 
SODIUM CLODRONATE 
STILBOESTROL 
TILUDRONIC 
TRIDESTRA 
TRISEQUENS 
UTOVLAN 
ZUMENON 
APPENDIX 5.6. 
STATISTICAL VARIABLES FOR THE SECOND STUDY 
Var. 
name 
Label Definition and creation Notes 
PATNR Patient ID Unique identifier for a study subject as given 
in the source data. 
INXDRG Index drug The study drug prescribed to a study subject 
on the index date. The variable categories 
will be named as following: 
EVISTA 
FOSAMAX 
DIDRONEL PMO 
CONTROL 
INXDAT Date of The date on which the study drug was + DATE WILL BE ASSIGNED TO THE 
Index drug initiated during the study exposure period CONTROL PATIENTS ACCORDING TO 
THE INDEX DATE OF THE PATIENTS 
THEY WERE MATCHED TO 
INXDIAG Diagnosis The diagnosis under which the index drugs 
for index was prescribed. 
drug Osteoporosis: OSTEO 
Other: OTHER 
If no diagnosis of osteoporosis was 
recorded, then missing value. 
PATAGE Patient age The age of the patient as of the year of the 
in index index date, computed from patient's age as 
year of December 1999 
HOST History of Mention of osteporosis-related diagnosis in Problem or Note of either: 
osteoporosi the patient record prior to index date M61 Osteoporosis 
s . 1268 FH: Osteoporosis 
STOP-3 Date at which the coverage of the last Patient must have at least 3 months drug 
Stop date - prescription of the first treatment episode free following stop date 
3 with index drug ended. Date when using a 
definition of drug-free period of 3 months. 
STOP-4 Stop date when using a definition of drug- Patient must have at least 4 months drug 
Stop date - free period of 4 months. free following stop date 
4 
STOP-5 Stop date when using a definition of drug- Patient must have at least 5 months drug 
Stop date - free period of 5 months free following stop date 
5 
STOP 6 Stop date when using a definition of drug- Patient must have at least 6 months drug 
- Stop date - free period of 6 mo nths free following stop date 
6 
FMOSTJ Cost of Total cost of the index therapy until stop Cost of Index therapy may vary accord 
Var. Label Definition and creation Notes 
name 
index date for patients identified in STOP-3 the definition of Stop Date, so individual 
therapy variables needed for each definition. 
COST-4 Cost of Total cost of the index therapy until stop 
index date for patients identified in STOP-4 
. 
therapy 
, COST-5 Cost of Total cost of the index therapy until stop 
index date for patients identified in STOP-5 
therapy 
COST-6 Cost of Total cost of the index therapy until stop 
index date for patients identified in STOP-6 
, therapy 
A2131 -6 Cost of H2 Cost of H2 antagonists (A02131) in the 6 
antagonists months prior to index date 
prior 
A2131+6 Cost of H2 Cost of H2 antagonists in the 6 months 
antagonists after index date 
after 
A2132-6 Cost of Proton pump inhibitors (A02132) in the 6 
PPi's prior months prior to index date 
A2132+6 Cost of Cost of Proton pump inhibitors (A02132) in 
PPi's after the 6 months after index date 
N2A-6 Cost of Cost of narcotic analgesics (N02A only) in 
narcotic the 6 months prior to index date 
analgesics 
prior 
N2A+6 Cost of Cost of narcotic analgesics (N02A only) in 
narcotic the 6 months after index date 
analgesics 
after 
N213-6 Cost of non- Cost of non-narcotic analgesics (N213) in 
narcotic the 6 months prior to index date 
analgesics 
prior . ___ N213+6 Cost of non- Cost of non-narcotic analgesics (N213) in 
narcotic the 6 months after index date 
analgesics 
after 
M1A-6 Cost of Cost of antirheumatic non-steroidals (M 1 A) 
NSAIDs in 6 months prior to index date 
prior 
M1A+6 Cost of Cost of antirheurnatic non-steroidals (M 1 A) 
NSAIDs in 6 months after index date 
after 
APPENDIX 6 
ABSTRACT BASED ON RESULTS OF FIRST STUDY IN MEDIPLUSO 
USE OF BISPHOSPHONATES AND THE COST OF TREATING 
GASTROINTESTINAL SIDE EFFECTS IN A UK CLINICAL PRACTICE 
SETTING. 
Urdahl HF1, Young P1, McKendrick j2 , Freemantle N1 'Medicines Evaluation Group, Centre for Health Economics, University of York, UK 2 Eli Lilly and Company Ltd, Dextra Court, Basingstoke, UK 
Background 
Gastrointestinal (GI) side effects have been associated with bisphosphonate use in 
clinical practice. This study assesses the cost implications for treating GI problems in women taking bisphosphonates in a UK primary care setting. 
Material and Methods 
Information was obtained from 140 general practices contributing data to the UK 
Primary Care Database from IMS Health, UK Mediplus@. Women included in the 
study were those initiating therapy on the bisphosphonates, alendronate or cyclical 
etidronate, between January 1996 through January 1999, with a prior period of 6 
months of no bisphosphonate use. Age matched women provided control data. The 
costs of the use of Proton Pump inhibitors (PPIs) and 1-12-antagonists were 
determined each year for 3 years and were controlled for concomitant use of non- 
narcotic analgesics (including NSAIDs). Cost data were non-normally distributed 
and many patients incurred no cost. Therefore, the non-parametric bootstrap was 
used to assess differences in the average cost of PPIs and H2-antagonists. 
Results 
666 women taking bisphosphonates (162 cyclical etidronate, 504 alendronate) and 
1332 controls were analysed. The average cost in the previous year for 1-12- 
antagonists was 25.12 in the control group and El 1.94 in the bisphosphonate 
group, and similarly P-10.08 and E30.10 for PPIs. During the first year of 
bisphosphonate use, the average cost of H2 antagonists increased by F-9.40 (95% 
Cl 4.30 to15.00) when compared to the controls. Similarly, the average cost of 
PPI's increased by El 0.10 during the f irst year (95% Cl 2.70 to 27.70) when 
compared to controls. Similar increases were observed in subsequent years. There 
was no significant increase in the number of women experiencing GI side effects. 
Conclusion 
The use of cyclical etidronate and alendronate are associated with a constant 
yearly increase in the costs of H2 antagonists and PPIs of approximately E9.50 per 
annum. Concomitant medication costs may be an important consideration when 
undertaking an economic evaluation for osteoporosis in primary care. 
